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1
Introduction
Chronic kidney disease (CKD) is a common disease in the western population as at least 8% of 
this population has a degree of CKD, placing them at a moderate to high risk to develop kidney 
failure1. This figure is increasing each year due to an aging population and an increase in the 
prevalence of diabetes and chronic vascular morbidity. Therefore, if the present trend continues, 
the number of people with CKD will double over the next decade2. 
Although there are strategies to slow down the progression to end stage renal disease (ESRD), 
there are currently no therapies to cure CKD. Therefore approximately 5% of CKD patients will 
progress into ESRD with the need of renal replacement therapy (RRT)3. Currently there are 
two RRT options for patients with ESRD: dialysis and kidney transplantation. Due to the lower 
mortality and higher quality of life, the best therapy at the moment is kidney transplantation2. 
However, as there is a shortage of organ donors, patients awaiting transplantation often need 
dialysis for several years. Moreover, long term outcomes after kidney transplantation are 
compromised by the effects of rejection and nephrotoxicity of immunosuppressive therapies2,4. 
There is therefore a need for novel treatment strategies to either prolong the survival of 
transplanted organs or to increase the availability of (bio-engineered) transplantable kidneys. 
Mesenchymal stromal cell therapy 
One strategy to improve graft survival is the enhancement of the immunological acceptance of 
the graft, preventing fibrosis and fostering the regenerative capacity of the transplanted kidney. 
Mesenchymal stromal cell (MSC) based therapy shows to be a promising candidate for these 
aspects as their properties may influence both inflammation and fibrosis2. 
Mesenchymal stromal cells are perivascular located cells originally isolated from the bone 
marrow (bmMSCs). Due to their perivascular location, MSCs can closely interact with several 
cell types including endothelial cells, resident macrophages, dendritic cells (DCs) and recruited 
inflammatory cells (Figure 1)2. Due to these interactions, MSCs show strong tissue homeostatic 
and immunomodulatory properties.









Stromal cells Epithelial cells 
Figure 1. The central role of MSCs in tissue homeostasis. Due to the perivascular location of 
MSCs, MSCs are able to closely interact with several different cell types within an organ. (Adapted 
with permission from Leuning et al. Seminars in Nephrology 2014)
Little is still known about the exact mechanism of action of MSCs as cellular therapy. Upon 
activation of MSCs in an inflammatory milieu (‘licensing’), MSCs express and excrete 
immunoregulatory molecules such as IDO and secrete several factors, including IL-6, TGF-β 
and prostaglandinE2 which are able to polarize monocytes towards immunosuppressive M2 
macrophages and favour the induction of regulatory T cells. Moreover, macrophages that 
phagocytose MSCs are polarized towards the immunosuppressive M2 phenotype as summarized 
in figure 2 2,5-10. In several experimental models of kidney disease and transplantation, MSC 
treatment was able to enhanced tissue repair and reduce fibrosis as reviewed in a meta-analysis 
elsewhere11.
In renal transplantation, the first clinical trials have demonstrated that MSC therapy is safe and 
feasible 12-15. Currently several ongoing trials focus on the effects of MSCs on rejection, ischemia 
reperfusion injury, mimimization of immunosuppressive therapies and improvement of long-
term graft survival16.
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Figure 2. Putative immunomodulatory mechanism of action of mesenchymal stromal cells 
(MSCs). MSCs are short-lived and might be lysed soon after being injected into the circulation. 
Macrophages that phagocytose lysed MSCs are polarized to the immunosuppressive M2 
phenotype. Activation or licensing by the proinflammatory microenvironment in the host (via 
licensing factors such as interferon γ (IFNγ), tumour necrosis factor (TNF) and IL1 or via direct 
interaction with activated immune cells), induces MSCs to express and secrete immunomodulatory 
molecules, such as indoleamine 2,3dioxygenase (IDO) and haemoxygenase (HO). These molecules 
have a role in suppressing the proliferation of target cells, including T cells, B cells and natural killer 
(NK) cells. Activated MSCs also induce polarization of monocytes towards immunosuppressive 
M2 macrophages via factors that include IL6 and prostaglandin E2 (PGE2). These macrophages 
secrete factors that contribute to the immunosuppressive state (including IL10 and IL6). They also 
produce CC chemokine ligand 18 (CCL18) and soluble HLAG (sHLAG), which in conjunction with 
MSC-derived factors, including transforming growth factor β (TGFβ) and PGE2, favour the induction 
of regulatory T (T
reg
) cells. (Reprinted with permission from Fibbe et al. Nature Reviews Nephrology 
2017)
For cellular therapy, in general 1-2x106 MSCs/kg bodyweight are given. Since the bone marrow 
only contains 0.001-0.01% primary MSCs, significant ex vivo amplification and culture is 
needed. The current standard clinical grade cell culture method of MSCs consists of culture on 
cell culture plastic in flasks or in cell factories. However, this method is time consuming and, 
due to the need of clean room facilities, costly. Therefore, there is a growing interest in closed-
system bioreactor culture. In these systems, cells are usually grown on microcarriers. However, 
little is known about how these differences in microenvironment influence the functionality of 
the cells17,18. 
Previously it has been shown that MSC-like cells can be isolated from most organs. These MSC-
like cells are mainly isolated from the perivascular compartment and exhibit tissue specific 
properties 19,20. Perivascular stromal cells could also be isolated from the human kidney21,22. Due 
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to tissue specific imprinting, kidney derived perivascular stromal cells may be more potent in 
kidney regeneration compared to other sources of MSCs and are therefore an interesting new 
cell source for clinical therapy22. 
A bio-engineered kidney
Another novel strategy to diminish the shortage of donor organs and the need for 
immunosuppressive therapies in the future is the development of an autologous bioengineered 
kidney. For this purpose there is a need for both cells and an instructive matrix for cell adherence 
and organization. To obtain such a matrix human or human size kidney can be decellularized 
in order to obtain the extracellular matrix without the cells (scaffold). This scaffold can then be 
recellularized with induced pluripotent stem cells (hiPSCs) derived kidney- and endothelial cells 
derived from the patient. 
First steps towards this bioengineered kidney have been made. Song et al. showed that 
when a rat kidney scaffold is recellularized with HUVEC and neonatal rat kidney cells, site 
specific recellularization was observed23. Moreover, others showed that rat kidney scaffolds 
can be recellularized with mouse embryonic stem cells which showed some differentiation 
into endothelial cells24-28. Although these studies are interesting first proof-of-concepts of a 
bioengineered kidney, all these studies were performed with either murine, porcine or kidney 
scaffolds and cells or with cell lines and are therefore not directly translatable to the human 
situation. 
In order to develop a human bioengineered kidney, human or human size scaffolds should be 
recellularized with large quantities of human kidney- and endothelial cells preferably derived 
from the patient himself to avoid an immune reaction after transplantation. For these purposes 
human induced pluripotent stem cells (hiPSCs) would be the most attractive candidate as 
patient derived iPSCs can be expanded and differentiated into both kidney progenitor cells and 
endothelial cells29,30. Human or human size kidney scaffolds can then be recellularized with these 
iPSC-derived kidney and endothelial cells as schematically shown in figure 3. 
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Figure 3. The concept of a bioengineered kidney by recellularizing a kidney scaffold with patient 
derived differentiated induced pluripotent stem cells. 
Aims and outline of this thesis
The aim of this thesis was to explore novel therapeutic strategies for kidney transplantation 
in the field of regenerative medicine. In chapter 2 latest insights, first clinical experiences and 
future perspectives and challenges of MSC therapy for kidney transplantation are discussed. 
At the moment, the focus of MSC therapy is mostly on bmMSCs. However, more and more 
evidence is arising that organ derived perivascular stromal cells exhibit MSC-like characteristics 
while at the same time they show tissue specific properties and reparative functions 19,20.
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In chapter 3 we show that kidney perivascular stromal cells (kPSCs) can be isolated from the 
human kidney and that these cells show, in contrast to bmMSCs, a organotypic expression 
signature and kidney specific regeneration properties. As we chose to focus on kPSCs as a novel 
candidate for cellular therapy in a clinical setting, we isolated these cells with a novel clinical 
grade isolation method of which the detailed protocol can be found in chapter 4. 
As the culture of both kPSCs and bmMSCs in a clinical grade manner is currently time 
consuming and costly, culture methods are now shifting towards bioreactor-based systems 
where cells are cultured on microcarriers. However, little is known about how these changes 
in microenvironment influence the functionality of the cells. In chapter 5 we investigated 
whether the microenvironment, specifically the topography of the culture surface, influence the 
secretome and thus functionality, of both kPSCs and bmMSCs. 
Next, we show that within the human kidney, stromal cells can not only be found in the kidney 
cortex but also within the kidney capsule. These capsule derived MSCs show distinct gene 
expression profiles and functionality compared to cortex derived kPSCs. This underpins the 
large functional diversity of phenotypic similar stromal cells in relation to their anatomic site, 
even within one organ (chapter 6).
All MSC types studied above could potentially be able to prolong transplant survival, promote 
kidney regeneration and reduce the amounts of immunosuppressive therapies. However, in the 
most ideal situation immunosuppressive therapies would not be necessary at all. In this scenario, 
an ESRD patient would be transplanted with an autologous kidney made from differentiated 
patient-derived induced pluripotent stem cells. In chapter 7 we show first critical steps towards 
this bioengineered kidney with the focus on the kidney vasculature. 
Finally, chapter 8 provides a general summary of the research presented in this thesis and further 
discusses the potentials of regenerative medicine for kidney diseases and transplantation.
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Chapter 2
Clinical translation of multipotent mesenchymal 
stromal cells in transplantation
Daniëlle G. Leuning, Marlies E.J. Reinders, Johannes W. de Fijter, and Ton J. Rabelink 
Seminars in Nephrology 2014
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Abstract
The prevalence of chronic kidney disease and end stage renal disease (ESRD) is increasing 
each year and currently the best therapeutic option for ESRD patients is kidney 
transplantation. However, although short-term graft outcomes after transplantation 
have improved substantially due to new and more potent immunosuppressive drugs, 
the long term survival has hardly changed. This is most likely caused by a combination 
of non-immunological side effects and sustained alloreactivity to the graft resulting 
in fibrosis. In addition, current immunosuppressive drugs have side effects, including 
nephrotoxicity, infections and malignancies that compromise long-term outcomes. 
Consequently, there is a strong interest in immunosuppressive therapies that maintain 
efficacy, while reducing side effects. As mesenchymal stromal cells (MSCs) have potent 
anti-inflammatory and anti-fibrotic properties, these cells are of particular interest as 
new candidates in transplant recipients. MSCs might play roles in the treatment of 
allograft rejection and fibrosis and in calcineurin minimization and induction protocols. 
In the present review we discuss both preclinical as well as clinical evidence of their 
therapeutic potential in kidney transplantation. In addition, challenges and obstacles for 
clinical translation will be discussed.
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Introduction 
Chronic kidney disease (CKD) is a common disease in the western population as at least 8% of 
this population has a degree of CKD, placing them at a moderate to high risk to develop kidney 
failure1. This figure is increasing each year due to an aging population and an increase in the 
prevalence of chronic (reno) vascular morbidity and diabetes. If the present trend continues, the 
number of people with CKD will double over the next decade. 
Although there are strategies to slow down the progression to end stage renal disease (ESRD), 
there are currently no therapies to cure CKD, therefore approximately 5% of patients with a 
diminished kidney function will progress into ESRD with the need of renal replacement 
therapy2. Currently the best therapy for these patients is kidney transplantation as this improves 
the life expectancy and quality of life of ESRD patients. 
In transplanted patients, the graft survival rate has increased in the last decades to over 90%, 
mainly due to the reduction of acute rejection within the first year after transplantation. However, 
long term graft survival has remained unaltered over the last two decades 3. Both immunologic 
and non-immunologic factors contribute to the development of fibrosis in the allograft, including 
ischemia reperfusion injury (IRI), ineffectively or untreated clinical and subclinical rejection, 
superimposed calcineurin inhibitor nephrotoxicity and exacerbating pre-existing donor disease. 
Moreover, long-term systemic immune suppression is increasingly recognized for its numerous 
side effects, of which infections and malignancies are the most important. There is therefore a 
need for novel treatment strategies to improve both the immunological acceptance of the graft 
as well as to prevent fibrosis and foster the regenerative capacity of the transplanted kidney. 
Mesenchymal stromal cell (MSC) based therapy shows to be a promising candidate for both 
situations as their properties may influence inflammation and fibrosis. 
MSC characteristics
MSCs represent a minor fraction of the bone marrow (0.01-0.001% ). They are typically located 
perivascularly where they control the vascular bone marrow niche and through differentiation 
into osteoblast give rise to the niche for long term repopulating stem cells 4. They are easily isolated 
from the bone marrow as they adhere to plastic and can substantially proliferate and expand in 
culture 5,6. Unfortunately there is no specific MSC marker and therefore a set of phenotypic 
and functional criteria were proposed by the International Society of Cellular Therapy (ISCT) 
including their plastic adherence, trilineage differentiation potential and the expression of the 
stromal markers CD73, CD90 and CD105 while being negative for the hematopoetic markers 
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CD14, CD34 and CD45 7. While several attempts have been made to select a more homogeneous 
MSC population by using surface markers such as e.g. STRO-1, there is so far no unique marker 
that allows direct MSC isolation and selection. This may be due to the fact that MSCs actively 
interact with surrounding cells through microvesicles and exchange of cell components 8.
In addition to the bone marrow a population of perivascular localized MSCs can be found in 
several, if not all, organs, including the kidney 9,10. In the mouse, kidney derived MSCs showed 
similar marker expression and differentiation potential compared to bone marrow (bm)MSCs; 
however, when looking at mRNA expression profile and in vivo differentiation potential, 
these cells appeared strikingly different 10. These differences may be caused by tissue specific 
imprinting during embryogenesis or local cues. This makes kidney ( and other organ) derived 
MSCs of particular interest as a new source for renal repair. Bruno et al. showed that kidney 
derived MSCs can be isolated from human glomeruli as well. Whether there are differences 
between these MSCs and bmMSCs and whether these differences lead to improved renal repair 
mechanism needs to be further elucidated 11. 
The ubiquitous presence of MSCs in tissues probably reflects to a large extend the embryological 
development of the structure of tissues and has also initiated the isolation and expansion of 
MSCs from other tissues for clinical use. These include adipose tissue, umbilical cord and dental 
pulp 12-14. We will discuss later the advantages and drawbacks of the use of these sources as 
compared to the use of bmMSCs.
Immunomodulatory and reparative functions of MSCs
Due to their perivascular location, MSCs can closely interact with several cell types including 
endothelial cells, resident macrophages, dendritic cells (DCs) and recruited inflammatory cells 
(figure 1).
The immunomodulatory potential of MSCs is the function most extensively studied. MSCs 
interact with several key players of both the innate as the adaptive immune system as extensively 
reviewed elsewhere 15,16. In short, MSCs are able to suppress T-cell proliferation and favor the 
formation of regulatory T-cells (Tregs). This is in human MSCs to large extent caused by the 
secretion of soluble factors including indoleamine 2,3-dioxygenase (IDO), transforming growth 
factor β (TGF-β) and prostaglandin E2 (PGE2) 17-19. With respect to B-cells the effects of MSC 
therapy is more variable and sometimes even contradictory. In the B-cell driven disease systemic 
lupus erythematosus (SLE), for example, some studies have shown a beneficial effect of MSC 
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therapy on kidney function, complement depositions and the levels of circulating double 
stranded DNA 16,20, while others did not see an effect on kidney function and survival 21 or even 









Figure 1. Central location of MSCs. MSCs have, due to their perivascular location, interactions 
with endothelial cells, stromal cells, tissue resident DCs, macrophages and infiltrating leucocytes. 
Because of all these interactions they are central in tissue homeostasis. 
MSCs do not only interact with the adaptive immune system but also with components of 
the innate immune response. MSCs are, for example, able to interfere with DC migration, 
maturation and antigen presentation via secretion of Interleukin (IL)-6, M-CSF, PGE2 and IL-
10 16. In addition, MSCs have also been shown to modulate natural killer cell (NK cell) responses 
23. These effects of MSCs may recapitulate their function in the bone marrow niches, where 
one of their main functions is to maintain an inflammatory milieu that allows for progenitor 
cell maturation and release of blood cells into the circulation 24. It is also important to realize 
that part of the regenerative properties of MSCs may depend upon their ability to polarize 
the immune system into a reparative phenotype. For example, M2 macrophages have been 
identified as tissue reparative myeloid cells in the kidney by producing a cytokine environment 
that supports tubular repair and proliferation rather than inflammation 25. In agreement, genetic 
or pharmacological blockade of CSF1 decreases M2 polarization and subsequently inhibits 
recovery from acute kidney injury 26.
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It is becoming, however, increasingly clear that MSCs do not always display this anti-
inflammatory phenotype. It turns out that in fact MSCs, like many cells of the immune system, 
can be polarized both into an anti-inflammatory (MSC2) phenotype or a pro-inflammatory 
(MSC1) phenotype ( for review see 17). The immunosuppressive phenotype of MSCs depends on 
exposure to interferon-gamma (IFNy), which in the presence of other inflammatory cytokines 
( such as TNFa, IL-1a or IL-1b) induces nitric oxide synthase (iNOS) in the case of rodent 
MSCs or IDO in the case of human MSCs. In the absence of IFNy or iNOS/IDO, the MSCs can 
actually turn into immune competent cells 27. Obviously this imposes an important challenge 
to the clinical administration of MSCs. Dependent upon the timing and the local milieu where 
they home to, they may lose their immunomodulatory properties.
MSCs also interact directly with endothelial cells via the production of paracrine factors 
(including vascular endothelial growth factor (VEGF) and angiopoietin 1 (ANG-1)) with the 
aim to stabilize and maintain the microvascular architecture and thus tissue perfusion 28,29. Not 
only paracrine mechanisms but also cell-cell contacts are of importance for vessel stabilization. 
As an example, knock down of the α6β1 integrin receptor in MSCs leads to decreased capillary 
sprouting and failure of vessels to associate with nascent vessels 30. Of note, perivascular MSCs 
may probably, beyond the point of regeneration, also contribute to fibrosis. Indeed, Humphreys 
et al showed using lineage tracing studies of FoxD1+ pericytes, that perivascular stromal cells can 
transform into myofibroblasts upon severe kidney injury, and contribute to renal fibrosis as a last 
resort repair mechanism 31.
In summary, MSCs are ubiquitous perivascular stromal cells that regulate tissue homeostasis. 
When primed by the adaptive immune system they can induce polarization of the immune 
system towards down regulation of inflammation and vascular stabilization. However, it is 
important to realize when applying these cells as a potential therapy, that without the proper 
priming components of the innate immune system MSCs can turn into cells that can activate the 
immune system and drive fibrotic repair.
MSC therapy in experimental models of kidney disease and transplantation
In several experimental models of kidney disease and transplantation, MSC treatment enhanced 
tissue repair and reduced fibrosis as reviewed in a meta-analysis elsewhere 32. Although there 
is a large variation in disease models, source (human/animal MSCs), amount, timing and 
administration route of MSCs in these studies, in general there is a benefit of MSC therapy 32. 
Interestingly, MSC infusion in a transplantation setting may not only reduce the inflammatory 
reaction but may also induce a state of allograft tolerance. In a sensitized murine kidney 
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transplantation model for instance, MSC infusion prior to transplantation resulted in long 
term graft survival, up to 60% for more than 2 months, while in control animals all grafts were 
rejected at 10 days post transplantation. There was a donor specific T-cell hypo responsiveness 
and an increase in Tregs in the mice who received the MSCs pre-transplantation. However, 
when MSCs were infused post-transplantation this effect was not seen and in fact, there was a 
decrease in kidney function after MSC infusion, indicating that the timing of infusion (and thus 
the environment) is of importance for MSC treatment 33. In another murine kidney allograft 
model the soluble factor IDO was shown to be crucial for long term allograft survival 34. 
It is thought that most of the aforementioned effects of MSCs are caused via paracrine mechanisms, 
including growth factors, microvesicles and other soluble factors such as IDO, vascular 
endothelial growth factor (VEGF) and insulin-like growth factor (IGF) 35-39. As demonstrated by 
Eggenhofer et al., i.v. infusion of murine bone marrow MSCs lead to accumulation in the lungs, 
where they disappear within 24h. This suggests that their local effects are endocrine or paracrine 
and transferred to other cell types, and this interaction may be crucial for the long term effects 
of MSCs 40.
MSCs in clinical trials: a bridge too far?
Bianco et al. criticized the ongoing clinical trials with MSCs as they argue that MSCs are not 
precisely enough characterized and are not bona fide stem cells 24. They stated that the MSC 
population is too heterogeneous with the current characteristics as defined by the ISCT 41 and 
with these characteristics the clonogenicity and in vivo trilineage differentiation potential is not 
proven. Moreover, they argue that although there is enough evidence for MSCs as a skeletal stem 
cell, there is hardly any evidence for their immunomodulatory and tissue regenerative potential 
and because of these uncertainties they suggest more preclinical research before clinical trials. 
However, for immunomodulatory functions MSCs may not need to fulfill the stem cell criteria. 
In fact, the word mesenchymal stem cell is misleading and the term mesenchymal stromal cell 
should be used instead. These mesenchymal stromal cells have a supportive role in all organs 
including tissue homeostasis and immune suppression, independent of their stem or progenitor 
potentials. And although the exact mechanisms of actions are still largely to be elucidated, both 
the preclinical and clinical data suggest immune suppression and a role of MSCs in kidney repair 
as summarized above. Therefore to our opinion, this should not be a limiting factor to perform 
clinical safety and feasibility studies. While animal studies may give some insights into safety 
and feasibility, the value of these studies is limited 42,43 probably due to the fact that genomic 
responses in mouse models poorly mimick human inflammatory diseases 44. There is thus a need 
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for proper study designs with more standardized cell isolation, culture and infusion protocols 
and clinical trials should not only focus primarily on clinical outcomes but also on mechanisms 
of action and safety of MSC therapies. 
Clinical studies using MSCs in kidney transplantion
In renal recipients, MSCs may be included in induction protocols, in the treatment of allograft 
rejection and fibrosis, and in calcineurin minimization protocols. The first phase I studies have 
been performed and are summarized in figure 2. Early studies focused on the role of MSCs 
in induction protocols. In a pilot study exploring safety and clinical feasibility 2 living-related 
kidney recipients were infused with bmMSCs 7 days after transplantation 45. MSC infusion was 
shown to be feasible, allowing enlarging of Tregs in the peripheral blood and control of memory 
CD8+T cell function 45. However, both patients showed a rise in serum creatinine 7-14 days 
after MSC infusion where a kidney biopsy excluded rejection but showed a focal inflammatory 
infiltrate. After treatment with methylprednisone there was a recovery of kidney function and 
1 year-post transplantation the renal function of both patients was stable. As a nice example of 
‘from bedside to bench and back to bedside’ development of new treatment strategies, the same 
group showed in a murine transplant model that MSC administration 1 day prior to kidney 
transplantation, opposed to post transplant administration, did not give graft dysfunction and in 
fact was able to induce tolerance 33. Therefore in the second study, also including 2 living related 
kidney recipients, pre-transplant infusion of autologous MSCs were given. No engraftment 
syndrome or increase in serum creatinine levels were seen, although in one patient an acute 
cellular rejection occurred 2 weeks post-transplantation. This may, at least partly, be triggered by 
withholding basiliximab induction as the authors wanted to exclude an effect of basiliximab on 
Treg expansion. However, compared to previously described patients and controls there were no 
differences in Treg counts with or without basiliximab induction. Comparable to the 2 patients 
described in the previous study, in these two patients a subtle decrease in memory CD8 T cells 
was seen as well 46.
In a larger randomized study by Tan et al, the effect of autologous bmMSC infusion was studied 
as an alternative to anti-IL-2 receptor antibody for induction therapy in adults undergoing living-
related donor kidney transplants 47. MSC infusions were given on the day of transplantation 
just prior to surgery and at day 12, and were combined with triple therapy, both with standard 
dose calcineurin inhibition as well as with a lower dose. The rejection rate with MSC induction 
appeared lower (8 %) as compared to induction therapy with IL2 receptor blockade, which was 
relatively high at 20 %. Importantly, rejection rates increased from 6 to 12 months up to 17 % 
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D0 D7 1yr
Tx (+BAS, ATG, CNI) 
Autologous MSC
2x106/kg i.v.
↑ Creatinine after infusion
↓ memory/effector CD8+T cells
↓ donor specific CD8+T cell cytotoxicity
n=2
D -1 D0 1yr
Tx (+ATG, CNI) 
Autologous MSC
2x106/kg i.v.
↓ memory/effector CD8+T cells
↓ donor specific CD8+T cell cytotoxicity
Acute rejection (n=1)
n=2
Perico 2011, Perico 2013
D0 D14 1yr
Tx (+low or normal dose CNI) 
Autologous MSC
1-2x106/kg i.v.
Faster recovery renal function after Tx
↓ acute rejection
↓ Opportunistic infections
n=53/group (MSC+ normal/low dose CNI 






Resolution subclinical rejection (n=2)
↑ Opportunistic infections (n=3)







5x106 i.r.a 2x106/kg i.v
No difference in renal function
No chimerism
Increased B-cell levels at month 3
n=6/group (MSC vs control)
Peng 2013
Figure 2. The set-up, timeline and results of the first clinical trials with MSC therapy for kidney 
transplantation. ↑: MSC infusion. Tx: transplantation, BAS: basiliximab, ATG: antithymocyte 
globulin, CNI: calcineurin inhibitor, CP: cyclophosphamide, i.v.: intravenous, i.r.a: intra renal artery
in the MSC arm, which may be related to the fact that initial depleting induction therapy was 
withheld. Moreover, the final rejection rates were substantially higher than what is usually 
observed in e.g. standard immune suppression regimes such as used in the Symphony study 48. 
In our own phase I clinical trial, safety and feasibility of autologous bmMSC therapy was tested 
in subclinical rejection and/or in interstitial fibrosis and tubular atrophy (IFTA) 49. Protocol 
biopsies were taken at 4 weeks and 6 months after transplantation and when these showed either 
subclinical rejection or IFTA, MSC therapy was given. MSC treatment showed to be feasible 
and there were no therapy related serious side effects. Two kidney recipients with a biopsy 
proven subclinical rejection showed a resolution of tubulitis without IFTA after MSC infusion. 
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Moreover, 3 out of in total six patients developed opportunistic infections after MSC therapy and 
in 5 patients a donor-specific down regulation of peripheral blood mononuclear cell (PBMC) 
proliferation was seen, all indicative of an immune suppressive effect of the MSCs in subclinical 
rejection and IFTA.
All studies listed above are performed with autologous, thus patient derived, MSCs. One study 
explored whether donor derived MSCs can also be used in transplant recipients. The investigators 
demonstrated that donor derived MSCs combined with low dose tacrolimus was safe and that 
patients who received MSCs had a similar renal function compared to controls with normal 
dose tacrolimus. There was no leucocyte chimerism after 3 months. There were almost no 
differences in leucocyte profiles and proliferation upon stimulation except an increase in B-cell 
levels in the MSC group compared to the control. Interestingly, in this study donorMSCs were 
first administered via the renal artery directly after reperfusion and secondly i.v. one month 
after transplantation 50. Unfortunately the group size is too small to draw conclusions about both 
the method of administration and the potential advantages or disadvantages of donor derived 
compared to patient derived MSCs. 
An interesting concept is to use MSCs as a means to minimize immune suppression. In our center, 
we have now embarked on a study to test the hypothesis whether MSCs in combination with a 
mTor inhibitor will facilitate tacrolimus withdrawal, reduce fibrosis and decrease the incidence 
of opportunistic infections compared to standard tacrolimus dose [NIH Gov NCT02057965]. 
Interestingly, in experimental studies the combination of mTor inhibitor and MSCs were shown 
to attenuate alloimmune responses and to promote allograft tolerance 51. Indeed, combination 
therapy of MSCs and low-dose Rapamycin (Rapa) in a murine heart allograft model achieved 
long-term heart graft survival (>100 days) with normal histology. The treated recipients readily 
accepted donor skin grafts but rejected third-party skin grafts, indicating the establishment of 
tolerance. Tolerant recipients exhibited neither intragraft nor circulating antidonor antibodies, 
but demonstrated significantly high frequencies of both Tol-DCs and Tregs in the spleens 51.
Current MSC based trials (table 1) assessed mainly feasibility and safety issues. To document 
the induction of immune suppression after the treatment and to correlate the presence and 
magnitude to clinical outcomes, is of major importance to be able to monitor immune responses 
in MSC treated patients. This is crucial to help the clinician with critical issues including 
safety, dosage, frequency and timing of MSCs and might provide mechanistic insight. A first 
important step is the validation and standardization of the assays used for immune monitoring, 
which will facilitate fair and meaningful comparisons between trials. Interestingly, the One 
Study Consortium, which recently initiated a serie of clinical trials aimed at using different 
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cell therapies to promote tolerance to renal allografts, developed a robust immune monitoring 
strategy including procedures for whole blood leukocyte subset profiling by flow cytometry. 
Local performance and central analysis of this panel yielded acceptable variability in a 
standardized assay at multiple international sites and panels and procedures might be adopted 
as a standardized method in monitoring patients in clinical trials 52.
Challenges and obstacles in clinical studies that use MSC
If all the preclinical and clinical data are taken together, MSC therapy in kidney transplantation 
appears promising. There are however important considerations and concerns that need to 
be addressed. There is, for example, little known about the best source, timing, dosage, route 
of administration and frequency of cell administration. Besides, there is a need for more 
information regarding the safety concerns when using MSCs as cell therapy. In addition, there 
is discussion about the best early study design. These important issues will be described below.
1] Culture conditions for MSC isolation and expansion
Since the bone marrow contains only 0.001-0.01% primary MSCs, significant ex vivo amplification 
and culture is needed. There is a large variation in culture and isolation techniques of MSCs used 
in the clinical trials so far. Although most research have been performed with MSCs isolated and 
expanded on tissue plastic, the culture and cryopreservation protocols differ to large extent as 
reviewed extensively in previous reports53. For example, MSCs are mostly cultured in 5% platelet 
lysates while some use 10% fetal calf serum. MSCs grown in platelet lysate based medium in 
general grow faster although there are large variations when platelets from different donors are 
used 54. The use of standardized media and culture conditions is required to minimize variability 
and increase reproducibility.
2] Sources of MSCs 
Most clinical studies up till now have studied the effect of bmMSCs. Another source of MSCs in 
clinical studies is the adipose tissue. Adipose tissue derived MSCs (ASCs) exhibit at first glance the 
same characteristics and immunomodulatory potential compared to bmMSCs. In experimental 
models of solid organ transplantation both bmMSCs and ASCs could inhibit rejection and/ or 
increase graft survival 33,55-58. We have recently made a direct comparison between both cell types 
in a humanized skin allograft rejection model and found that both human bmMSCs and human 
ASCs were effective in inhibiting skin allograft rejection. Local administration of bmMSCs as 
well as ASCs reduced inflammation by inhibiting the recruitment of T cells and decreasing 
IFNγ, TNFα, IL-6 and IL-1β expression in the skin grafts59. 
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Unfractionated adipose tissue has already been used as a stem cell source in clinical trials by the 
company Cytori®, claiming to have a device which can isolate adipose-derived regenerative cells. 
The cells isolated with this device have been studied in several clinical trials for cardiovascular 
diseases including the APOLLO trial where the cell mixture was injected after myocardial 
infarction (MI). In this situation cell infusion gave a 4% increase in left ventricular function 
compared to control. It is important to realize that these are not (expanded) ASCs, but a mixture 
that includes adipose stromal cells, endothelial progenitor cells, leucocytes, endothelial cells and 
vascular smooth muscle cells and therefore most likely adipose MSCs will be part of this mixture 
60. However, this undefined mixture is very different from characterized adipose tissue derived 
MSC expansions and therefore the results from these clinical studies are difficult to relate to 
ongoing clinical studies using bmMSC or cultured ASCs.
Another source of MSCs are MSCs derived from the umbilical cord, either from the blood or 
from the stroma (Warton Jelly, hWJSCs). hWJSCs can be easily harvested from the umbilical 
cord, have a higher frequency of proliferation and higher colony-forming unit capacity compared 
to bmMSCs while having the same immunomodulatory potential. Therefore, as isolation of 
hWJSCs is non-invasive as opposed to the bone marrow aspiration to acquire bmMSCs and 
have a higher gain in cell numbers, hWJSCs can easily be banked and may in the end be a very 
attractive source of MSCs for clinical purposes 61.
3] Autologous or allogeneic MSCs
Until now most studies have used autologous cells. However, due to the expansion period, 
quality controls and logistics, it takes several weeks to months to manufacture autologous cells, 
which is a long time for patients in need for treatment. Allogeneic MSCs offer the advantage of 
availability for clinical use without the delay required for expansion. This is of major importance 
in the case of indications where the treatment is needed without delay, for example in calcineurin 
toxicity and allograft rejection. In these indications autologous therapy would only be possible 
when the cells are harvested in advance, however this is very costly and limits this approach 
more or less to patient designated therapy. Another theoretical benefit of using allogeneic MSCs 
is that the age of the donor is controlled, and cells can be selectively derived from young donors. 
This is important because MSC number and functionality have been shown to decrease with 
age. Indeed, MSCs derived from older donors showed longer population doubling times, less 
proliferation and a decrease capacity for osteoblast differentiation 62. 
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Because of these disadvantages of autologous MSCs, several (even large multi-centre phase III) 
studies switch to “off the shelf ” allogeneic MSCs in diseases as GvHD, autoimmune diseases 
and vascular diseases 63. The basis of this switch to use allogenic MSCs for clinical application is 
the assumption that MSCs do not express HLA class II molecules and costimulatory molecules 
and have such immunosuppressive properties that they can avoid immune responses entirely, 
thereby avoiding rejection of the cells. Whether this assumption is based on enough data is 
extensively reviewed elsewhere 64. While multiple patients have received allogeneic MSCs in 
several clinical trials without adverse events related to anti donor immune response, suggesting 
that no acute immune mediated complications occur, it should be noticed that these were not 
immune compromised patients such as transplant recipients. At the same time preclinical 
literature is suggesting that allogeneic MSCs, because they do express HLA class I molecules, can 
give rise to donor specific T cell and antibody responses. In transplantation there are conflicting 
preclinical results regarding allogeneic MSCs. Some preclinical studies showed an accelerated 
graft rejection after allogeneic MSC administration 65,66 while others showed that allogeneic 
MSCs can work synergistically with immunosuppressive drugs and promote graft survival 16,34,40. 
Within the transplantation setting only one clinical study investigated allogeneic, donor derived 
MSCs 50, however, unfortunately the authors did not look into whether HLA specific antibodies 
were produced. 
In transplantation, the use of specific criteria when applying allogeneic MSCs may minimize the 
risk of sensitization, these include no sharing of HLA type between MSCs and the kidney donor, 
and absence of antibodies of the recipient to the MSCs. In addition, immune responses and 
incidence of allograft rejection, which could be elicited by allogeneic MSCs should be accurately 
monitored during the course of the study 64. These assays should include the development of 
donor specific HLA antibodies (DSA). Alloantibody assays of serum represent a relative simple 
and highly sensitive means to examine immunogenicity of allogeneic cells and are used routinely 
in clinical transplant practice to avoid potentially catastrophic antibody-mediated rejection. The 
importance of these de novo HLA specific DSA as a major cause of allograft failure in the long 
term has recently been confirmed in numerous studies 67,68. In most studies, the incidence of 
these de novo DSA is below 15% 68. Recently, it was shown that DSA with the ability to activate 
complement, as determined by this novel C1q assay, are associated with greater risk of acute 
rejection and allograft loss 69. Indeed, assessment of the complement-binding capacity of donor-
specific anti-HLA antibodies appears to be useful in identifying patients at high risk for kidney 
allograft loss.
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4] MSCs derived from patients with renal disease
As most trials use autologous MSCs, differences in donors can give rise to variations in MSC 
behavior. 
As the first studies with MSCs have been performed with autologous MSCs the question whether 
kidney function influences the quality and the potency of the MSCs had to be addressed. 
We showed that bmMSCs derived from ESRD patients have similar growth potential, 
characteristics and immunomodulatory potential compared to bmMSCs from healthy controls 
70. This was also reported for human ASCs from patients with renal disease 71. Others however, 
showed that exposure to uremic serum gave functional incompetence of murine MSCs 72 and 
an osteoblast like phenotype in human bmMSCs 73. Both studies, however, exposed MSCs from 
healthy donors to uremic conditions and not MSCs derived from renal disease patients. In the 
latter, at least for ASCs, no effect of exposure to uremic serum was seen 71.
5] Timing, dosage, route and frequency of administration of MSC infusion 
Besides differences in MSC isolation and expansion techniques, there is also variation in timing, 
dosage, route and frequency of administration between different trials. Which factors are 
important still largely remains to be elucidated.
That these factors can be important is illustrated by looking at the timing of MSC infusion. In a 
mouse model of graft versus host disease (GvHD), MSCs were most effective when administered 
after the onset of disease and had no protective effect when administered at the day of bone 
marrow transplantation, suggesting a pro-inflammatory environment is necessary for MSCs to 
polarize into an anti-inflammatory phenotype 17. In contrast, in kidney transplantation, both the 
preclinical studies as the two clinical trials of Casaraghi and Perico et al. showed a decrease in 
kidney function when MSCs were administered within a week post transplantation (therefore 
still in a pro-inflammatory environment after surgery) while this was not seen when MSCs were 
infused one day prior to transplantation 33,45,46. 
Next to the timing also the cell dose should be addressed. In GvHD patients, doses of 0.4x106 
to 9 x106BM MSC per kg body weight have been tested 74. Doses from 0.8 x 106 were effective, 
but no clear dose-dependent effect was obtained. In patients that underwent myeloablation, 
infusion of 1x106 and 2.2x106 MSC per kg body weight showed no toxic effects 75. Trials in 
Crohn’s disease patients are currently testing doses of 2 x 106 and 8 x 106 bmMSCs per kg body 
weight, or amounts of 600x106 and 1200x106 MSC per patient 76. In the POSEIDON trial the 
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effects of both autologous and allogeneic MSCs were tested in ischemic cardiomyopathy, three 
different doses were evaluated (resp. 20, 100 and 200x106 cells). Interestingly, although all doses 
improved cardiac function and quality of life, the lowest dose of 20 x106 was more effective 
than the highest dose of 200 x106 77. Of note, as this differs from previous swine studies where 
the higher dose was more potent, this emphasizes the differences between animal models and 
humans and the drawback of translating animal data into clinical trials78. 
Doses of MSC in renal transplantation so far have chosen above what is considered the minimal 
effective dose, and below a potential toxic dose. Doses of 0.7-2 million cells/kg per infusion 
were feasible and suggestive for immunosuppression 49. In particular within the transplantation 
setting dose finding is of importance as, comparable to other immunosuppressant therapies, a 
balance between immune suppression to avoid rejection and over immune suppression resulting 
in opportunistic infections and a higher risk of malignancies has to be found. 
Most trials in kidney transplantation up till now have used intravenous administration of 
cells. In the study of Peng et al. they investigated the direct administration of MSCs within the 
renal artery, but as the group size is small and donor derived MSCs are delivered as opposed 
to the autologous MSCs in the other trials, it is not possible to draw conclusions about which 
route of delivery is more potent 50. Next to injection of MSCs into the vasculature, MSCs could 
also be directly injected into the kidney or underneath the kidney capsula, in line with the 
intramyocardial and transendocardial delivery for cardiac diseases. However, even in cardiac 
diseases it still remains to be elucidated which method is favorable as there are only a few studies 
comparing different routes of administration and the results are conflicting 79. 
In addition, the frequency of MSC injections is something which should be addressed. 
Interestingly, in children with steroid resistant graft versus host disease a long lasting response 
was hardly observed in patients who received one infusion, while most responders had 2 or 
more infusions 80. Whether multiple infusions are also necessary in the transplantation setting 
still needs to be further investigated. The studies currently published all use one to two infusions 
and the time in between these infusions also varies between studies (fig 2). However, as group 
sizes are small and protocols differ, it is also difficult to draw conclusions about the frequency 
of MSC therapy. 
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6] Potential risks
The potent progenitor as well as the immunomodulatory characteristics of MSCs carry inherent 
safety risks, including too much immune suppression, tumorigenicity and ectopic tissue 
formation as reviewed elsewhere 53. 
As MSCs are particularly known for their immune suppressive functions a logic side effect of MSC 
therapy would be over immune suppression. This could also be seen in our phase I trial, where 3 
out of 6 patients developed opportunistic virus infections after MSC infusions that are typically 
associated with too much immune suppression. These included BK nephropathy, primary 
CMV infection more than 6 months after valganciclovir prophylaxis had been discontinued, 
and one concerned a CMV reactivation. Of note, in none of the patients that received MSCs 
regular immune suppression was lowered when the MSCs were given, as they all had signs of 
rejection or IFTA in the biopsy 49. In contrast, in the trial of Tan et al. the investigators observed a 
reduction of opportunistic infections after MSCs therapy. However, CMV donor recipient status 
was negative in 151 of 154 patients, probably explaining the low incidence of CMV infections in 
their population 47.
As MSCs can also exhibit a pro-inflammatory phenotype it is of importance to monitor the safety 
and immune function of MSCs prior to transplantation. Therefore the ISCT-MSC committee 
has recently proposed standardized methodology and immune assays for MSC isolation and 
verification of immune suppressive function prior to transplantation with the aim to achieve 
safe, comparable and unambiguous results on MSC efficacy in clinical trials81. Allogeneic MSCs 
have the highest risk of immunogenicity 64 and anti-donor responses should be monitored 
accurately as reviewed above. 
There has been initial concern with respect to the risk of malignant transformation during 
the expansion period. More recently, genetic features of MSCs expanded with fetal calf serum 
(FCS) or with platelet lysates (PL) were tested in 4 cell-therapy facilities during 2 multicenter 
clinical trials. In this study, some transient and donor-dependent recurring aneuploidy was 
detected in vitro, independently of the culture process. However, MSCs with or without 
chromosomal alterations showed progressive growth arrest and entered senescence without 
evidence of transformation either in vitro or during a 8 week follow up after infusion in immune 
compromised mice 82. There is also the risk that genetically normal MSCs may promote the 
growth of pre-existing tumors. MSCs can be targeted to the tumor by soluble factors such as 
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stromal cell-derived factor 1 (SDF-1), platelet derived growth factor a (PDGF-a) and VEGF and 
may be conditioned into tumor-resident MSCs, which can promote tumor growth via e.g. CCL2, 
thereby recruiting immunosuppressive macrophages17. 
The immune suppressive properties may also decrease immune surveillance of tumors. This is of 
particular importance in transplant recipients, who, due to the use of immune suppressive drugs 
already have an increased risk in developing malignancies. Therefore it will be hard to link the 
development of carcinomas to the use of MSC therapy in transplant recipients. It is clear that 
long term follow up should be performed in MSC treated patients and one should discuss the 
extent of screening protocols which should be applied before MSC infusions.
Early study design: small cohorts of patients or large clinical studies 
Uncertainties regarding the above mentioned issues raise the question what study design is 
most suitable in this first phase of clinical trials with MSC therapy and cell therapy in general. 
Randomized controlled trials (RCT), although they are considered the most powerful trial set 
up, are not designed to pick up signals that infringe patient safety and require large amounts 
of patients, making them less suitable for addressing safety considerations and optimizing 
treatments in the first stages of clinical trials. Another disadvantage of RCTs is the high risks of 
failure in relationship to the costs, particularly in the setting of cell therapy. One therefore has 
to consider study designs that harbor adaptive features i.e., changes in design or analyses guided 
by examination of the accumulated data at interim points so that studies can be more efficient, 
prevent unnecessary exposure to risk and are more informative (e.g., by providing broader 
dose-response information)(figure 3). In addition, one could consider establishing registries to 
follow up on the long term outcome of patients that have been included in MSC studies. Clearly, 
adaptations during the development program may alter trial conduct and consequently result 
in a biased assessment of the treatment effect. An Independent Data Monitoring Committee 
(IDMC) that has well described roles and responsibilities, and that is qualified in methodology 
therefore needs to be established for an objective and unbiased assessment of the treatment 
effect of the cell product under investigation.
A particular aspect of the clinical development of MSC therapy is that they are considered 
an Advanced Therapeutic Medicinal Product (ATMP). This implies that MSCs can only be 
administered in either one of 3 possible ways: within the setting of a research protocol, as a 
hospital exemption ( for a predefined small number of patients) or as a registered product 83. 
As MSCs are by definition a heterogeneous cell mixture that lack unique surface markers, this 
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implies that the actual fabrication process and not the cell type needs to qualify for a registered 
status. This would require either the development of randomized clinical trials for each 
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Figure 3. The pathway of cell therapy from preclinical research to clinical translation. The 
value of small animal models for the human situation is limited and therefore preclinical research 
should involve the use of human cells in humanized models (such as in transplantation setting a 
humanized skin graft model) for a proof of concept in a humanized situation. Clinical studies should 
start with small safety and feasibility studies and first continue with an adaptive study design in 
order to be able to address dose finding, delivery method and route and frequency of administration 
before starting large phase III trials. 
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Future perspectives of cell therapy in kidney transplantation
The focus of cell therapy for kidney transplantation has so far mainly been on MSC therapy. This, 
however is something which will probably change within the next couple of years as embryonic 
stem cells (ES) and in particular induced pluripotent stem cells (iPS) are interesting new sources 
for cell therapy. The NIH center for regenerative medicine recently awarded LONZA Walkersville 
inc. to generate induced pluripotent stem cells (iPS) under good manufacturing practice (cGMP) 
84 . Combining this with the recent exciting results showing that iPS cells can be directed to 
differentiate into ureteric bud commited progenitor cells 85 and that embryonic stem cells can 
be directed to both ureteric bud and metanephric mesenchyme, the two main compartments in 
nephrogenesis 86, gives a new perspective on stem cell therapy in kidney diseases. Either patient 
derived iPS or iPS derived from an HLA matched databank can be programmed towards kidney 
progenitor cells and administered as cellular therapy. Whether these cells are safe and potent for 
tissue repair of course still needs to be addressed, however this new field looks promising. 
Another new interesting field is the use of genetically engineered MSCs as a vehicle to deliver 
cytokines directly into the microenvironment. Here MSCs are transformed with therapeutic 
genes. For example in Huntington disease this technique is described to deliver brain derived 
neurotrophic factor and in a rat model of myocardial infarction a novel transfection method 
of MSCs to overexpress hypoxia inducible VEGF is described 87,88. It would be interesting to 
see whether genetically engineered MSCs overexpressing for example anti-inflammatory and 
anti-fibrotic cytokines and growth factors will enhance kidney repair more potent compared to 
unmodified MSCs. 
Concluding remarks
As MSCs can be both anti-inflammatory and anti-fibrotic, they are of particular interest as a 
new therapy in kidney disease and organ transplantation. Indeed, in several preclinical models 
of kidney disease and transplantation, MSC therapy showed a beneficial effect on renal function 
and graft survival. In some models even a state of tolerance was induced. The first clinical studies 
with MSC therapy in kidney transplantation showed that MSC therapy is safe and feasible and 
the first results are promising. However, there are still a lot of questions to be addressed regarding 
optimal timing, dosage, timing and frequency of infusions. In particular because preclinical 
data suggest that when MSCs are injected in an anti- or suboptimal inflammatory environment 
they might not only be less effective but may also exhibit a pro-inflammatory phenotype and 
therefore may even work counteractive. These are important considerations for setting up new 
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clinical trials and we therefore recommend to use an adaptive study design for clinical trials with 
(mesenchymal stromal) cell therapy. In this manner, trials will be safer, more efficient and more 
informative. 
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Abstract
Mesenchymal stromal cells (MSCs) are immunomodulatory and tissue homeostatic cells 
that have shown beneficial effects in kidney diseases and transplantation. Perivascular 
stromal cells (PSCs) identified within several different organs share characteristics of bone 
marrow derived MSC (bmMSCs). These PSCs may also possess tissue-specific properties 
and play a role in local tissue homeostasis. We hypothesised that human kidney-derived 
PSCs (hkPSCs) would elicit improved kidney repair compared to bmMSCs. Here we 
introduce a novel, clinical grade isolation method of hkPSCs from cadaveric kidneys 
by enriching for the perivascular marker, NG2. hkPSCs show strong transcriptional 
similarities to bmMSCs, but also show organotypic expression signatures, including 
the HoxD10 and HoxD11 nephrogenic transcription factors. Comparable to bmMSCs, 
hkPSCs showed immunosuppressive potential and, when co-cultured with endothelial 
cells, vascular plexus formation was supported which was specifically in the hkPSCs 
accompanied by an increased NG2 expression. hkPSCs did not undergo myofibroblast 
transformation after exposure to TGFβ, further corroborating their potential regulatory 
role in tissue homeostasis. This was further supported by the observation that hkPSCs 
induced accelerated repair in a tubular epithelial wound scratch assay which was 
mediated through HGF release. In vivo, in a neonatal kidney injection model, hkPSCs 
re-integrated and survived in the interstitial compartment, while bmMSCs did not show 
this potential. Moreover, hkPSCs gave protection against the development of acute 
kidney injury in vivo in a model of rhabdomyolysis mediated nephrotoxicity. Overall, this 
suggests a superior therapeutic potential for the use of hkPSCs and/or their secretome in 
the treatment of kidney diseases.
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Introduction
Mesenchymal stromal cells (MSCs) are immune modulatory and anti-fibrotic cells originally 
isolated from the bone marrow (bmMSCs) and are characterized by their spindle shaped 
morphology and ability to adhere to plastic. bmMSCs are able to differentiate into fat, bone and 
cartilage and express the stromal markers CD73, CD90 and CD105 while being negative for 
CD34 and CD45.1,2 In several experimental models of kidney disease (among others cisplatin, 
glycerol and ischemia-induced injury), MSC treatment enhanced tissue repair and reduced 
fibrosis.3,4 In a transplantation model, MSC therapy could prolong graft survival and a regulatory 
T-cell dependent tolerance was observed.5 These promising results led to the first clinical trials 
with bmMSCs in renal transplantation. Although the group sizes were small and the studies 
were mainly set up to show safety and feasibility of MSC therapy, the first results suggest an 
immunomodulatory effect of bmMSC therapy.6-9
Previously it has been shown that perivascular stromal cells with characteristics similar to 
bmMSCs exist within many different solid organs, including skeletal muscle, pancreas, adipose 
tissue and placenta.10 Due to the perivascular location of these cells, close interaction is possible 
with several cell types, including endothelial cells, epithelial cells, resident macrophages, 
dendritic cells and recruited inflammatory cells. Therefore, these cells are most likely important 
for tissue homeostasis and control of repair processes and inflammation.11
MSC-like cells could also be isolated from murine kidneys based on Sca-1 expression. These 
renal Sca1+Lin-CD45- cells showed a unique phenotype and immunomodulatory potential.12-14 
Murine kidney colony forming cells (kCFU-F) were also Sca-1+ and although these kCFU-F 
have a comparable stromal marker expression and trilineage differentiation potential compared 
to bmMSCs, there is a distinct gene and protein expression profile.15 This suggests that although 
kCFU-F and bmMSCs may look similar, functionally there may be differences. Li et al. showed 
that these cells are indeed different from bmMSCs. In particular the cell fraction isolated based on 
expression of HoxB7, a collecting duct marker, was able to undergo epithelial-to-mesenchymal 
transition and upon delivery into neonatal mice kidneys these cells integrated back into the 
collecting duct while bmMSCs lacked this capacity.16
We hypothesized that perivascular stromal cells can also be isolated from the human kidney 
(hkPSCs) in a clinical grade manner and that these cells have tissue-specific functions. Extensive 
characterization of hkPSCs, both in vitro and in vivo, show a capacity for these cells to stabilize 
endothelial cells, reduce renal injury and support tubular repair. The latter to a greater extent 
than bmMSCs, suggesting indeed organotypic properties.
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Materials and Methods
Isolation and expansion of clinical grade human kidney derived perivascular stromal cells
Cells were isolated from human transplant grade kidneys discarded for surgical reasons using 
clinical grade protocols, enzymes and products. For all kidneys a research consent was given and 
the study was approved by the local medical ethical committee and the ethical advisory board 
of the consortium.
Kidneys were flushed with UW cold storage solution (Bridge to life, Elkhorn, Wisconsin, US)) 
containing heparin (Leo Pharma, Ballerup, Denmark) directly after surgery and stored on 
ice. Within 30 hours kidneys were flushed again with UW and the perirenal fat and kidney 
capsule were removed. The renal artery was cannulated and the kidney was perfused via a pump 
driven (Masterflex Applikon, Schiedam, the Netherlands) recirculation system at 37 degrees 
with DMEM-F12 (Lonza) at 300ml/min. . Afterwards the kidney was perfused with collagenase 
(2500 units, NB1, Serva) and DNAse (2,5 ml Pulmozyme, Genentech) at 37°C with a flow of 
300ml/min. After approximately 30 minutes, the tissue was digested and after gentle massage 
the resulting cell suspension was collected and washed in DMEM-F12 containing 10% fetal calf 
serum. Cells were then either directly put into culture or frozen in liquid nitrogen. The complete 
standard operation procedure (SOP) for the isolation procedure can be found in Supplementary 
file 1.
Kidney cell suspensions were cultured in alphaMEM (Lonza, Verviers, Belgium) containing 5% 
platelet lysates, glutamine (Lonza, Basel, Switzerland) and penicillin/streptomyzine (Lonza) and 
cells were cultured in tissue culture flasks until confluency was reached. At passage 1 cells were 
trypsinized and NG2 cell enrichment was performed using MACS according to manufacturer’s 
protocol (Miltenyi Biotech, Gladbach, Germany). The NG2 positive fraction was cultured in 
aMEM containing 5% platelet lysate. The cultures were maintained at 37°C and 5% carbon 
dioxide. Half of the medium was refreshed twice a week. When the cells reached confluence, 
the cells were collected using trypsin (Lonza) and re-plated at 4 x103 cells/cm2. Experiments 
were performed with FACS confirmed homogeneous NG2 positive hkPSCs between passages 
4-8 cultured in aMEM 5% platelet lysate unless stated differently.
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Isolation and expansion of human bone marrow derived mesenchymal stromal cells
Ethical committee approval and written consent from the donors was obtained for the aspiration 
of human bone marrow. Heparinized bone marrow was aspirated under local or general 
anesthesia. The mononucleated cell fraction was isolated by Ficoll density gradient separation 
and plated in tissue culture flasks at a density of 160 x103 mononucleated cells/cm2 in alphaMEM 
(Lonza) supplemented with penicillin/ streptomycin (Lonza) and 5% platelet lysate. The cultures 
were maintained at 37°C, 5% carbon dioxide. Half of the medium was refreshed twice a week. 
When the MSC colonies or cultures reached confluence, the cells were collected using trypsin 
(Lonza) and re-plated at 4 x103 cells/cm2. Experiments were performed between passages 4-8.
Morphology and immunophenotype analysis
The expanded cell populations were characterized by morphology (spindle shaped cells) which 
was imaged with an inverted bright-field microscope (Leica DFC 295). For immunophenotyping, 
the cells were stained for NG2, PDGFR-β, CD146, CD73, CD90, CD105, CD31, CD34, CD45, 
CD56, HLA class I (ABC) and HLA class II (DR). All specific fluorochrome-labeled antibodies 
and isotype controls were purchased from BD Bioscience (BD Bioscience, Franklin Lakes, NJ, 
USA) except for CD105 (Ancell Corporation, Bayport, MN, USA).
Microarray sample preparation and data analysis
RNA was isolated from biological triplicates using Trizol reagent (Life Technologies, Bleiswijk, the 
Netherlands) and the RNeasy kit (Qiagen, Heidelberg, Germany) according to the manufacturer’s 
protocol. The quality and quantity of RNA was assessed using a Nanodrop spectrophotometer 
(Nanodrop Technologies, Wesington, USA) and a Bioanalyzer (Agilent Technologies, Santa 
Clara USA). Gene expression profiling was performed by Aros Applied Biotechnology (Aarhus, 
Denmark). cDNA and cRNA synthesis, labeling and subsequent hybridization on the Human 
HT12 V4 Gene Expression Beadchips (Illumina Inc., San Diego, USA) were performed according 
to manufacturer’s protocols. The beadchips, targeting more than 47000 gene transcripts, were 
scanned using iSCAN system (Illumina Inc., San Diego, USA) and fluorescence intensities 
were uploaded into GenomeStudio Software (Illumina Inc, San Diego, USA) Genes with a 
detection p-value of >0.05 for all samples were excluded. Average signals>200 in either the 
bmMSCs or hKPSCs were considered above background levels. Subsequent data was quantile 
normalized and the Pearsons correlation coefficient was calculated (r2). Differential expression 
was analyzed using the gene expression module of Genome Studio (Illumina). For the table of 
the top differential expressed genes, genes were sorted on highest diff. score . False discovery 
rates (FDR) were calculated according to Benjamini and Hochberg for a total number of 8462 
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transcripts. All genes in the top 5 up- and down-regulated genes showed significant differential 
expression. For the heatmap in Fig. 3A the delta average signal of bmMSCs vs hkPSCs was set 
to 200 (which is the threshold of the measurement) and 2600 genes selected were analysed for 
clustering in R software. Clustering in R software was also performed for 27 homeobox genes. 
Expression of HoxD10 and HoxD11 was confirmed by Quantitative real-time polymerase 
chain reaction (QPCR) in duplo of the same biological triplicates. QPCR was performed using 
iQ SYBR Green Supermix on iCycler realtime detection system (BioRad, Veenendaal, the 
Netherlands) as per the manufacturer’s instructions. The real-time PCR primers of HoxD10 are 
AGACAGTTGGACAGATCCGAA(fw) and CGAAATGAGTTTGTTGCGCTTAT (rv) and of 
HoxD11 TCGACCAGTTCTACGAGGCA (fw), and AAAAACTCGCGTTCCAGTTCG (rev). 
The amplification reaction volume was 12.5 µL in total, consisting of 6.25 µL iQ SYBR Green 
PCR master mix, 0.5 µL primers, 2.5 µL cDNA and 3.25 µL water. Messenger RNA (mRNA) 
level was normalized to the housekeeping gene glycerine aldehyde-3-phosphate dehydrogenase 
(GAPDH).
Tri-lineage differentiation potential
hkPSCs and bmMSCs were cultured in adipogenic, osteogenic and chondrogenic medium 
according to the manufactures protocols (Lonza). After 3 weeks of culture, in the adipogenic 
differentiation assay lipid droplets were stained using Oil Red O and in the osteogenic 
differentiation assay calcium depositions were stained with Alizarin Red. For chondrogenic 
differentiation cell pellets were formalin-fixed (4% PFA O/N) and embedded in paraffin. 
Subsequently 5 µm sections were de-paraffinized, rehydrated and stained with 1% toluidine blue 
for 20 min. All differentiation assays were analysed with an inverted bright-field microscope 
(Leica DFC 295).
Cytokine excretion, peripheral blood mononuclear cell isolation and proliferation assay
hkPSCs and bmMSCs of 3 different donors were plated in flat-bottom 96-well plates and after 5 
days of culture supernatants were harvested and cytokine expression profiles were determined in 
the supernatant with the Bio-Plex Human Cytokine 17-Plex Panel following the manufacturer’s 
instructions (Bio-Rad Laboratories, Veenendaal, the Netherlands). Cytokines in culture medium 
were also measured as a negative control.
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy blood 
donors by density gradient centrifugation using Ficoll-isopaque and frozen in liquid nitrogen 
until use. Cultured hkPSCs and bmMSCs (passage 6-8) of 3 different donors were plated in flat-
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bottom 96-well plates (Costar, Sigma-Aldrich) and allowed to attach overnight in DMEM-F12 
with 10% normal human serum (NHS). Culture in 10% NHS was chosen as platelet lysates are 
able to suppress PBMC proliferation on their own (data not shown). PBMCs were stimulated with 
anti-CD3/antiCD28 Dynabeads (Invitrogen) and were seeded in triplicate at a concentration 
of 1x105 cells/well. Stromal cells were added to the PBMC proliferation assay in a ratio of 1:4 
and 1:8. After 5 days 3H-thymidine (0.5 mCi) was added and after 16 hours 3H-thymidine 
incorporation was determined as a measure of proliferation.
Vascular plexus assay
Human umbilical cords were obtained from the Leiden University Medical Center (Leiden, The 
Netherlands) after informed consent from the parents.
Human umbilical vein endothelial cells (HUVECs) were isolated according to Jaffe et al17, 
with minor modifications: trypsin/EDTA (Sigma/Aldrich, Steinheim, Germany) was used to 
enzymatically detach the endothelial cells from the vein and the endothelial cells were cultured 
on fibronectin-coated flasks (isolated from bovine plasma; Sigma/ Aldrich) and refreshed twice 
a week with EC-medium consisting of M199 Earl’s salt with L-glutamine (Invitrogen, Carlsbad, 
US), supplemented with 10% (v/v) fetal calf serum (PAA Cell Culture Company), pen/strep 
(PAA Cell Culture Company, Pasching, Germany) 1000 IU of heparin (Leo Pharma, Ballerup, 
Denmark) and 25 mg bovine pituitary extract (BPE) (Invitrogen). HUVECs were used at passage 
2-3.17
Stromal cells and HUVECS were cocultured in a 96-wells plate (Costar, Sigma-Aldrich) for 
1 week in a 4:1 ratio as described previously.18 After 1 week cells were fixated for 10 minutes 
with ice-cold methanol (100%) and endothelial sprouting was visualized with CD31 immune 
fluorescence (BD Bioscience, Franklin Lakes, NJ, USA, Zeiss LSM500). The percentage capillary 
coverage was analyzed with imageJ software. NG2 immunofluorescence (BD Bioscience) was 
determined (Zeiss LSM500) and quantified as mean fluorescent intensity in image J.
TGF-β stimulation
hkPSCs and bmMSCs were seeded in a density of 200.000 cells in a 6 wells plate and 
stimulated for 48hours with 10 ng/ml TGF-β1 (preprotech, London, United Kingdom). Cells 
were subsequently trypsinized, permeabilized with 0.1% saponine and labeled with α-SMA 
(BD Bioscience). α-SMA expression was analyzed with flow cytometry and mean fluorescent 
intensities were calculated (Kaluza, Beckman Coulter, Indianapolis, USA).
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Kidney epithelial wound scratch assay
hkPSCs and bmMSCs of 3 different donors were plated in a density of 200.000 cells/well in a 
6 well culture plate (Costar, Sigma-Aldrich) and cultured for 48 hours. HK2 cells were seeded 
in PTEC medium consisting of a 1:1 ratio of Dulbecco’s modified Eagle’s medium and Ham’s 
F-12 (Lonza) supplemented with insulin (5µg/ml), transferrin (5µg/ml), selenium (5ng/ml), 
hydrocortisone (36 ng/ml), tr-iodothyrinine (40 pg/ml) and epidermal growth factor (10 ng/
ml) (Sigma-Aldrich) in a density of 500.000 cells/well in a 6 wells cell culture plate (Costar) 
and cultured until confluent. A scratch wound was created in the monolayer of HK2 cells using 
a 200µl pipette tip. After the scratch, cells were washed with PBS and provided either with 
fresh medium (aMEM 5% PL) or with complete conditioned medium from either hkPSCs or 
bmMSCs. Scratched were imaged at 4, 7, 14 and 28 hours at the same position in duplicateswith 
an inverted bright-field microscope (Leica DFC 295). The scratch area was measured at each 
time point using ImageJ software and the percentage wound closure was calculated.
Growth factors in the conditioned medium of kPSCs were measured using a custom made 
growth factor panel following manufacturer’s instruction. (R&D systems, Minneapolis, USA). 
The HGF-receptor was blocked with an HGF receptor/c-MET antibody (R&D systems) in a 
concentration of 1 µg/ml 1 hour prior to the wound scratch assay and after adding the hkPSC 
supernatant. In the control conditions an isotype antibody (goat IgG, homemade) was added.
Neonatal injection model
Animal experiments were approved by the University of Queensland Animal Ethics Committee 
and adhered to the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes. Neonates of outbred CD1 mice were used for neonatal injection. hkPSCs and 
bmMSCs of resp. 3 and 2 different donors were injected into the neonatal kidneys at postnatal 
day 1 (PND1) using a microinjection pipet in a protocol adapted from the protocol previously 
described 16. In short, neonates were anesthetized and a small incision in the skin was made. 
Cells were re-suspended in PBS and mixed with Fluoresbrite Yellow Green microspheres (2.0 
µm; Polyscience) in a ratio of 1:50 for identification of injection sites in the neonatal kidney. 
Using a Eppendorf microinjector, cells were injected into the kidney through the muscle layer in 
a volume of 300nl, corresponding with 3000-5000 cells. Kidneys were harvested at 4 days post-
injection. In total 7 mice were analyzed; 3 mice with hkPSCs from 3 different donors; 3 mice 
with bmMSCs from 2 different donors and 1 sham operated mouse. In all mice, injection into 
the kidney was confirmed by fluorescence of the co-injected microspheres.
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Glycerol-induced rhabdomyolysis model of acute kidney injury
Animal experiments were performed in accordance with institutional, regional, and state 
guidelines and in adherence with the Italian National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. Rhabdomyolysis-induced acute kidney injury was studied in 
6-week-old male C57Bl/6 mice ((Envigo RMS Srl, San Pietro al Natisone, Italy) by intramuscular 
injection on day 0 with hypertonic glycerol (8 ml/kg body weight of a 50% glycerol solution; 
Sigma-Aldrich) into the inferior hind limbs as described previously.19 hkPSCs were labeled 
with the PKH26 Red Fluorescence Cell Linker Kit (Sigma-Aldrich) according to manufacturer’s 
instructions, and labeling efficiency was verified by flow cytometry. Cells were acquired 
before and after labeling using a MACSQuant Analyzer Flow Cytometer and analyzed with 
MACSQuantify software (Miltenyi Biotec GmbH, Bergish Gladbach, Germany). Cell vitality 
was monitored using propidium iodide staining and we observed >95% living cells. The mice 
received PKH26-labelled hkPSC following one of two injection routes. Subcapsular injection: 
Four hours following kidney injury, mice (n=6 for BUN measurement, n=4 for confocal 
microscopy) were anesthetized with Avertin (2,2,2-Tribromoethanol, 250mg/kg, Sigma-
Aldrich) and subjected to dorsal incision on the left side to exteriorize the left kidney. A 1-mm 
incision was made in the capsule of the kidney and 750,000 cells were injected in 25µl of sterile 
PBS using a Hamilton syringe equipped with a 27G blunt-ended needle. After cell infusion, the 
kidney capsule was cauterized with an electric scalpel, and the dorsal incision was sutured. The 
mouse was rehydrated with subcutaneous injection of 500ul saline solution and maintained in 
a warm environment for 2 hours post-surgery. Control mice were injected saline solution (n=6 
for BUN measurement, n=4 for confocal microscopy). Intravenous retro orbital injection: Four 
hours and 24 hours following kidney injury, mice (n=6 for BUN measurement, n=4 for confocal 
microscopy) were anesthetized with isoflurane (Aerrane, Baxter, Rome, Italy) and injected 
retroorbitally through the venous plexus with 750,000 cells in 150 µl of sterile PBS each time 
using a 27G needle. Control mice were injected saline solution (n=8 for BUN measurement, n=4 
for confocal microscopy).
Blood samples were obtained from the submandibular venous sinus at day 0, 4, 6 and 14, and 
blood urea nitrogen (BUN) levels were measured by Reflotron System (Roche Diagnostics, 
Rotkreuz, Switzerland). Four animals per group were sacrificed at day 6 and kidney, lungs and 
liver were harvested for confocal microscopy.
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Immunofluorescence of kidney sections
Neonatal injection model: kidney samples were fixed in 4% PFA followed by 30% sucrose 
overnight and embedded in TissueTek OCT compound (Sakura Finetek, Torrance, CA). 
Samples were frozen in liquid nitrogen and stored at -80°C. Ten micrometer thick sections were 
cut and post-fixed with 4% PFA for 10 minutes at room temperature. Stainings were performed 
using the manufacturer’s protocol (Mouse on Mouse (MOM) kit,Vector labs, Brunswig 
Chemie, Amsterdam, the Netherlands). Samples were stained with antibodies against human 
mitochondria, nuclei and collagen IV (Abcam, Cambridge, UK) and analysed using a TCS SP8 
laser confocal microscope (Leica, Eindhoven, the Netherlands). Rhabdomyolysis-induced acute 
kidney injury model: Confocal microscopy was performed on 10 μm sections of renal frozen 
tissues using a TCS SP5-II laser confocal microscope (Leica, Milan, Italy). Staining for FITC-
labeled Dolichos Biflorus Agglutinin (DBA) and FITC-labeled Lotus tetragonolobus agglutinin 
(LTA) (Vector laboratories, Burlingame, California) was performed following manufacturer's 
instructions. To-pro-3 (Invitrogen Carlsbad, CA, USA) was used for counterstaining nuclei.
Statistical analysis
Differences between two groups were analyzed using unpaired two-sample t test. When more 
than two groups were analysed a two way ANOVA test was used with as posthoc test the 
Bonferroni’s comparison test. Differences were considered statistically significant when p<0.05. 
Data analysis was performed using GraphPad Prism, version 5.0 (Graphpad Prism Software 
Inc. San Diego, USA). For statistical analysis of the microarray data p-values were corrected for 
multiple testing according to Benjamini and Hochberg.
Results
A novel method to isolate clinical grade human kidney-derived perivascular stromal cells 
(hkPSCs)
In order to evaluate whether hkPSCs are a potential new cell source for use in cell therapy 
to treat kidney disease in a clinical setting, we chose to develop a clinical grade acceptable 
standard operation procedure (SOP) with the use of clinical grade materials and enzymes. This 
protocol is developed based on the pancreatic islet isolation protocol currently in use for clinical 
application in our center.20 Perivascular stromal cells were isolated based on NG2 expression. 
NG2 is an integral membrane proteoglycan which is associated with perivascular cells during 
vascular morphogenesis.21 Within the human kidney, NG2 is mainly expressed around the large 
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arteries and the afferent and efferent arteriole (Fig 1a). NG2 expression is more restricted than 
the expression of CD271, an enrichment marker for bmMSCs 22 (Fig 1b) or PDGFR-β positive 
perivascular cells (Fig 1c). These markers are also expressed within the glomeruli and around 
the peritubular capillaries of the kidney. NG2 positive cells were isolated from a pool of ten 
transplant-grade kidneys discarded for surgical reasons. Experiments were performed and 
results are shown for three different donors. The average donor age was 62 years with an average 
estimated creatinine clearance (Cockroft) of 105 ml/min. In order to isolate NG2 positive cells, 
these kidneys were perfused with collagenase to dissociate into single cells, enriched based on 
plastic adherence then sorted based on NG2 expression at the first passage (Fig 1d).
Characterization of human kidney derived perivascular stromal cells
NG2 positive hkPSCs showed a bright field morphology similar to bmMSCs (Fig 2a) and, like 
bmMSCs, were positive for the pericyte markers NG2 and PDGFR-β as shown with confocal 
microscopy (Fig 2b). Growth characteristics are shown from flow cytometry confirmed NG2 
homogeneous populations, at around passage 9 hkPSCs reached senescence (Fig 2c). In addition 
to NG2 hkPSCs were positive for the surface markers PDGFR-β, CD146, CD73, CD90, CD105 
while being negative for CD31, CD34, CD45 and CD56, as determined by FACS (Fig 2d). This 
marker expression is robust as depicted by the mean fluorescent intensity (MFI) of cells of three 
different donors (Fig 2e). Whereas human bmMSCs were able to differentiate into all three 
lineages, hkPSCs could differentiate towards osteocyte and chondrocyte, while no adipogenic 
differentiation was observed (biological triplicates) (Fig 2f).
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Figure 1. Isolation method of human kPSCs. A) NG2 is expressed in the human kidney mainly 
around the arteries, arterioles and afferent and efferent arterioles of the glomerulus. CD271 (B) 
and PDGFR-β (C) are also expressed within the glomeruli and around the peritubular capillaries. 
D) Schematic representation of the isolation method. In order to obtain NG2 positive hkPSCs, 
human kidneys are continuously perfused with digestive enzymes to single kidney cells. Afterwards 
crude kidney cell suspensions were cultured on plastic for selection on plastic adherence and 
subsequently sorted for NG2 positivity resulting in the appearance of spindle shaped cells. Scale 
bars = 50 mm (A, left), 20 mm (A, right), and 50 mm(B, C). Abbreviations: kPSCs, kidney-derived 
perivascular stromal cells; PDGF-R-b, platelet-derived growth factor-receptor
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Figure 2. Characterization of human kPSCs. A) hkPSCs have a similar morphology compared to 
bmMSCs and are positive for NG2 and PDGFR-B as shown with confocal images (B). C) Growth 
characteristics of hkPSCs D) Representative FACS analysis show that hkPSCs are positive for 
the pericytic markers NG2, PDGFR-β and CD146 and the MSC markers CD73, CD90 and CD105 
while being negative for CD31, CD34, CD45, CD56. hkPSCs express type I HLA (HLA-ABC) and 
are negative for type II HLA (HLA-DR). E) Mean fluorescent intensity of the different markers (n=3 
donors.) F) Tri-lineage differentiation. hkPSCs differentiate into bone and cartilage but not into 
adipocytes. Scale bars = 200mm(A, F) and 20mm(B). Abbreviations:BM-MSC,bone marrow-derived 
mesenchymal stromal cells; FITC, fluorescein isothiocyanate; HLA,humanleukocyte antigen;kMSC, 
kPSC, kidney-derived perivascular stromal cells; PDGF-R-b, platelet-derived growth factor-receptor
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Organ specific gene expression profile of human kidney derived perivascular stromal 
cells
In order to further compare hkPSCs to bmMSCs, Illumina microarray expression profiling was 
performed on biological triplicates of different donors. Analysis of expression levels of 35000 
transcripts showed that most genes showed a similar expression level (Pearson correlation 
coefficient of 0,9625) suggesting high similarity between the two cell types (Fig 3a). However, 
2600 genes were differentially expressed and hierarchical clustering was able to distinguish 
based upon cell source (Fig 3b). Table 1 shows the top 5 up and down regulated genes comparing 
bmMSCs and hkPSCs based on differential p-value. The top 50 up and downregulated genes 
can be found in supplemental table 1. Interestingly, homeobox factor HoxD11 is in the top 5 
most upregulated genes in hkPSCs. Homeobox transcription factors, which are important in 
anatomical patterning during development, showed hierarchical clustering when comparing 
bmMSCs with hkPSCs (Fig 3c). Homeobox paralogues Hox10 and Hox11 are important in 
kidney development.23,24 Both genes are highly expressed in hkPSCs but not in bmMSCs, as 
confirmed by PCR (fig 3d). These results indicate that, although hkPSCs and bmMSCs may 
display a similar phenotype of surface markers, there are tissue specific differences in expression 
profile between the cell types.
Immunomodulatory capacity of human kidney-derived perivascular stromal cells
One important and extensively studied feature of MSCs is their anti-inflammatory and 
immunomodulatory potential. MSCs are able to regulate proliferation and cytotoxicity of T cells, 
macrophages and B-cells which are also major players in kidney disease and transplantation, as 
reviewed elsewhere.25 Therefore, we evaluated the immunomodulatory potential of hkPSCs in 
comparison to bmMSCs. Unstimulated human kPSCs and bmMSCs showed a similar expression 
profile for all major cytokines (Fig. 4a). We also evaluated the immunosuppressive capacity of 
hkPSCs. In a peripheral blood mononuclear cell (PBMC) suppression assay, where PBMCs were 
activated by polyclonal CD3/CD28 activation in the absence or presence of stromal cells, both 
hkPSCs and bmMSCs inhibited proliferation in a dose dependent manner (Fig 4b). However, 
bmMSCs were more potent in inhibiting proliferation at a lower cell ratio (8:1 PBMCs: MSC 
ratio) compared to hkPSCs.
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Figure 3. Transcriptome analysis of human kPSCs compared to bmMSCs. A) When comparing 
all transcripts (35000), bmMSCs and hkPSCs show a similar expression profile as depicted by a 
pearson correlation score of 0.9625. B) hkPSCs and bmMSCs show an hierarchical clustering per cell 
type. C) Hierarchical clustering is also observed in Hox genes. D) Differential expression of HoxD11 
and HoxD10, homeobox factors important for nephrogenesis, as confirmed by PCR. (GEO accession 
GSE77227, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77227) Abbreviations: BM-
MSC, bone marrow derived mesenchymal stromal cells; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; kPSC, kidney-derived perivascular stromal cells
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Co-culture of endothelial cells with human kidney-derived perivascular stromal cells 
stabilizes vascular network formation
To evaluate whether cultured hkPSCs still have pericytic properties, cells were co-cultured with 
human umbilical vein endothelial cells (HUVEC). HUVECs were not able to form endothelial 
sprouts in monoculture. However, when co-cultured with either bmMSCs or hkPSCs, vascular 
plexus formation occurred (Fig 4c). There were no significant differences in vascular network 
formation between the cell types (Fig 4d). Interestingly, when cocultured with endothelial cells, 
hkPSCs showed an increase in NG2 expression while this was not observed with bmMSCs (Fig 
4e,f). Both bmMSCs and hkPSCs mainly secreted Vascular Endothelial Growth Factor (VEGF) 
and there was no difference b etween the cell types in the levels of VEGF, angiopoetin 1  and 
angiopoetin 2 produced.(Fig 4g).
hkPSCs do not become myofybroblasts after stimulation with TGF-β
As stromal cells in general have the capacity to become myofibroblasts after st imulation with 
TGF-β, thereby contributing to fibrosis, w e evaluated whether hkPSCs have t his capacity. 
Interestingly, stimulation of hkPSCs with TGF-β did not increase α-SMA expression suggesting 
that hkPSCs did not become myofibroblasts (Fig 4 h,i).
Enhanced renal epithelial wound repair capacity of human kidney-derived perivascular 
stromal cells
In order to evaluate the effect of hkPSCs on renal tubular epitheliar repair, a scratch in a 
monolayer of human kidney proximal tubular epithelial cells (HK2) was made. Under control 
culture conditions, at least 28 hours was necessary for 80% wound closure. Interestingly, when 
conditioned media from hkPSCs was added, significant closure was already observed after 4 
hours with 80% of the wound closed after 7 hours (mean of duplicate experiments from three 
different donors). Importantly, 14 hours was required to reach an 80% wound closure in parallel 
experiments with the conditioned media from bmMSCs, (Fig 5a,b). This shows that hkPSCs can 
produce factors able to better support renal epithelial repair. HGF is most likely an important 
factor in this activity as HGF was secreted at high levels by hkPSCs but not by bmMSCs whereas 
no differences were observed in the levels of other growth factors (PDGF-AA, PDGF-BB, 
endothelin1, FGF-a, FGF-B) (Fig 5c). Moreover, blocking the HGF-receptor on the epithelial 
cells resulted in a decreased wound healing. (Fig 5d,e)

































































































































































































































100 101 102 103
100 101 102 103
d.leuning-layout.indd   64 22/05/2018   16:42
65Human kidney perivascular stromal cells for kidney regeration
3
Interstitial integration and survival of human kidney-derived perivascular stromal cells in 
the neonatal kidney
To determine the role of hkPSCs in kidney development, hkPSCs were injected into neonatal 
mice at postnatal day 1 using microinjection (Fig 6a,b). Interestingly, at day 4 post-injection, 
human kPSCS were able to integrate and survive within the cortical, but not the medullary 
interstitium of the mouse kidney with no evidence for rejection. (Fig. 6c). No such persistence 
was observed when human bmMSCs were injected (Fig 6d), consistent with our previous studies 
16 No integration into tubular structures was seen with either human bmMSCs or hkPSCs upon 
injection. The persistence of viable human hkPSCs for 4 days within the renal interstitium 
suggests a differential integration capacity for this stromal cell type.
Figure 4. Immunomodulatory and vascular stabilization function of hkPSCs A) Cytokine 
expression profile of unstimulated human kPSCs and bmMSCs B) PBMC suppression assay. 
Proliferation of activated peripheral blood mononuclear cells (PBMCs) was decreased when 
cocultured with both hkPSCs and bmMSCs in a dose dependent matter. (ratio is number of 
activated PBMCs vs number of MSCs) C) When HUVECs are cocultured with either hkPSCs and 
bmMSCs endothelial networks were formed, which was not observed in monoculture. There were 
no significant differences in vascular plexus formation comparing coculture with bmMSCs or 
hkPSCs (D). E) When hkPSCs were cocultured with endothelial cells the expression of NG2 was 
increase; this was not seen with bmMSCs. F) Quantification of NG2 positivity with and without 
coculture with endothelial cells. G) No differences were observed in excretion of vascular growth 
factors by hkPSCs compared to bmMSCs. H) After stimulation of hkPSCs with 10 ng/ml TGF-β 
there was no increase in α-SMA expression. This was not observed for bmMSCs. White: isotype 
control, red: unstimulated cells, green: cells stimulated with 10ng/ml TGF-β I)Quantification of 
α-SMA positivity. n=3 biological triplicates. *p<0.05, ** p<0.001, n.s. non-significant. Scale bar = 50 
mm (C, E). Abbreviations: Ang, angiopoietin; BM-MSC, bone marrow-derived mesenchymal stromal 
cells; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-
stimulating factor;HUVEC, human umbilical vein endothelial cells; IFN, interferon; IL, interleukin; 
kPSC, kidney-derived perivascular stromal cells; MIP-1, macrophage inflammatory protein 1; MCP-
1, monocyte chemoattractant protein 1; n.s., nonsignificant; PBMC, peripheral blood mononuclear 
cells; TGF, transforming growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial 
growth factor; w/o, without.
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Human kidney-derived perivascular stromal cells integrate in the renal interstitium and 
improve renal function in a glycerol-induced rhabdomyolysis acute kidney injury model
To access the effect of hkPSCs in kidney injury, we injected the cells in a glycerol-induced 
rhabdomyolysis acute kidney injury model. We evaluated the effect of hkPSCs via two routes 
of administration: renal subcapsular and intravenously. Blood Ureum Nitrogen (BUN) 
measurements show that, at the peak of acute kidney injury (AKI), renal function was significantly 
preserved in the hkPSC- treated group, independent of route of delivery (Fig 6 e,g). After both 
routes of delivery, interstitial integration of the PKH26-labelled hkPSCs was observed within 
the kidney, although less cells were observed after intravenous injection (0.0247±0.002 cells/
field subcapsular versus 0.0164±0.0051 cells/field i.v.). After subcapsular injection cells were 
mainly distributed in an area of 990µm around the area of injection. After intravenous injections 
cells most cells were observed in the medulla region and less in the cortex (0.0203±0.006 vs. 
0.0095±0.0066) (Fig 6 f,h).
Figure 5. hkPSCs are able to enhance epithelial repair in a wound scratch assay. A) Brightfield 
images showing representative images of the wound scratch assay in control medium or 
conditioned medium of hkPSCs and bmMSCs across a time period of 14 hours. B) Quantification 
of the rate of wound closure in all three conditions after 0, 4, 7, 14 and 28 hours. The wound 
closes significantly faster in the presence of hkPSC conditioned medium compared to bmMSC 
conditioned medium or control medium. C)Excretion of growth factors in the conditioned medium. 
HGF is excreted by hkPSCs but not by bmMSCs. D) Brightfield images showing representative 
images of the wound scratch assay with and without HGF-R blocking E) Quantification of the rate 
of wound closure after 0,4,7,12 and 24 hours. n=3 biological triplicates. * p<0.05, ** p<0.001, *** 
p<0.0001 Abbreviations: BM-MSC, bone marrow-derived mesenchymal stromal cell; FGF, fibroblast 
growth factor; HGF, hepatocyte growth factor; h, hour; kPSC, kidney-derived perivascular stromal 
cell; n.s., nonsignificant; PDGF, platelet-derived growth factor; t, time.
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Discussion
It has previously been reported that perivascular stromal cells from several different human organs 
share features with MSCs.10 More recently it has been shown that organ derived perivascular 
cells may exhibit tissue-specific functions.26 Human myocardial perivascular cells, for example, 
stimulate angiogenic responses under hypoxia and differentiate into cardiomyocytes in vivo; 
characteristics not seen in perivascular cells isolated from other tissues.27
Here we sought to isolate human kidney-derived perivascular stromal cells and show that these 
cells have distinct properties compared to human bmMSCs. In order to evaluate the functionality 
of these cells, their interaction with several different renal cell types, including endothelial cells, 
proximal tubular cells and (infiltrating) immune cells, was studied. There were similarities 
between human bmMSCs and hkPSCs, however, hkPSCs showed a distinct mRNA expression 
profile, did not differentiate into adipocytes and displayed a more potent kidney epithelial 
wound healing capacity. Futhermore, hkPSCs were able to integrate into the interstitium of the 
developing kidney, while bmMSCs did not. Finally, hkPSCs could preserve kidney function in a 
glycerol-induced rhabdomyolysis model of acute kidney injury.
Figure 6. hkPSCs are able to survive and integrate into the kidney interstitium in a neonatal 
injection method and in a model of AKI and gave preservation of renal function. A) Cells and 
fluorescent microspheres were injected into the kidney of neonatal mice (PND1). B) Injection into the 
kidney was confirmed by fluorescent microspheric beads (*). C) hkPSCs injected into the kidneys 
of neonatal mice (PND1) were localized in the cortical interstitium as shown with specific antibodies 
for human mitochondria and human nuclei respectively (arrows). D) No bmMSCs could be found in 
the kidney 4 days after injection. E) Blood Ureum Nitrogen (BUN) measurements after i.v. injection 
of hkPSCs in a glycerol-induced rhabdomyolysis model. F) hkPSCs were localized mainly in the 
interstium of the medulla after i.v. infusion and did not integrate in the LTA positive proximal tubuli 
or DBA positive collection duct. G) BUN after subcapsular administration of hkPSCs in a glycerol-
induced rhabdomyolysis model. H) hkPSCs integrated in the interstium in the cortex and not in the 
medulla. No integration in the tubuli was observed. Scale bars = 500 mm (B) and 50 mm (C, D, F, 
H). Abbreviations: BM-MSC, bone marrow-derived mesenchymal stromal cell;BUN, blood ureum 
nitrogen; kPSC, kidney-derived perivascular stromal cell.
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As there is a lack of specific markers of MSCs, the ISCT has proposed criteria to define MSC’s. 
These include plastic adherence, the marker expression of CD73, CD90 and CD105 while being 
negative for CD14, CD34 and CD45 and the capacity to differentiate into bone, cartilage and 
fat in vitro 1. The hkPSCs we isolated did not fulfill these criteria as there was no adipocyte 
differentiation. However, these criteria are based on bone marrow-derived MSCs and the lack 
of this capacity might actually be beneficial as it has previously been shown that MSCs injected 
into the renal artery in a glomerulonephritis model can turn into adipocytes in the glomeruli 
accompanied by glomerular sclerosis around these adipocytes.28
MSCs are important for tissue homeostasis most likely via the secretion of several soluble 
factors and microvesicles containing amongst others mRNAs and miRNAs.29,30 Indeed, bmMSC-
conditioned medium is able to accelerate wound healing in vitro.31,32 and in a mouse model of 
glycerol induced acute kidney injury, enhanced recovery in kidney function was observed when 
either MSCs or MSC-derived microvesicles were injected.29 The same is most likely true for 
organ-derived perivascular stromal cells. Conditioned medium from murine kidney MSC-like 
cells was able to enhance kidney epithelial wound healing in an in vitro wound scratch assay.16 
Here we show that the conditioned medium from human kPSCs elicited accelerated repair 
in a tubular epithelial wound scratch assay, suggesting tissue-specific paracrine signaling. An 
important factor in this signaling is most likely hepatic growth factor (HGF) as HGF is highly 
secreted by kPSCs and not by bmMSCs. Moreover, after blocking of the HGF-receptor the effect 
of hkPSCs on wound healing was diminished. HGF has long been recognized as an important 
factor in kidney regeneration and attenuation of renal fibrosisin several different animal 
models.33 HGF is primarily produced in non-epithelial cells, such as fibroblasts and pericytes, 
and is able to block myofibroblast activation and therefore renal fibrosis. Moreover, HGF can 
prevent tubular epithelial cell death both in vitro and in vivo, the latter resulting in improved 
renal function after acute kidney injury.34-36 HGF is most likely also important in human kidney 
regeneration as a high expression of HGF in protocol biopsies after kidney transplantation 
correlated with lower levels of fibrosis.37
While this study is not the first to describe an MSC-like population in the human kidney 38, 
hkPSCs isolated through the current protocol represent a distinct population. Resident kidney 
MSCs as described by Bruno et al. 38 were isolated from the glomeruli whereas the hkPSCs 
described in the current protocol were isolated based on NG2 expression. As NG2 is mainly 
expressed around the large vessels (fig 1a), this is more likely to represent a different perivascular 
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population. Another major difference is that hkPSCs are not positive for CD24, Pax2, Oct4 or 
NANOG (supplementary fig. 1) and are, in contrast to glomerular MSCs, not able to differentiate 
into adipocytes.
The differences between human kPSCs and bmMSCs mentioned above may reflect differences in 
imprinting by the tissue of origin. This was previously also observed for fibroblasts isolated from 
different organs.39 In the current study, the expression profile of homeobox genes, which are 
important for anatomical patterning, showed a differential upregulation of HoxD10 and HoxD11 
expression by hKPSC with the latter gene in the top 5 most differentially expressed genes. Both 
Hox10 and Hox11 are crucial for nephrogenesis. Hox10 genes function in the differentiation 
and integration of the FoxD1+ renal cortical stroma while Hox11 genes are expressed in the 
metanephric mesenchyme. Loss of either Hox10 or Hox11 gene function results in the loss 
of ureteric bud induction, reduced branching and decreased nephrogenesis; phenotypes only 
described for Hox10 and 11 mutants and not for other Hox mutants.23,24 This potential tissue 
‘memory of origin’ may be reflected in the observed differences in potential to integrate back 
into the kidney when injected into the renal parenchyma. Such integration was never observed 
for the bone marrow MSCs, while the hkPSCs migrated into the renal interstitium and survived. 
While we observed integration into the cortical interstitial compartment, we did not observe any 
integration into the epithelium. Previously, it was reported that murine kidney-derived MSC like 
cells can integrate into the developing collecting duct. However, the human kPSCs were isolated 
from the perivascular fraction based on NG2 expression, while Li. et al isolated murine MSC-
like cells based on HoxB7 expression and thus the collecting duct epithelial compartment16. 
When looking at the expression pattern of the homeobox factors, HoxB7 expression in the 
human kPSCs was low, while HoxD11 expression was high, suggesting a different origin likely 
reflected in their distinctt integration capacity and function. It remains possible that a human 
kidney MSC-like population similar to that isolated from mouse or reciprocally a murine kPSC 
population similar to the hkPSC described here may exist.
Interestingly, hkPSCs were able to integrate back into the renal interstitium and reduce the 
severity of kidney injury in vivo in a rhabdomyolysis model. This was independent of the 
route of delivery as both subcapsular and intravenous injected hkPSCs were able to preserve 
renal function. However, with the subcapsular injections integration of the hkPSCs into the 
interstitium appeared more pronounced as did the reno-protective effect.
Whether human kPSCs are more suitable for cell therapy for kidney diseases compared to 
bmMSCs, which are currently studied in clinical trials, still remains to be further elucidated. 
Their capacity to reintegrate into the renal stroma, to improve tubular epithelial wound repair 
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and to preserve function in an AKI model would suggest that hkPSCs may have an organotypic 
role in maintaining and restoring renal interstitial homeostasis without showing the risk of 
increasing fibrosis. To be able to compare these cell types for future cell therapy purposes we chose 
to isolate the hkPSCs with a standard operation procedure (SOP) in a clinical grade manner, 
with clinical grade enzymes, materials and methods which would allow direct translation into 
a clinical product. Using this protocol, large quantities of clinical grade isolated hkPSCs can 
be obtained. The yield from one human kidney would be an average of 2.7x1012 hkPSCs after 
passage 6. Hence, one donor kidney could yield sufficient number of hkPSCs for the treatment 
of several different patients as a cell therapy. This makes human kPSCs an interesting new cell 
source to develop for regenerative medicine for kidney diseases.
Conclusions
These data show that human kPSCs show distinct functional properties compared to bmMSCs 
with respect to growth factor excretion, interstitial integration and amelioration of kidney injury, 
suggesting significant potential for hkPSCs and/or their secretome as therapeutic candidates for 
the treatment of kidney disease.
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Abstract
Mesenchymal Stromal Cells (MSCs) are tissue homeostatic and immune modulatory cells 
that have shown beneficial effects in kidney diseases and transplantation. Perivascular 
Stromal Cells (PSCs) share characteristics with bone marrow MSCs (bmMSCs). However, 
they also possess, most likely due to local imprinting, tissue-specific properties and play 
a role in local tissue homeostasis. This tissue specificity may result in tissue specific 
repair, also within the human kidney. We previously showed that human kidney PSCs 
(kPSCs) have enhanced kidney epithelial wound healing whereas bmMSCs did not have 
this potential. Moreover, kPSCs can ameliorate kidney injury in vivo. Therefore, kPSCs 
constitute an interesting source for cell therapy, particularly for kidney diseases and renal 
transplantation. Here we show the detailed isolation and culture method for kPSCs from 
transplant-grade human kidneys based on whole-organ perfusion of digestive enzymes 
via the renal artery and enrichment for the perivascular marker NG2. In this way, large 
cell quantities can be obtained that are suitable for cellular therapy.
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Introduction
Mesenchymal Stromal Cells (MSCs) are immune modulatory cells that were originally isolated 
from the bone marrow. They are characterized by their spindle shaped morphology, ability to 
differentiate into fat, bone and cartilage, and plastic adherence. MSCs express the stromal markers 
CD73, CD90, CD105 while being negative for the markers CD31 and CD451,2,3. MSCs are a 
promising candidate for cell therapy due to their tissue homeostatic and immunomodulatory 
capacities. bmMSCs are currently being studied in clinical trials for several diseases, including 
kidney diseases and kidney transplantation as reviewed elsewhere4.
Previously it was shown that perivascular cells from several different solid organs, including 
adipose tissue, placenta and skeletal muscle share characteristics with MSCs9. However, these 
cells also exhibit tissue-specific functions which can result in organotypic repair10. Human 
myocardial perivascular cells, for example, stimulated angiogenic responses after hypoxia and 
differentiated into cardiomyocytes, while perivascular cells isolated from other tissues did not 
show these potentials11.
Perivascular stromal cells can also be isolated from the mouse12,13,14 and human kidney15,16. We 
extensively characterized kPSCs and compared these to bmMSCs. We found that kPSCs, similar 
to bmMSCs, have immunosuppressive capacities and can support vascular plexus formation. 
However, there are tissue specific differences between the cell types, as kPSCs showed an 
organotypic transcriptional expression signature, including the nephrogenic transcription 
factors HoxD10 and HoxD11. kPSCs, in contrast to bmMSCs, did not undergo myofibroblast 
transformation after stimulation with TGF-β and were unable to differentiate into adipocytes. 
Furthermore, kPSCs accelerated epithelial integrity in a kidney tubular epithelial wound scratch 
assay, a phenomenon which was not observed with bmMSCs. This enhanced wound repair was 
mediated through hepatocyte growth factor release. Moreover, kPSCs ameliorated kidney injury 
in a mouse model of acute kidney injury15. Therefore, kPSCs seem to have superior renal repair 
capacities and are an interesting new source for cell therapy in kidney diseases.
In order to be able to use kPSCs for cell therapy purposes, kPSCs should be isolated in a clinical 
grade manner with clinical grade enzymes and protocols. Moreover, to be able to treat several 
patients with kPSCs from 1 donor, sufficient cell numbers should be obtained. Here we show 
in detail, the clinical grade isolation procedure of kPSCs from whole transplant grade kidneys, 
yielding sufficient numbers of cells to be used for clinical cellular therapy.
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Protocol
The local medical ethical committee and ethical advisory board of the European consortium 
(STELLAR) approved the research and collection of human transplant grade kidneys discarded 
mainly for surgical reasons. Research consent was given for all kidneys.
1. Preparations for Cell Culture
1.1 Prepare a pool of platelet lysates.
1.1.1 Store the platelets that have expired for less than 2 d in -80 °C until use (for a 
maximum of 1 year).
NOTE: The platelets were originally sourced from a commercial vendor. Hospital 
surplus material distributed by the local blood bank were obtained.
1.1.2 Thaw the platelets of at least 5 donors (preferably 10) O/N at 4 °C.
1.1.3 Pool the platelets in a large sterile bottle, transfer to conical centrifuge tubes and 
spin down for 10 min at 1,960 x g at 4 °C.
NOTE: The volume of platelets depends on the number of donors and the amount 
of hospital surplus material per donor.
1.1.4 Pipette the supernatant to blood bags (50 mL/bag) through the barrel of a 50 mL 
syringe. Store at -80 °C.
1.2 Preparation of cell culture medium.
1.2.1 Defrost one bag of platelet lysates in a water bath at 37 °C.
1.2.2 Add 1 L (i.e.  2 bottles) of Minimum Essential Medium - alpha modification 
(alphaMEM), 5 mL 200 mM glutamine, and 20 mL of penicillin (5,000 U/mL)/
streptomycin (5,000 µg/mL) (pen/strep) to the bag.
1.2.3 Incubate for 3 h at 37 °C.
1.2.4 Shake the bag for degelling by gently tapping on the bag when the bag is resting on 
a flat surface.
1.2.5 Filter the 5% platelet lysates medium by pulling the lysates through the filter of the 
transfusion system with a sterile 50 mL syringe.
1.2.6 Aliquot the medium in 50 mL tubes and store in -80 °C until use.
NOTE: Every new batch of platelet lysates is tested in cell culture and compared to 
the previous batch by growing cells of interest (bmMSCs or kPSCs) to confluency in 
both batches. In cell numbers and viability, the kPSCs or bmMCs grown in the new 
batch should not differ more than 10%, and the marker expression of CD73, CD90, 
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CD105 and CD31, CD34 and CD45 as analyzed by flow cytometry should not differ. 
The methods of cell culture are described in section 6 of the protocol (Culture of 
kPSC).
2. Preparations for Cell Harvest
2.1 Preparation of solutions.
2.1.1 Prepare the plain medium by adding 10 mL of pen/strep to 500 mL (1 bottle) of 
Dulbecco's Minimum Essential Medium (DMEM)-F12.
2.1.2 Prepare the washing medium by adding 50 mL of Normal Human Serum (NHS) 
and 10 mL of pen/strep to 1 bottle of DMEM-F12.
2.1.3 Prepare the enzyme-stock buffer by adding 2.9 mL 1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1.2 mL NaHCO32.5% [w/v] and 160 µL 
CaCl2 (1 M) to 160 mL University of Wisconsin solution.
2.1.4 Prepare the collagenase solution by slowly adding 20 mL of enzyme stock buffer 
to the bottle of GMP-grade collagenase containing >2,000 U/bottle collagenase. 
Dissolve at 4 °C for approximately 40 min. Gently shake several times during the 
dissolving period.
2.1.5 Prepare the freeze medium by adding 5 mL dimethyl sulfoxide (DMSO) to 45 mL 
NHS.
2.2 Preparation of perfusion tray (Figure 1A).
2.2.1 Clean the flow cabin and cover with surgical drapes. Heat a water bath to 
approximately 40 - 45 °C to heat the perfusion tray to 37 °C. Put on surgical gowns 
and surgical gloves.
2.2.2 Connect a sterilized perfusion tray to the water bath to preheat the perfusion tray 
with warm water. Make sure that there is no air in the perfusion tray by starting with 
the perfusion tray in the vertical position. If necessary add more water to the water 
bath to prevent air infusion into the perfusion tray.
2.2.3 Place the LS25 tube in the pump. Leave both sterile ends of the tube in the flow 
cabinet. Place a Kocher's forceps on one end of the tube and allow to rest on the 
bottom of the perfusion tray. Place a sterile gauze on top of the tube to prevent 
obstruction. Attach a Luer connector on the other tube end.
2.2.4 Add approximately 100 mL of plain medium into the perfusion tray and start 
flushing the tube on a pump speed of 100 mL/min.
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3. Kidney Cell Isolation
3.1 Preparation of the kidney.
3.1.1 Remove the kidney from the double sterile bags and place on the sterile perfusion 
tray (Figure 1B). Remove the perirenal adipose tissue and kidney capsule with 
scissors and gentle tearing (Figure 1C) and identify the renal artery on the aortic 
patch as shown in Figure 1D.
3.1.2 Cannulate the renal artery with the accessory spike, fix with a sterilized tie-rip, and 
attach to the pump tube end with the Luer connector while the pump is on. If the 
tubes are not completely filled, first add more medium to the tray and flush tubes 
by starting the pump (Figure 1E - F). Flush the kidney with plain medium via the 
pump with a flow of 100 mL/min.
3.2 Collagenase treatment and kidney cell isolation.
3.2.1 Add collagenase (20 mL, >2,000 U) and DNase (2.5 mL, 1 mg/mL) to the perfusion 
tray (Figure 1G). Turn the kidney from time to time gently by hand. Wait until 
the kidney becomes soft and the perfusion liquid becomes less transparent 
(approximately 30-40 min).
3.2.2 Gently massage the kidney (Figure 1H) until a cell suspension is obtained (Figure 1I). 
Remove non-digested material and the spike in the renal artery.
3.3 Washing and collection of kidney cells.
3.3.1 Add 50 mL of the NHS to the cell suspension. Drain the cell suspension from the 
perfusion tray by putting the pump at low flow and placing the tube first connected 
to the kidney above the 50 mL tubes (Figure 1J).
3.3.2 Centrifuge at 300 x g for 7 min at 4 ˚C and remove the supernatant. Wash the pellets 
with washing medium containing 10% NHS and again centrifuge at 300 x g for 7 
min. Repeat washing once more. Measure the volume of the cell pellets and add an 
equal volume of cell culture medium.
3.3.3 Either cryopreserve the cells from here by adding freezing medium 1:1 to the cell 
suspension and store in cryogenic vials according to standard protocols, or continue 
to culture the cells (section 4).
NOTE: The cell suspension contains cell clumps and requires extra steps to obtain 
single cells, which results in an increase in cell death. Therefore, the cells are kept in 
suspension and are not counted at this stage.
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4. Cell Culture of Crude Kidney Cells
4.1 Add approximately 1 mL of the cell suspension to 24 mL of alphaMEM 5% platelet lysates 
(cell culture medium) in a T175 cell culture flask (Figure 1K) and culture at 37 °C, 5% 
CO2. Remove the medium and cell debris after 2 d from the adherent cells and refresh the 
medium with 25 mL of cell culture medium.
4.2 Refresh the culture medium twice a week by removing half of the medium (12.5 mL) and 
adding fresh medium (12.5 mL) using aseptic techniques.
4.3 Culture until confluent (usually 5 - 7 d) (Figure 1L). Remove the medium, wash twice with 
PBS and trypsinize the cells by adding 5 mL trypsin to each T175 flask for 5 min at 37 °C. 
Wash in culture medium and centrifuge at 490 x g for 5 min and remove the supernatant.
5. Cell Enrichment for NG2 by Magnetic Cell Separation (Figure 1M)
5.1 Prepare the cell separation buffer according to manufacturer's protocol.
5.2 Resuspend the trypsinized kPSCs in 10 mL cell separation buffer. Centrifuge at 
490 x g for 5 min, discard the supernatant and resuspend the cells in 300 µL cell 
separation buffer.
5.3 Add 100 µL FcR blocking reagen/5 x 107 cells, add 100 µL anti-melanoma (NG2) 
beads per 5 x 107 cells, and incubate for 30 min at 4 °C. Separate the NG2-positive 
fraction according to manufacturer's protocol. Add 10 mL of medium and centrifuge 
cells for 5 min at 490 x g.
5.4 Count the cells using a Bürker counting chamber according to manufacturer's 
protocol. Seed the cells in a culture flask (approximately 4 x 103  cells/cm2) and 
incubate.
NOTE: Seed the cells in the following concentrations: <250,000 in a T25 flask, 
250,000- 500,000 in a T75 flask, and 700,000-800,000 in a T175 flask. After magnetic 
cell enrichment, a positive fraction of approximately 1 - 2% is isolated. However, 
as this step is cell enrichment and not cell sorting, other cell types will be present 
in the culture (Figure 1N). After several passages (usually around 4 - 5), only a 
homogenous kPSC-population is present (Figure 1P).
6. Culture of kPSCs
6.1 Refresh the medium twice a week by removing half of the medium and replace it with 
freshly thawed culture medium (Figure 1N).
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NOTE: The kPSCs tend to be more viable and proliferative when only half of the medium 
is refreshed.
7. Passaging of kPSCs
NOTE: Passage the kPSCs at either 90 - 100% confluency, or when 3D structures appear 
(see Figure 1O), or when there hasn't been cell growth for more than a week. The latter two 
particularly might occur at early passages after cell enrichment. In this case, after passaging, the 
cells will usually start to grow again in monolayer culture (Figure 1P).
7.1 Remove the medium from the 90 - 100% confluent cells (keep the medium for later use). 
Wash the flask twice with PBS (1 mL in T25, 5 mL in T75, 10 mL in T175). Add trypsin 
(0.5 mL in T25, 2 mL in T75, 5 mL in T175) and incubate for 5 min at 37 °C. Add the old 
medium to the flask and resuspend gently.
7.2 Transfer to a 15 or 50 mL tube (depending on the volume) and centrifuge at 490 x g for 
5 min. Count the viable cells and plate <250,000 in a T25, 250,000 - 500,000 in a T75, or 
700,000 - 800,000 in a T175 (approximately 4 x 103 cells/cm2).
7.3 Test the kPSCs at passage 5 or 6 (e.g., scratch assay, section 7).
NOTE: Characterize the propagated cells by flow cytometry using standard protocols. 
Marker expression of NG2, PDGFR-β, CD146, CD73, CD90, CD105, HLA-ABC should all 
be positive and CD31, CD34, CD45 and HLA-DR should be negative. Test for mycoplasma, 
bacteria and fungi in the culture medium according to standard protocols of the clinical 
microbiology lab. Test the kPSCs functionally in a kidney epithelial wound scratch assay. 
Experiments are usually performed with sterile, flow cytometry-confirmed homogeneous 
kPSC populations with wound healing capacity between passage 6-8.
7.4 Cryopreserve the kPSCs by adding 0.5 mL cryopreservation medium to 0.5 mL cell 
suspension (2 million cells per mL of culture medium) using standard protocols. 
NOTE: After thawing, seed the kPSCs at a higher density (106 cells in a T175).
8. Functional Test of kPSCs: Kidney Epithelial Wound Scratch Assay
8.1 Culture the kPSCs in a 6-well plate at a density of 200,000 cells/well in 2 mL culture medium. 
After 48 h of culture at 37 °C, 5% CO2, collect the supernatant. This is the conditioned 
medium.
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8.2 Seed the HK-2 (proximal tubular epithelial cells)17 in 2 mL of Proximal Tubular Epithelial 
Cell (PTEC) medium consisting of a 1:1 ratio of DMEM-F12 supplemented with insulin 
(5 mg/mL), transferrin (5 mg/mL), selenium (5 ng/mL), hydrocortisone (36 ng/mL), 
triiodothyrinine (40 pg/mL), epidermal growth factor (10 ng/mL) and pen/strep, in a 
density of 500,000 cells per well in a 6-well cell culture plate.
8.3 Culture for 48 h at 37 °C, 5% CO2. Remove the cell culture medium of the HK-2s and create 
a scratch wound in the monolayer of HK-2s by making a scratch with the tip of a yellow 
pipette point from the top to the bottom of the well. Wash the HK-2s with PBS and add the 
conditioned medium of the kPSCs or control medium. Mark on the bottom of the plate the 
area to be imaged. 
NOTE: The HK-2s should be confluent. Image two areas per well.
8.4 Image the scratch at 4, 8, 12 and 24 h at the same marked position with an inverted bright-
field microscope.
8.5 Measure the scratch area in Image J using the polygon selection tool to determine the 
percentage of closure.
Representative results
The clinical grade kPSCs isolation method is summarized in Figure 1. Crude kidney cells are 
isolated from human transplant grade kidneys by collagenase perfusion. The resulting cell 
suspension is cultured until confluent in 5% platelet lysates. Then the perivascular stromal cell 
fraction is isolated based on NG2 expression.
kPSCs are plastic adherent spindle-shaped cells (Figure 2A) and are positive for the stromal 
markers CD73, CD90, CD105 and perivascular markers NG2, PDGFR-B and CD146, while 
negative for CD31, CD34, CD45 and HLA-DR (Figure 2B). Typically, a homogeneous population 
of kPSCs can be reached at passage 4 and kPSCs reach senescence around passage 9 - 10 (Figure 
2C). We therefore advise to perform experiments between passage 5-8.
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To evaluate the functional capacity of the isolated kPSCs, we perform an  in vitro  kidney 
epithelial wound scratch assay on every new batch of kPSCs, as we previously showed that the 
conditioned medium of kPSCs can accelerate epithelial wound healing in this scratch assay15. 
The kPSC conditioned medium is made by culturing kPSCs for 48 h in alphaMEM 5% platelet 
lysates and collecting the supernatant. Next, the immortalized human kidney proximal tubule 
epithelial cells (HK-2)17 are cultured until confluent and then a scratch wound is made. Then 
either the conditioned medium of kPSCs or control medium is added to the wells and the speed 
of wound healing is measured. When the conditioned medium of kPSCs is added, the wound 
closes significantly faster (Figure 2D).
Figure 1: Clinical grade isolation method of human kPSCs. Transplant grade kidneys are 
cannulated and perfused with collagenase via the renal artery (1A-1G) and the resulting cell 
suspension is washed and either cryopreserved or put into culture (1H-1K). After the cells reach 
confluency (1L), NG2 cell enrichment is performed (1M). Cells are trypsinized when they either are 
confluent, have stopped proliferating or when 3D structures appear (1N-1P). The release criteria 
for kPSCs are sterility, marker expression and the capability to enhance tubular epithelial wound 
healing (1Q). Arrow: renal artery. Scale bar = 200 μm.


































Figure 2: Characterization of human kPSCs. A) kPSCs are spindle-shaped, plastic adherent cells. 
B) kPSCs are positive for mesenchymal markers CD73, CD90, CD105, perivascular markers NG2, 
PDGFR-β and CD146, while negative for CD31, CD34 and CD45. kPSCs express MHC-class I 
(HLA-ABC) but not class II (HLA-DR). C) Growth characteristics of three different kPSC donors from 
flow cytometry confirmed a homogeneous NG2 positive populations (at passage 4). kPSCs reach 
senescence around passage 9-10. D) kPSCs are able to enhance kidney epithelial repair in a wound 
scratch assay. Representative images of control medium and kPSC conditioned medium at t=0, 4, 
8 and 12 h are shown. Scale bar in A) = 200 μm, in D) = 100 μm.
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Discussion
Perivascular cells have been isolated from many different human solid organs, including 
pancreas, fat, cartilage and the kidney9,15,16. Most methods, however, are based on small samples 
of tissue, which are dissected and afterwards treated with digestive enzymes. Moreover, this is 
usually not performed with clinical grade products. This makes these strategies less suitable for 
direct clinical translation where large quantities of clinical-grade cells are necessary.
Here we show a novel isolation method of human kPSCs for whole organs based on perfusion 
with clinical grade enzymes and materials. The protocol is adapted from the clinical islets of 
Langerhans isolation protocol currently in use for clinical application in our center18.
This is the first clinical grade method where large quantities of kPSCs can be achieved. The 
variability in cell yield is largely donor dependent. However, when the cell yield we currently 
obtain from a fraction of the crude cell suspension of three different donors is extrapolated, 
in theory, an average yield of 2.7 x 1012 kPSCs per donor could be achieved. As MSC therapy 
typically consists of 2 cell infusions with 1 - 2 x 106 cells/kg body weight4, these cell numbers are 
sufficient for allogenic treatment of several patients.
One critical step in the isolation procedure is the duration of collagenase digestion. When the 
digestion period is too short, large clumps of tissue will remain, which will be harder to culture. 
When the perfusion period is too long, increased cell death may be observed. Therefore, as 
soon as the kidney starts to become soft and the fluids less transparent, the kidney should be 
massaged gently and the collagenase treatment should be stopped.
Another critical step is the culture of the cells after NG2 cell enrichment. Sometimes after the 
NG2 cell enrichment, the perivascular cells do not start to proliferate or start to grow in 3D 
structures. In this case, when the cells are trypsinized and reseeded, the cells will usually start to 
grow in monolayer culture.
As starting material, human transplant grade kidneys discarded mainly for surgical reasons were 
used. These are functional organs without major fibrosis. We acknowledge that this might be a 
limitation as this is a relatively rare and hard to obtain organ source. Explanted kidneys might 
be another source; however, depending on the reason of kidney explantation, these kidneys 
might contain more fibrosis and thus myofibroblasts, and therefore care should be taken since 
myofibroblasts might be isolated and cultured instead of perivascular cells.
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As the kPSCs isolated with this protocol show organo-typic properties with kidney epithelial 
wound healing capacities15, cell therapy with kPSCs in kidney diseases and transplantation 
would be an interesting future application. For this purpose, there are several strategies of cell/
cell product delivery. The first strategy is IV infusion of kPSCs, as used currently in the bmMSC 
clinical studies. Another interesting application is the use of kPSCs or kPSC-excreted factors 
in machine perfusion before transplantation. In this way, the quality of the explanted kidney 
might improve which could lead to improved kidney function after transplantation. For both 
strategies, kPSCs are an interesting new cell source to further explore for clinical purposes.
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Abstract
Mesenchymal stromal cells (MSC) secrete factors that contribute to organ homeostasis 
and repair in a tissue specific manner. For instance, kidney perivascular mesenchymal 
stromal cells (kPSCs) can facilitate renal epithelial repair through secretion of 
hepatocyte growth factor (HGF) while the secretome of bone marrow MSCs gives 
rise to immunosuppression. Stromal cells function in a complex 3-dimensional (3D) 
connective tissue architecture that induces conformational adaptation. Here we tested 
the hypothesis that surface topography and associated cell adaptations dictate stromal 
cell function through tuning of the cytokines released. To this end, we cultured human 
bone marrow and kidney perivascular stromal cells in the TopoWell plate, a custom-
fabricated multi-well plate containing 76 unique bioactive surface topographies. Using 
fluorescent imaging, we observed profound changes in cell shape, accompanied by 
major quantitative changes in the secretory capacity of the MSCs. The cytokine secretion 
profile was closely related to cell morphology and was stromal cell type specific. Our data 
demonstrate that stromal cell function is determined by microenvironment structure 
and can be manipulated in an engineered setting. Our data also have implications for the 
clinical manufacturing of mesenchymal stromal cell therapy, where surface topography 
during bioreactor expansion should be taken into account to preserve therapeutic 
properties.
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Introduction
Mesenchymal stromal cells are immunomodulatory and regenerative cells originally isolated 
from the bone marrow (bmMSCs). The functionality of MSCs largely depends on the secretion 
of soluble factors such as growth factors and cytokines. For the immunomodulatory potential 
of MSCs, for example, indoleamine 2,3-dioxygenase (IDO), prostaglandin E2, macrophage 
colony-stimulating factor (M-CSF) and interleukin (IL)-6 are of major importance1,2, while 
for vascular stabilization the secretion of VEGF and angiopoietin-1 is essential3,4. Due to these 
characteristics, bmMSCs are an interesting cell source for cellular therapy for, amongst others, 
graft versus host disease (GvHD) and kidney transplantation and currently several trials are 
being performed with these cells 2,5,6. 
Mesenchymal stromal cells are a diverse cell population with different functionalities throughout 
the body 7-9. We showed, for example, that kidney derived perivascular stromal cells (kPSCs) 
display a distinct organotypic gene expression profile as well as different functionality compared 
to bmMSCs9. kPSCs were, in contrast to bmMSCs, able to support kidney epithelial wound 
healing, which could be attributed to the specific production of hepatocyte growth factor (HGF) 
by kPSCs9. It is of relevance to know whether such organotypic features can be preserved during 
MSC culture for clinical purposes.
The current standard clinical grade cell culture method of bmMSCs and kPSCs consists of culture 
on cell culture plastic in flasks or in cell factories. However, this method is time consuming and, 
due to the need of clean room facilities, costly. Therefore, there is a growing interest in closed-
system bioreactor culture systems. In these systems, cells are usually grown on microcarriers10,11. 
These microcarriers can be different in material and culture surface compared to standard cell 
culture plastic. However, little is known about how these differences in microenvironment 
influence the functionality of stromal cells. 
In order to study the effects of both the chemistry and surface structure of the microenvironment 
on cell behavior, we previously developed the TopoChip. The TopoChip is a high-throughput 
screening tool for bioactive algorithm-generated surface topographies, allowing to screen 
biomarker expression in cells exposed to over 2000 unique surface topographies on application-
specific materials of interest 12. On the TopoChip, we identified surfaces able to induce osteogenic 
differentiation of bmMSCs in vitro and bone bonding in vivo. Similarly, we were able to optimize 
clonogenic growth of IPSCs, growth of human hepatocytes and bmMSC proliferation where we 
observed a correlation between cell shape and cell physiology, based on high content imaging of 
single biomarkers12-14.
d.leuning-layout.indd   97 22/05/2018   16:43
98 Chapter 5
This system does, however, not allow the assessment of the secretome of the cells studied. To 
allow analysis of multiple genes or secreted proteins we therefore subsequently developed the 
TopoWellPlate (TWP), comprising a 96 well plate with unique topographies selected based on 
cell shape diversity from the earlier TopoChip experiments 15.
Here, using the TWP technology, the effect of surface topographies on major growth factors 




As described previously, the topography enhanced well plates (TWP) are produced using a 
multiple step cleanroom process15,27. In short, a supervised machine learning approach was 
used to identify multiple defined surface topographies which are able to induce 11 morphology 
classes including specific cell (8) and nuclear (3) morphologies in a robust and reproducible 
manner. Topography numbers used in this manuscript are derived from the second generation 
TopoChip12 produced in polystyrene. Instead of the full topography identifier, we use a short 
notation throughout this manuscript. For example, T2_PS_0365 will be referred to as 0365. 
The short 4 digit annotations are built-up as followed: the first two digits represent the row 
number counted from the top, and the second two digits represent the column number. These 
surface topographies were included in a 96-well plate lay-out as design for a chromium mask for 
photolithography of a silicon wafer. Using a polydimethylsiloxane (PDMS, curing agent: base 
= 1:10 w/w, Sylgard 184 silicone elastomer kit, Dow Corning Corporation) and Ormostamp 
(Micro Resist Technology GmbH, Germany) intermediate mould, we created topographically 
enhanced polystyrene films (Goodfellow, United Kingdom) by hot embossing. Subsequently 
the topographically enhanced polystyrene films were fused to bottomless 96-well plates 
(Greiner Bio-One) using thermal bonding, giving rise to leakage and chemical contaminant 
free TopoWellPlates. Prior to cell culture, TopoWellPlates were sterilized with 70% ethanol and 
washed thoroughly with phosphate buffered saline.
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Isolation and expansion of clinical-grade human kidney-derived perivascular stromal 
cells
Kidney perivascular stromal cells were isolated and cultured as described in detail previously9. In 
short, cells were isolated from a human transplant-grade kidney discarded for surgical reasons. 
Specific research consent was given for all kidneys by either the donor, confirmed by the next of kin 
or by the next of kin directly according to Dutch legislation. None of the transplant donors were 
from a vulnerable population. The study was approved by the local medical ethical committee of 
the Leiden University Medical Centre (p13.054) and the ethical advisory board of the European 
Union consortium STELLAR. All methods were performed in accordance with the relevant 
guidelines and regulations. The kidney was perfused via the renal artery with collagenase (2500 
units, NB1, Serva) and DNAse (2,5ml Pulmozyme, Genetech) at 37°C with a flow of 100ml/min. 
After approximately 30 minutes, the tissue was digested and the resulting cell suspension was 
washed and collected. Cells were either directly cultured at 37°C, 5% carbon dioxide or frozen 
in liquid nitrogen. Kidney cell suspensions were cultured in alphaMEM (Lonza) containing 
5% platelet lysates, glutamine (Lonza) and penicillin/streptomycin (Lonza). At passage 1 NG2 
cell enrichment was performed using MACS according to manufacturer’s protocol (Miltenyi 
Biotech, Gladbach, Germany) and afterwards cells were cultured in alphaMEM containing 5% 
platelet lysates in a density of 4x103 cells per cm2 9. Experiments were performed with kPSCs 
from one donor at passage 7. 
Isolation and expansion of human bone marrow-derived mesenchymal stromal cells
Ethical committee approval from the ethical advisory board of the Leiden University Medical 
Centre was given and written consent from the donors was obtained for the aspiration of human 
bone marrow. Heparinized bone marrow was aspirated under local or general anaesthesia. 
The mononuclear cell fraction was isolated by Ficoll density gradient separation and plated in 
tissue culture flasks at a density of 160x103 mononuclear cells per cm2 in alphaMEM(Lonza), 
supplemented with penicillin/streptomycin (Lonza) and 5% platelet lysate. The cultures were 
maintained at 37°C, 5% carbon dioxide. Half of the medium was refreshed twice a week. When 
the MSC colonies or cultures reached confluence, the cells were collected using trypsin (Lonza) 
and replated at 4x103 cells per cm2. Experiments were performed with bmMSCs from one donor 
at passage 7.
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Cytokine secretion profiling
kPSCs and bmMSCs were seeded on 3 TopoWellPlates per cell type in a density of 6700 cells/
well. Cells were cultured for 48 hours in 200µl 5% alphaMEM platelet lysates/well before the 
culture medium was collected. Subsequently, growth factors and cytokines were measured of the 
3 plates per cell type with a custom-made Luminex® multiplex ELISA following manufacturer’s 
protocols (R&D Systems, Minneapolis, MN). 
Imaging for data normalization
After removal of the supernatant, cells were fixed with 4% PFA for 10 minutes, washed twice 
with PBS and stained for phalloidin and Hoechst (Thermo Fisher Scientific, Landsmeer, the 
Netherlands). Cells were imaged at 5x magnification (Leica AF6000, Leica Biosystems) and 
nuclei/field of view were determined for 1 field per view for all wells with Image J software. 
Wells with less than respectively 200 cells per field of view (kPSC) or 150 cells per field of view 
(bmMSCs) were excluded from further analysis to prevent biased results based on cell numbers. 
Data analysis
To assess the quality of the data, we calculated the coefficient of variation (CV) of each triplicate 
measurement by dividing their respective standard deviation with the mean of the measurements 
and is represented as a percentage. 
The averaged concentrations of secreted growth factors and cytokines from the individual cell 
culture supernatants (separated analyses per cell type in triplicate) were used to create a scaled 
heatmap. To create a heatmap in which the different factors could be compared, we standardized 
the data according to z-scores. Dissimilarities between secreted factors as well as the topography 
specific secretion fingerprints were calculated using Euclidean distances and visualized in 
dendrograms via Ward’s clustering (analysis in R ver.3.3.228, using packages: “cluster” ver. 2.0.6. 
29, and “ggplot2” ver. 2.2.130). 
For the clustering of surface topography induced secretion fingerprints, we calculated the 
ideal number of clusters to divide the topographical responses in cytokine secretion profile in 
comparable groups per cell types. Subsequently, the cell morphologies – as classified before 
– were assigned to each topography-induced secretion profile to visualize the effect of cell 
morphology on secretion profiles.
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Statistical analysis
Statistical analysis was performed with Graph Pad Prism (Graph Pad Prism Software Incl. San 
Diego, USA). Differences between kPSCs and bmMSCs were analysed using a two-way ANOVA 
with Bonferroni’s posthoc comparison analysis.
Data availability statement
The datasets generated during and/or analysed during the current study are available from the 
corresponding author on reasonable request.
Results
Stromal cells show an organotypic cytokine secretion profile 
When looking at the reference unpatterned wells most of the factors (FGF, VEGF, MCP-1, IL-8, 
IL-1ra, and Thrombospondin-2) are secreted in similar amounts comparing kPSCs and bmMSCs. 
GM-CSF, IFN-y and TNF-α were below detection limit in all conditions. Interestingly, HGF 
and SDF-1α showed significant differences in secretion. HGF, important for kidney epithelial 
wound repair, was not detectable in bmMSC-conditioned medium and high in kPSCs (890 pg/
ml) and SDF-1α was secreted in a more then 100 fold higher concentration by kPSCs compared 
to bmMSCs (respectively 1579 and 10 pg/ml) (Fig 1A). SDF-1 is, as HGF, an important factor 
for kidney regeneration16. 
Both kPSCs and bmMSCs showed a marker expression typical for MSCs, as these cells were 
positive for the pericyte markers NG2, PDGFR-β and CD146 and the MSC markers CD73, 
CD90 and CD105 while being negative for CD31, CD34, CD45, CD56 (supplementary figure 1 
and 2).
Stromal cells cultured on different topographies show pronounced differences in cell and 
nuclear morphology
The TWP consists of 76 unique bioactive algorithm-generated surface topographies (Fig 1B). We 
previously observed that surface topography can greatly influence the phenotype of mesenchymal 
stromal cells 12,15. To evaluate cell- and nuclear morphology of bmMSCs and kPSCs cultured on 
the different topographies on the TWP, we stained the actin cytoskeleton and nucleus of the 
cells and we observed pronounced differences in cell and nuclear morphology both in bmMSCs 
and kPSCs (fig 1B, supplementary fig3). In figure 1C, an example of a surface topography on the 
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TWP is shown, with the corresponding cell morphology of kPSCs and bmMSCs cultured on this 
specific topography (fig. 1D). Nuclear counting displayed little effect of different topographies 
on cell numbers (figure 1E and F). However, in few cases viable cell numbers were below the 
lower threshold (dashed line figure 1E, F) and to exclude an effect on cytokine and growth factor 
secretion caused by cell density, these wells were excluded. 
Cell type specific effects of topography on cytokine and growth factor secretion
When comparing the 76 different surface topographies in growth factor and cytokine expression 
profile, major differences can be observed between secretion levels between topographies of 
several growth factor and cytokine levels, such as HGF, SDF1α and trombospondin-I while 
others showed a more stable secretion such as VEGF (figure 2). Importantly, the variation 
between the triplicates for most cytokines is low as shown by the coefficient of variation (CV) of 
each triplicate measurement (figure 2). There were however two exceptions, FGF secreted by the 
kPSCs is highly variable which is due to the low secretion resulting in higher relative variability. 
Furthermore, we notice a higher variability for IL-8 secreted by the BM-hMSCs, which can most 
likely be attributed to technical variation.
Figure 1. Cell behavior on the TopoWellPlate A) Cytokine and growth factor secretion of bmMSCs 
and kPSCs cultured on unpatterned “flat” culture surfaces. B) Development of the TopoWellPlate. 
Cells were cultured on 76 unique algorithm generated topographies in a 96 wells plate resulting 
in different cell (8) and nuclear (3) morphologies. C) Example of a surface topography on the 
TWP (#1901). D) kPSC and bmMSC cell morphology when cultured on topography 1901. E) Cell 
numbers of kPSCs and F) bmMSCs cultured for 48 hours on different topographies were stable. 
Below dashed line: excluded values based on cell number. ***p<0.001, Abbreviations: kPSC: 
kidney-derived perivascular stromal cell; bmMSC: bone marrow-derived mesenchymal stromal cell; 
FGF: fibroblast growth factor; HGF: hepatocyte growth factor; VEGF: vascular endothelial growth 
factor; MCP-1: monocyte chemotactic protein-1; IL: interleukin; GM-CSF: granulocyte macrophage 
colony-stimulation factor; IFN-y: interferon gamma; TNF-α: tumor necrosis factor alpha; SDF-1 α: 
stromal cell-derived factor 1 alpha; TSP2: thrombospondin-2; DIC: differential interference contrast; 
Br: branched; BN: bizar nuclei; EN: eccentric nuclei; IS: interesting shapes; MP: multipolar; NCM: 
normal cell morphology; ON: oval nuclei; P: pancake; S: stick; SB: small and branched; SP: 
stretched pancake. Scalebar C: 25 μm, scalebar D: 200 μm
























































































































































































































































































































d.leuning-layout.indd   4 22/05/2018   16:43
























































































































































































































































































































Figure 2. Cytokine and growth factor secretion on different culture surfaces. A) Concordance 
of replicas of bmMSCs as shown by the coefficient of variation (CV) of each triplicate. B) Cytokine 
and growth factor secretion of bmMSCs cultured on different classes of surface topographies. 
C) Coefficient of variation of cytokines and growth factors secreted by kPSCs. D) Cytokine 
and growth factor secretion of bmMSCs cultured on different classes of surface topographies. 
Abbreviations: kPSC: kidney-derived perivascular stromal cell; bmMSC: bone marrow-derived 
mesenchymal stromal cell; FGF: fibroblast growth factor; HGF: hepatocyte growth factor; VEGF: 
vascular endothelial growth factor; MCP-1: monocyte chemotactic protein-1; IL: interleukin; GM-
CSF: granulocyte macrophage colony-stimulation factor; IFN-y: interferon gamma; TNF-α: tumor 
necrosis factor alpha; SDF-1 α: stromal cell-derived factor 1 alpha; TSP2: thrombospondin-2; DIC: 
differential interference contrast; Br: branched; BN: bizar nuclei; EN: eccentric nuclei; IS: interesting 
shapes; MP: multipolar; NCM: normal cell morphology; ON: oval nuclei; P: pancake; S: stick; SB: 
small and branched; SP: stretched pancake; CV: coefficient of variation. 
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Similar results were obtained when secretion levels were adjusted for cell numbers (supplementary 
figure 4). Moreover, each topography resulted in a unique kPSC and bmMSC cytokine secretion 
profile as depicted in figure 3A and 3B respectively. Some cytokines are secreted similarly when 
comparing kPSCs to bmMSCs during culture on the various topographies, but some noticeable 
differences were observed as well. bmMSCs cultured on topography 0365, for example, showed a 
2.3 and 2.2 fold decrease in secretion of IL-6 and MCP-1 respectively compared to flat reference 
wells while IL-6 and MCP-1 secretion by kPSCs stayed rather stable (respectively 1.08 and 1.27). 
In the principal component analysis (PCA) plots, disparate secretory responses to the same 
defined topographies can be observed between the two organotypic stromal cell populations. 
Moreover, the topography induced variability in function exceeds the variability observed when 
such topography is compared to a flat surface as reference, underscoring the strong influence of 
surface structure on adaptive stromal cell function (supplementary figure 5).
Stromal cell cytokine secretion is closely related to cell morphology
We analyzed whether the cytokine profiles correlated to classes of predefined adaptive cell 
morphology to the various topographies15. kPSCs with similar cell shape are enriched in 
cytokine profile classes (figure 3A). For instance, when looking at the 9 different clusters, the 
first 2 clusters contained 15 topographies and all cells in these clusters show a similar broad and 
flat morphology indicated as “pancakes” or “stretched pancakes”. 
Figure 3. Unique secretome fingerprint of kPSCs and bmMSCs cultured on different 
topographies related to cell shape. A) Heatmap of the secretome of kPSCs cultured on the 76 
different topographies and 4 reference unpatterned “flat” culture surfaces, including a dendrogram 
of the secretome of kPSCs showing clustering into 9 different classes. This clustering according 
to secretome is closely related to clustering according to cell morphology. B) Heatmap of the 
secretome of bmMSCs including adendrogram of the secretome of bmMSCs showing clustering 
into 8 different classes which is again closely related to cell morphology. Abbreviations: kPSC: 
kidney-derived perivascular stromal cell; bmMSC: bone marrow-derived mesenchymal stromal cell; 
FGF: fibroblast growth factor; HGF: hepatocyte growth factor; VEGF: vascular endothelial growth 
factor; MCP-1: monocyte chemotactic protein 1; IL: interleukin; GM-CSF: granulocyte macrophage 
colony-stimulation factor; IFN-y: interferon gamma; TNF-α: tumor necrosis factor alpha; SDF-1 α: 
stromal cell-derived factor 1 alpha; TSP2: thrombospondin-2.
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Similar results were obtained with bmMSCs. When clustered based on secretion profile, 8 
different clusters were defined which clustered according to specific cell shape adaptations 
(figure 3B). For example, bmMSCs cultured on the 16 topographies that constitute the last two 
clusters, characterized by a relatively high cytokine secretion profile, have a predominance of 
multipolar and branched cell morphology (figure 3B). Together, this indicates that the cytokine 
secretion profile of both kPSCs and bmMSCs is correlated to the morphology of the cells.
Surface topography influences the secretion of functional important factors IL-6, SDF-1β 
and HGF
From a clinical perspective it is of interest to identify surface structures and cellular responses 
of MSCs that preserve the secretion of cytokines involved in tissue homeostasis. This is of 
particular relevance to the use of microcarriers in bioreactor systems for expansion of MSCs 
as noticeable differences could be observed in the secretion of these factors on the different 
topographies. This is depicted in box plots of the fold change of cytokine and growth factor 
secretion of both bmMSCs and kPSCs compared to control (fig 4A, B). For example, when 
bmMSCs are cultures on surface 0365 they will respond with a very elongated morphology 
with eccentric nuclei (figure 4C) and a 2.3 fold decrease in IL-6 secretion, one of the effector 
cytokines in immune regulation by bmMSCs (figure 4D). Similarly, specific topographies could 
be identified that foster the combined secretion of HGF and SDF-1α by kPSCs,two cytokines that 
have been implicated in kidney regeneration9,16-18. HGF and SDF-1α showed a strong correlation 
in secretion levels (figure 4E) with a Pearson’ s correlation of 0.81 (p<0.0001). Moreover, this was 
also highly associated with cell shape as surface structures that resulted in a normal cell shape, 
long elongated small cells (“sticks”) or cells with a multipolar morphology showed the highest 
levels of HGF and SDF1 secretion (respectively 40, 20 and 30% in the top 10 highest secretion of 
HGF and SDF-1 α), while broad spreading cells on top of the topographies resulted in the lowest 
levels (“pancakes” and “stretched pancakes”, both 50% in the top 10 lowest secretion of HGF and 
SDF-1 α) (figure 4F). 
Another noticeable difference was observed with respect to thrombospondin-2, which is 
expressed higher in both kPSCs and bmMSCs on most surfaces compared to flat reference 
surfaces. As thrombospondin-2 is a matricellular protein involved in cellular adaptation 19, this 
points to the active stromal cell adaptation induced by the cell surface changes.
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Figure 4. Surface topographies influence secretion of functional important factors A) There is 
a large variation in trophic factor secretion of kPSCs on different topographies as depicted as fold 
change compared to reference “flat” culture surface and shown in boxplots. B) Similar variation was 
observed with bmMSCs C) Cell morphology of bmMSCs cultures on the topography with the largest 
difference in cytokine secretion D) The largest difference in secretion of trophic factors of bmMSCs 
was observed for IL-6. E) Correlation between HGF and SDF-1α secretion. F) Characteristic cell 
shapes of kPSCs on topographies with the highest and lowest secretion of HGF and SDF-1α. Scale 
bar 40μm. Abbreviations: kPSC: kidney-derived perivascular stromal cell; bmMSC: bone marrow-
derived mesenchymal stromal cell; FGF: fibroblast growth factor; HGF: hepatocyte growth factor; 
VEGF: vascular endothelial growth factor; MCP-1: monocyte chemotactic protein 1; IL: interleukin; 
GM-CSF: granulocyte macrophage colony-stimulation factor; IFN-y: interferon gamma; TNF-α: 
tumor necrosis factor alpha; SDF-1 α: stromal cell-derived factor 1 alpha; TSP2: thrombospondin-2.
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Discussion
In contrast to 2D in vitro cell culture, stromal cells normally function in vivo in a 3D connective 
tissue environment where they stretch between the different cell types and communicate via 
paracrine signaling5. While stromal cells are a diverse cell population important for tissue structure, 
organization and homeostasis, little is known about how changes in the microenvironmental 
structure influence stromal cell function in reverse. Here we show for the first time, using a novel 
high throughput screening platform, that changing the microenvironment in vitro, specifically 
via surface topographies, is able to change the shape of stromal cells and influence quantitatively 
the cytokine secretion profile of stromal cells. Qualitative, however, organotypic, stromal cell 
secretory characteristics are preserved irrespective of microenvironmental surface factors. This 
points to a deeper imprinting of MSC function depending on the tissue, or site, of origin.
Only little data is available on the role of the microenvironment on MSC function. We and 
others previously demonstrated that in vitro culture conditions can greatly influence the 
cytokine expression profiles and thus their therapeutic efficacy. Treatment of bmMSCs with the 
small molecule dibutyryl-cAMP induced the expression of a panel of pro-osteogenic cytokines 
among which BMP2 and IGF1 resulting in a profound increase in in vivo bone formation20,21. 
Substrate stiffness can also greatly influence cell function as several cell types, including 
bmMSCs, showed not only different cell morphology but also different secretory profiles based 
on substrate elasticity22-26. Our current data extend these observations in that not only stiffness 
but also the cell shape adaptations enforced by surface morphology is an important determinant 
of the secretory profile of MSCs. In particular, the quantitative capacity to secrete cytokines and 
chemokines seemed to be directly related to these cell shape adaptations.
In line with the observation that stromal cells derived from different parts of the body show 
different functionality7-9, we found cell type specific differences in cytokine and growth factor 
secretions between kPSCs and bmMSCs which were qualitatively preserved independent of the 
surface topography. Moreover, while bmMSCs cultured on specific topographies resulted in 
changes of cytokine secretion, no differences were observed for kPSCs cultured on these same 
topographies, and vice versa. These observations point to a deeper organotypic programming of 
MSCs that is independent of its microenvironment. 
As the concentration of important factors for the homeostatic function of stromal cells, including 
HGF and IL-6, varied directly with topographies, our findings are of importance for the 
development of bioreactor culture systems. The culture surface of the carriers in these bioreactors 
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should be designed in such a way that there is preservation of important characteristics of these 
cells, taking into account the cellular adaptations to the ultrastructure of the surface on which 
they grow.
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Supplementary figure 1. Marker expression of bmMSCs as analysed by flow cytometry. These 
cells are positive for the pericytic markers NG2, PDGFR-β and CD146 and the MSC markers CD73, 
CD90 and CD105 while being negative for CD31, CD34, CD45. Cells expressed type I HLA (HLA-
ABC) and are negative for type II HLA (HLA-DR). Blue: isotype control, orange: bmMSC.
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Supplementary figure 2. Marker expression of bmMSCs as analysed by flow cytometry. These 
cells are positive for the pericytic markers NG2, PDGFR-β and CD146 and the MSC markers CD73, 
CD90 and CD105 while being negative for CD31, CD34, CD45. hkPSCs express type I HLA (HLA-
ABC) and are negative for type II HLA (HLA-DR). Blue: isotype control, orange: kPSC.
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Supplementary figure 3. Cell and nuclear morphology of both bmMSCs (left panels) and kPSCs 
(right panels) cultured on different classed of surface topographies.
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Supplementary figure 4. Cytokine and growth factor secretion of bmMSCs and kPSCs cultured on 
different classes of surface topographies adjusted for cell numbers.
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Supplementary figure 5. Principal component analysis (PCA) of kPSCs and bmMSCs cultured on 
76 unique surface topographies.
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The human kidney capsule contains a functionally 
distinct mesenchymal stromal cell population
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Abstract
We recently demonstrated that the adult human kidney cortex contains a perivascular 
stromal cell (kPSC) that shows organotypic properties and is important for repair and 
stabilisation of kidney function. Not only the kidney cortex but also the kidney capsule 
contains stromal cells that are important for the three dimensional organisation of the 
kidney during nephrogenesis. They provide the barrier function of the capsule which is 
critical for homeostatic processes such as pressure natriuresis. We postulated that stromal 
cells derived from the kidney capsule may therefore also have specific properties and 
functions. To this end, we isolated these capsule mesenchymal stromal cells (cMSC) from 
human cadaveric kidneys that were not suitable for transplantation. There were several 
similarities between cMSCs and kPSCs including support of vascular plexus formation, 
phenotypic marker expression and resistance against myofibroblast transformation. 
However, compared to kPSCs, cMSCs showed distinct mRNA and miRNA expression 
profiles, showed increased immunosuppressive capacity, and displayed strongly reduced 
HGF production, contributing to the inability to enhance kidney epithelial repair. 
Therefore cMSCs are a distinct, novel human kidney-derived MSC-population and 
these data underpin the large functional diversity of phenotypic similar stromal cells in 
relation to their anatomic site, even within one organ. 
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Introduction
The kidney capsule consists of a layer of stromal cells surrounded by a sheet of connective tissue 
and is of major importance during kidney development and adult kidney homeostasis. During 
kidney development 3 different locations of stromal cells can be observed; capsular, cortical 
and medullary stromal cells. Nephrogenesis takes place in the outer nephrogenic zone, the 
region just below the kidney capsule1-4. Stromal cells within the kidney capsule are of major 
importance for nephrogenesis. Normally the kidney capsule consists of a continuous layer of 
Foxd1 and Hox10 positive stromal cells. However, in Foxd1-null embryos, the capsule contains 
several different cell types including endothelial cells and Bmp4- expressing cells resulting in 
delayed and disorganized nephrogenesis. Moreover, the defects in capsule formation resulted 
in adherence to the body wall and failure of kidney ascension which leads to fused kidneys on 
a pelvic location5. Comparable to Foxd1-null mice, triple mutants of the renal stromal marker 
Hox10 also show a failure of capsule formation with similar effects on nephrogenesis6. 
In the adult kidneys, the kidney capsule is important for kidney homeostasis. The strong layer 
of connective tissue is of importance for preserving the renal interstitial hydrostatic pressure 
(RHIP) which is necessary for pressure natriuresis. Decapsulation of the kidney in rats resulted 
in lower RIHP and reduced pressure-natriuretic response7. Moreover, in adult mice, stromal 
cells from the kidney capsule could be isolated and showed mesenchymal stromal cell (MSC) 
features such as the ability to adhere to plastic, the presence of MSC-markers such as Sca-1, 
trilineage differentiation capacity and clonogenicity. Moreover, these murine capsule MSCs 
were able to migrate into the injured kidney after ischemic injury and seemed to protect against 
kidney injury as decapsulation of the kidneys resulted in deceleration of recovery of kidney 
function8. However, little is known about the human kidney capsule. 
We recently isolated and characterised perivascular stromal cells from the human adult kidney 
cortex (kPSC) and compared them to mesenchymal stromal cells (MSC) from the bone marrow 
(bmMSC)9. bmMSCs are immunomodulatory cells with reparative properties and have shown 
beneficial effects in kidney diseases and transplantation10-12. We showed that, although there 
are similarities between bmMSCs and kPSCs, there are also major differences. kPSCs show 
a different, organotypic gene expression, most notably the renal homeobox genes, Hox10 
and Hox11, as well as different function. For example, in contrast to bmMSCs, they had the 
capacity to reintegrate into the renal cortex and stimulated kidney tubular epithelial repair9. 
These data suggest that kPSCs may have retained organotypic properties. In this respect, we 
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were interested to see whether stromal cells isolated from the human renal capsule would show 
distinct functionalities compared to the cortical kPSCs based on their site-specific role during 
organogenesis. 
Here we show that within the human kidney stromal cells of the kidney capsule share common 
general characteristics of MSCs, but yet are functionally distinct from the cortical kidney 
perivascular stromal cells (kPSCs) we previously described. 
Materials and methods
Isolation and expansion of human kidney capsule-derived MSCs (cMSC)
Cells were isolated from kidney capsules from human transplant grade kidneys not suitable 
for transplantation due to surgical reasons. Specific research consent was given for all kidneys 
by either the donor, confirmed by the next of kin or by the next of kin directly according to 
Dutch legislation. None of the transplant donors were from a vulnerable population. The study 
was approved by the local medical ethical committee of the Leiden University Medical Centre 
(p13.054) and the ethical advisory board of the European Union consortium STELLAR. Kidney 
capsules were carefully removed from the kidney and pericapsular fat was removed. Slices 
of 1 cm3 were made and cultured with the kidney side down in a small layer of alphaMEM 
(Lonza, Verviers, Belgium) containing 5% platelet lysates (PL), 1 mmol/L glutamine (Lonza) 
and penicillin/streptomyozine (Lonza) in a T75 cell culture flask until outgrowth culture was 
obtained. Cultures were maintained at 37°C and 5% carbon dioxide. Half of the medium was 
refreshed twice a week. After confluency was reached, cells were collected using trypsin (Lonza) 
and replated at 4x103 cells/cm2. Experiments were performed with cMSCs between passage 4-8. 
The population doubling was calculated with the following formula: Cumulative PD=Σlog(N1/
N0). PD is population doubling, N1 the accumulated cell number at the end of incubation and 
N0 the accumulated cell number at the beginning of incubation.
Isolation and expansion of human kidney cortex perivascular stromal cells (kPSC)
kPSCs were isolated from human transplant grade kidneys as described previously [9]. Shortly, 
after removal of the kidney capsule for cMSC isolation, kidneys were perfused via the renal 
artery with collagenase (2500 units, NB1, Serva) and DNAse (2,5ml Pulmozyme, Genetech) at 
37°C with a flow of 100ml/min. After approximately 30 minutes, the tissue was digested and the 
resulting cell suspension was washed and collected. Cells were either directly cultured or frozen 
in liquid nitrogen. Kidney cell suspensions were cultured in alphaMEM (Lonza) containing 
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5% platelet lysates, glutamine (Lonza) and penicillin/streptomyzine (lonza). At passage 1 NG2 
cell enrichment was performed using MACS according to manufacturer’s protocol (Miltenyi 
Biotech, Gladbach, Germany) and afterwards cells were cultured in alphaMEM containing 5% 
platelet lysates. Experiments were performed between passage 4-8. bmMSCs were isolated as 
described previously [9]. 
Morphology and immunophenotype analysis
Cells were imaged with an inverted bright-field microscope (Leica DFC 295). For 
immunophenotyping, the cells were directly labelled for NG2, PDGFR-β, CD146, CD73, CD90, 
CD31, CD34, CD45, CD56, HLA class I (ABC),HLA class II (DR) (BD Bioscience, Franklink 
Lakes, NJ, USA) and CD105 (Ancell Corporation, Bayport, MN, USA) and analysed by flow 
cytometry (Accuri C6, BD Bioscience). 
Trilineage differentiation potential
cMSCs and kPSCs were cultured in adipogenic, osteogenic and chondrogenic medium 
according to manufacturer’s protocol (Lonza). Calcium deposits were shown with Alizarin Red 
in the osteogenic differentiation assay. In the adipogenic differentiation assay, lipid droplets were 
stained using Oil Red O. In the chondrogenic differentiation assay, cell pellets were formalin-
fixed (4% PFA o/n) and embedded in paraffin. 5 µm sections were de-parafinnized, rehydrated 
and incubated with 1% toluidine blue for 20 minutes. All differentiations were analysed with an 
inverted bright-field microscope (Leica DFC 295).
Microarray sample preparation and data analysis
RNA was isolated from biological triplicates of both cMSCs and kPSCs of the same donor using 
Trizol reagent (Life Technologies, Bleiswijk, the Netherlands) and the RNeasy kit (Qiagen, 
Heidelberg, Germany) according to the manufacturer’s protocols and as described previously 
[9]. RNA quality and quantity were assessed using the Bioanalyzer (Agilent Technologies, 
Santa Clara USA) and Nanodrop spectrophotometer (Nanodrop Technologies, Wesington, 
USA). Gene expression profiling was performed by Aros Applied Biotechnology (Aarhus, 
Denmark). cDNA and cRNA synthesis, labelling and hybridization on the Human HT12 V4 
Gene Expression Beadchips (Illumina Inc., San Diego, USA) were performed according to 
manufacturer’s instructions. The beadchips were scanned using iSCAN system (Illumina Inc., 
San Diego, USA) and fluorescence intensities were uploaded into GenomeStudio Software 
(Illumina Inc., San Diego, USA). Genes with a detection p-value of >0.05 for all samples were 
excluded. Subsequent data was quantile normalized and the Pearson’s correlation coefficient 
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was calculated (r2). Average signals>200 in either the kPSCs or cMSCs were considered above 
background levels. Differential expression was analysed using the gene expression module of 
Genome Studio (Illumina). For the table of the top differential expressed genes, genes were 
sorted on highest DiffScore (Illumina). For the heatmap the delta average signal of cMSCs vs. 
kPSCs was set to 200 (which is the threshold of the measurement) and the resulting 3034 genes 
selected were analysed for clustering in R software.
miRNA profiling
For miRNA-profiling, reverse transcription of total RNA of cMSCs and kPSCs of 3 donors was 
performed using the miRNA reverse transcription kit (Thermo Biosystems, Foster City, CA). 
cDNA was preamplified using Megaplex PreAmp primers pools A V2.1 (Thermo Biosystems) 
according to manufacturer’s protocol. 384 miRNAs including six controls (RNU44, RNU48, 
4*U6) were profiled using TaqMan® Array MicroRNA Human Card A V2.0 (Thermo Biosystems). 
Samples were normalized to RNU48 expression. The heatmap of 240-CT values are shown for the 
top 250 differentially expressed microRNAs. 
TGF-β stimulation assay
cMSCs and kPSCs of three different donors were seeded in a density of 200.000 cells per well in 
a 6 wells plate (costar) and stimulated for 48 hours with 10 ng/ml TGF-β1 (PreproTech, London, 
United Kingdom). Afterwards, cells were trypsinized, permeabilized with 0.1% saponin and 
labelled with α-SMA (BD Bioscience). α-SMA expression was analysed with flow cytometry 
(Accuri C6, BD Bioscience ) and mean fluorescent intensities were calculated (Kaluza, Beckman 
Coulter, Indianapolis, USA).
Vascular plexus assay
Primary human glomerular-derived micro vascular endothelial cells (hgMVEC) were purchased 
from Cell Systems (ACBRI-128, Kirkland, WA) and cultured in EGM2 medium (Lonza). kPSCs 
or cMSCs of three different donors were cocultured with hgMVECs in a 96-wells plate (Costar, 
Sigma-Aldrich) for 1 week in a 4:1 ratio (hgMVEC:cMSC/kPSC) as described previously [13]. 
After 1 week, cells were fixated with ice-cold methanol (100%) for 10 minutes and endothelial 
sprouting was visualized with CD31 immune fluorescence (BD Bioscience, Franklin Lakes, NJ, 
USA, Zeiss LSM500). The percentage capillary coverage was analysed with imageJ software. 
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Peripheral blood mononuclear cell isolation, proliferation assay and cytokine analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy blood 
donors obtained from the local blood bank by density gradient centrifugation using Ficoll-
isopaque and frozen in liquid nitrogen until use. cMSCs of 3 donors and kPSCs of 2 donors 
were plated in triplo in flat-bottom 96-well plates (Costar, Sigma-Aldrich) and allowed to attach 
overnight in DMEM-F12 with 10% normal human serum (NHS) as described previously [9]. 
cMSCs and kPSCs were seeded in increasing cell numbers to eventually get a ratio of 1:128 
(MSC:PBMC) (766 cells) to 1:4 (25.000 cells). PBMCs were stimulated with anti-CD3/antiCD28 
Dynabeads (Invitrogen) and added to the kPSCs/cMSCs in a concentration of 1x105 cells/well. 
After 5 days the supernatant was collected and 3H-thymidine (0.5 mCi) was added. After 16 
hours 3H-thymidine incorporation was determined as a measure of proliferation. Cytokine 
excretion was analysed in the supernatant with the Bio-Plex Human Cytokine 17-Plex assay 
following manufacturer’s protocols (Bio-Rad Laboratories, Veenendaal, the Netherlands).
Kidney epithelial scratch assay
cMSCs and kPSCs of 3 different donors were plated in a density of 200.000 cells/well in a 6 
well culture plate (Costar, Sigma-Aldrich) and cultured for 48 hours [9]. Subsequently, the 
supernatant was collected for the use as conditioned medium. Growth factors in the conditioned 
medium of cMSCs and kPSCs were measured using a custom made growth factor multiplex-
elisa panel following manufacturer’s instruction. (R&D systems, Minneapolis, USA). Proximal 
tubular epithelial cells (PTEC), HK-2 [14] were seeded in PTEC medium consisting of a 
Dulbecco’s modified Eagle’s medium (DMEM) F-12 (Lonza) supplemented with insulin (5µg/
ml), transferrin (5µg/ml), selenium (5ng/ml), hydrocortisone (36 ng/ml), tr-iodothyrinine (40 
pg/ml) and epidermal growth factor (10 ng/ml) (Sigma-Aldrich) in a density of 500.000 cells/
well in a 6 wells cell culture plate (Costar) and cultured until confluent. A scratch wound was 
created in the monolayer of HK-2 cells using a 200µl pipette tip. After the scratch, cells were 
washed with PBS and provided with either fresh medium (alphaMEM+5%PL) or with complete 
conditioned medium from either cMSCs or kPSCs. Scratches were imaged at 3, 6, 12 and 24 
hours at the same position in duplicates with an inverted bright-field microscope (Leica DFC 
295). The scratch area was measured at each time point using ImageJ software and the percentage 
wound closure was calculated. 
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Statistical analysis
Statistical analysis was performed with Graph Pad Prism (Graph Pad Prism Software Incl. San 
Diego, USA). Differences between kPSCs and cMSCs were analysed using either an unpaired 
two-tailed t-test or, when more variables are analysed a two way ANOVA with Bonferroni’s 
posthoc comparison analysis. Differences were considered statistically significant when p<0.05. 
Results
MSC-like cells can be isolated from the human kidney capsule
In order to analyse the presence and phenotype of stromal cells in the adult human kidney 
capsule, we stained the kidney capsule for the stromal markers CD73, CD105, PDGFR-β and 
α-SMA. All these markers are expressed in both the kidney capsule and in the perivascular 
regions of the cortex (Fig 1A). Via outgrowth culture of the kidney capsule on cell culture plastic, 
spindle shaped cells could be obtained (cMSC) (Fig 1B). 
Maker expression of cMSCs isolated from three donors were compared to the kidney 
perivascular stromal cells (kPSC) sorted from the same kidneys based on NG2-expression as 
we described previously [9]. cMSCs were, like kPSCs positive for the surface markers CD73, 
CD90, CD105 and HLA-ABC while being negative for CD31, CD34, CD45 and HLA-DR (Fig 
2A). This marker expression was robust and similar to the marker expression of kPSCs isolated 
from the same donors (Fig 2B). cMSCs showed chondrogenic, osteogenic and adipogenic 
differentiation capacity, which is different from kPSCs which lack adipogenic differentiation 
(Fig 2C). In contrast to kPSCs, there was no NG2-enrichment step needed to isolate cMSCs. 
As shown in figure 2D, there is, as observed with other MSC populations, donor variation in 
growth characteristics in both population doubling and in the moment of reaching senescence. 
Senescence was observed between 50-70 days of culture. 
cMSCs show a distinct mRNA and miRNA expression profile 
In order to evaluate the differences between cMSCs and kPSCs in more detail, Illumina 
microarray expression profiling was performed on biological triplicates. kPSCs and cMSCs 
were derived from the same donors. 35000 transcripts were analysed and cMSCs and kPSCs 
had a similar expression profile of most genes with a Pearson correlation coefficient of 0,9594 
(Fig 3A), suggesting high similarities between the cell types. However, still approximately 3000 
genes were differentially expressed. Hierarchical clustering showed clustering between cMSCs 
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and kPSCs indicating more similarities between cMSCs of different donors, than between 
cMSCs and kPSCs of the same donor (Fig 3B). This suggests that cMSC and kPSC are distinct 
cell populations. Table 1 shows the top 5 up and down regulated genes comparing the two cell 
types. The top 50 differentially expressed genes can be found in supplemental table 1. mRNA 
expression profiles. Expression profiles of cMSCs were also compared to those of bmMSCs and 
also here cMSCs and bmMSCs clustered according to cell source (supplemental figure 1A). 
Similar results were observed for the expression profile of miRNAs. Most miRNAs showed a 
similar expression profile with a Pearson correlation coefficient of 0.8614. However, 114 out of 
315 miRNAs showed a fold increase of 2 or more (supplemental table 2) and again hierarchical 
clustering was observed according to cell source and not according to donor as depicted in the 
heatmap (Fig 3D) The heatmap of cMSCs compared to bmMSCs can be found in supplemental 
figure 1B.
Figure 1: cMSC localization and isolation method A) The human kidney capsule contains a layer 
of cells which is positive for the stromal markers CD73, CD105, PDGFRβ and α-SMA. B) Outgrowth 
culture of the human kidney capsule gives rise to spindle shaped cells. Abbreviations: PDGFR-β: 
platelet-derived growth factor receptor beta, α-SMA: alpha smooth muscle actin. Scale bar 50μm




















































Figure 2: Characterization of cMSCs A) cMSCs are positive for MSC markers CD73, CD90 and 
CD105 while being negative for CD31, CD34, and CD45. This marker expression was quantified by 
mean fluorescent intensities (MFI) of three different donors and compared to the MFIs of kPSCs of 
the same donors (B). C) cMSCs are able to differentiate into cartilage, bone and fat. The latter was 
not observed in kPSCs. D) Growth characteristics of cMSCs. Abbreviations: cMSC: human kidney 
capsule-derived mesenchymal stromal cells. kPSC: kidney cortex-derived perivascular stromal 
cells. PDGFR-β: platelet-derived growth factor receptor beta, HLA: human leucocyte antigen, PD: 
population doubling. Scale bar 250μm.
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cMSCs did not transform into myofibroblasts after stimulation with TGF-β
As the kidney capsule contains a strong fibrous layer we evaluated whether cMSCs have the 
capacity to transform into myofibroblasts. However, comparable to kPSCs, cMSCs did not show 
an increased a-SMA expression after stimulation with TGF-β (Fig 4A). This indicates that cMSCs 
do not transform into myofibroblasts upon in vitro stimulation. This is in contrast to bmMSCs 
for which we previously showed that they do increase α-SMA expression upon stimulation [9]. 
Vascular network formation was stabilized by coculture of human glomerular endothelial 
cells with cMSCs and kPSCs
Due to their perivascular location, we hypothesized that kPSCs are able to stabilize endothelial 
cells to a greater extent than cMSCs. When looking at angiogenic growth factors, kPSCs indeed 
excrete vascular endothelial growth factor (VEGF) in higher levels than cMSCs. No differences 
were observed in angiopoietin 1 (ang1) excretion (Fig 4B). To assess the functional consequences, 
cMSCs and kPSCs were cocultured with human glomerular micro vascular endothelial cells 
(hgMVECs). hgMVECs alone were not able to form vascular networks, however, coculture with 
either cMSCs or kPSCs gave rise to the formation of vascular tubular structures in a vascular 
network (Fig 4C). There were no d ifferences in  the amount of  vascular tubular st ructures as  
quantified in figure 4D.
Figure 3. Transcriptome analysis of human cMSCs compared to kPSCs of the same donor 
kidneys. A) cMSCs and kPSCs show in general similar expression profiles when comparing all 
transcripts (35000) as depicted by a Pearson correlation of 0,9594. B) When analyzing the 3000 
differentially expressed genes, cMSCs and kPSCs show hierarchical clustering according to isolation 
area and not according to donor as depicted in the dendrogram and heatmap. C) When comparing 
all 315 analyzed miRNAs, cMSCs and kPSCs showed a similar miRNA expression profile (Pearson 
correlation coefficient of 0.86) with hierarchical clustering into cMSC and kPSCs as depicted in the 
dendrogram and heatmap of the top 50 differentially expressed miRNAs.(D). Biological triplicates. 
Abbreviations: cMSC : kidney capsule-derived MSC, kPSC: kidney cortex perivascular stromal cell, 
FI: fluorescent intensity. GEO accession number GSE101973, https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE101973.





















































Figure 4. Functional similarities between cMSCs compared to kPSCs. A) Analysis of α-SMA 
expression in kPSCs and cMSCs after TGF-β stimulation show no up regulation of α-SMA. B) 
Excretion of angiogenic factors VEGF, Ang1 and Ang2 by kPSCs and cMSCs. cMSC excrete less 
VEGF compared to kPSCs. C) representative CD31 immunofluorescence of hgMVECs in coculture 
with either kPSCs or cMSCs show capillary network formation D) There is no significant difference 
in capillary coverage comparing kPSCs with cMSCs. Abbreviations: cMSC: human kidney capsule-
derived mesenchymal stromal cell, kPSC: kidney cortex-derived perivascular stromal cell, α-SMA: 
alpha smooth muscle actin, TGF-β: transforming growth factor beta, w/o: without, MFI: mean 
fluorescent intensity. hgMVEC: human glomerular micro vascular endothelial cells, capp: capillary 
coverage, VEGF: vascular endothelial growth factor, Ang: angiopoietin, n.s.: non-significant. *p<0.05
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cMSCs are more immunosuppressive compared to kPSCs
To evaluate the immunosuppressive capacity of cMSCs a peripheral blood mononuclear cell 
(PBMC) suppression assay was performed. In this assay, PBMCs were activated with polyclonal 
CD3/CD28 activation in the absence or presence of increasing amounts of cMSCs or kPSCs. 
While kPSCs were only able to inhibit PBMC proliferation at high MSC:PBMC ratios (1:8 and 
1:4), cMSCs already showed an effect at lower cell numbers and showed significantly more 
inhibition than kPSCs (Fig 5A). This is to a similar extent compared to the inhibition by bmMSCs 
as shown in supplemental figure 2A. Moreover, the excretion of the pro-inflammatory cytokine 
IFN-y by the activated PBMCs was lower in coculture with cMSCs than in coculture with kPSCs 
indicating more immunosuppression by the cMSCs (fig 5B). When looking at general cytokine 
excretion profiles, unstimulated cMSCs and kPSCs excrete similar levels of major cytokines (Fig 
5C). However, the secretome of unstimulated MSCs does not reflect their functionality while the 
decrease in IFN-y excretion by PBMCs does. 
cMSCs were not able to enhance human kidney epithelial repair
We previously showed that the conditioned medium of kPSCs was, in contrast to the conditioned 
medium of bmMSCs, able to accelerate kidney tubular epithelial repair in a kidney epithelial 
wound scratch assay and that this effect was HGF depended [9]. When looking at major growth 
factors, most growth factors showed similar excretion profiles, with the exception of HGF. HGF 
was excreted in a more than 200 fold lower concentration by cMSCs compared to kPSCs. This 
also resulted in a decreased epithelial wound healing by the conditioned medium of cMSCs 
as shown in figure 5E and quantified in figure 5F. This lack of kidney epithelial wound scratch 
healing capacity is similar to what is observed with bmMSCs as shown in supplemental figure 
2B. 
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Discussion
Previously it has been shown that from most organs MSC-like cells can be isolated. These organ-
derived MSC like cells are mainly isolated from the perivascular compartment and exhibit tissue 
specific properties15, 16. From the human kidney cortex perivascular stromal cells could also be 
isolated and these cells showed kidney-specific regeneration and integration properties when 
compared to bmMSCs 9, 17. 
Here we show that within the human kidney, not only in the cortical perivascular compartment 
of the kidney but also in the kidney capsule, a MSC-like cell population is present. Although 
there were similarities between the cell types in for example marker expression and vascular 
stabilisation properties, there were also major differences. Though isolated from the same donors, 
cMSCs showed a distinct mRNA and miRNA expression profile with clustering according to cell 
type and not to donor. Moreover, cMSCs showed increased immunosuppressive capacities while 
lacking the properties to accelerate kidney epithelial wound healing. Thus, cMSCs are a distinct 
kidney-derived MSC-like cell population. 
Figure 5: Functional differences between cMSCs and kPSCs. A) Within a PBMC suppression 
assay, cMSCs were able to suppress PBMC proliferation significantly more than kPSCs. B) cMSCs 
were able to decrease the IFN-y excretion in the PBMC suppression assay, indicating more 
immunosuppression by cMSCs. C) Unstimulated kPSCs and cMSCs excreted similar levels of 
major cytokines. D) When looking at growth factors, cMSC-conditioned medium contained a 200-
fold lower concentration of HGF compared to kPSCs while no significant differences were observed 
in other growth factors. E) While kPSCs are able to accelerate wound closure in a kidney epithelial 
wound scratch assay, cMSCs did not show this potential, as quantified in F). Abbreviations: cMSC: 
human kidney capsule-derived mesenchymal stromal cell, kPSC: kidney cortex derived perivascular 
stromal cell, act.: activated, PBMC: peripheral blood mononuclear cells, IFN-γ: interferon gamma, 
GM-CSF: granulocyte-macrophage colony-stimulating factor, MCP-1: monocyte chemo attractant 
protein-1, MIP-1b: macrophage inflammatory protein-1beta, TNF-a: tumor necrosis factor alpha, 
FGF: fibroblast growth factor, HGF: hepatic growth factor, Endo-1: endothelin 1, PDGF: platelet-
derived growth factor. *p<0.05, ** p<0.01, ***p<0.001.
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Only few studies have been performed comparing MSC-like cells isolated from one tissue. 
Functional differences have been described between different isolation sides of adipose tissue 18, 
19. Naftali-Shani et al., for example, showed that MSCs isolated from the pericardial fat, epicardial 
fat and subcutaneous fat showed distinct cytokine excretion profiles, mRNA expression profiles 
and reparative properties. Interestingly and unexpectedly, cardiac dysfunction after myocardial 
infarction was worst after transplantation of MSCs from the epicardial fat compared to 
subcutaneous fat MSC transplantation and control 18.
MSCs are usually studied as candidate cells for cellular therapies. Although the in-organ 
differential functionality of MSCs are of interest to our understanding of the structural biology 
of the kidney, cMSCs are less likely to be used as candidate for clinical therapies. In clinical trials 
usually 2 cell infusions of 1-2 million cells per kilogram body weight are given 12. To obtain such 
cells numbers, cMSCs should be isolated from several different donors for infusion into one 
patient, which makes the use of cMSCs less feasible compared to other MSC sources. 
This is the first description of the functional characteristics of human kidney capsule-derived 
MSCs. Moreover, this is the first extensive functional comparison between kidney cortex 
derived and kidney capsule-derived MSC-like cells. The differences observed between the cells 
types in gene expression profile and functionality may reflect site-specific differentiation during 
organogenesis 
Conclusion
cMSCs are a distinct, novel human kidney-derived MSC-population which underpins the large 
functional diversity of phenotypic similar stromal cells in relation to their anatomic site, even 
within one organ.
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Supplemental figure 1. Gene and miRNA expression profiles of cMSCs compared to 
bmMSCs and kPSCs. A) Heatmap of mRNA expression profiles of cMSCs, bmMSCs and kPSCs 
show hierarchical clustering according to cell source. B) Heatmap of miRNA expression profiles. 
Abbreviations: cMSC: human kidney capsule-derived mesenchymal stromal cell, kPSC: kidney 
cortex derived perivascular stromal cell































































Supplemental figure 2. Functional comparison of kPSC, bmMSC and cMSC. A) Within a PBMC 
proliferation assay cMSCs were able to supress PBMC proliferation significantly more than kPSCs 
and to a similar extent as bmMSCs. B) Both bmMSCs and cMSCs were not able to accelerate 
epithelial wound healing while kPSCs did show this potential. Abbreviations: cMSC: human kidney 
capsule-derived mesenchymal stromal cell, kPSC: kidney cortex derived perivascular stromal cell, 
act.: activated, PBMC: peripheral blood mononuclear cells, n.s non- significant, *p<0.05, ** p<0.01, 
***p<0.001.
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Abstract
The bioengineering of a replacement kidney has been proposed as an approach to address 
the growing shortage of donor kidneys for the treatment of chronic kidney disease. One 
approach being investigated is the recellularization of kidney scaffolds. In this study, we 
present several key advances towards successful re-endothelialization of whole kidney 
matrix scaffolds from both rodents and humans. Based on the presence of preserved 
glycosoaminoglycans within the decelullarized kidney scaffold, we show improved 
localization of delivered endothelial cells after pre-loading of the vascular matrix with 
VEGF and angiopoietin 1. Using a novel simultaneous arterio-venous delivery system, 
we report the complete re-endothelialization of the kidney vasculature, including the 
glomerular and peritubular capillaries, using human iPSC-derived endothelial cells. 
Using this source of endothelial cells, it was possible to generate sufficient endothelial 
cells to recellularize an entire human kidney scaffold, achieving efficient cell delivery, 
adherence and endothelial cell proliferation and survival. These major advances move 
the field closer to a human bioengineered kidney. 
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Introduction
Kidney transplantation is at present the best therapy for patients with end stage renal disease 
(ESRD). However, there is a shortage of donor organs while the incidence of ESRD is increasing1. 
Moreover, long term outcomes after kidney transplantation are compromised by the effects of 
rejection and nephrotoxicity of immunosuppressive therapies. An autologous bioengineered 
kidney with patient-derived cells would therefore constitute an attractive alternative. One 
proposed, but as yet unachieved, approach to generating such a replacement tissue is via the 
decellularization and subsequent recellularization of kidney matrix scaffolds. 
Several considerations have to be taken into account when developing a clinically applicable 
bioengineered kidney using such an approach. Recellularization should be performed with 
human cells, preferably patient-derived or HLA-matched. In addition, large numbers of cells are 
required for whole organ recellularization, and hence scalability is a major challenge. Human 
inducible pluripotent stem cell (hiPSC)-derived kidney and endothelial cells are an interesting 
cell source for bioengineering, given their potential for expansion and possibility for autologous 
transplantation2,3. However, the ultimate success of the approach will also rest with the capacity 
for a decellularized scaffold to support and instruct the delivered cells.
The first studies investigating the use of decellularized kidney scaffolds showed that the vascular 
compartment of rat kidney scaffolds can be recellularized with either primary endothelial 
cells or mouse embryonic stem cells, some of which showed differentiation into endothelial 
phenotypes4-8. Such studies were performed with mouse and rat scaffolds and cells. However, 
the resulting endothelial coverage after recellularization was low, as only around 5% coverage 
was reported5. To date, no bioengineering attempts have been performed using human kidney 
scaffolds recellularized with human cells. 
These results reflect the need for novel strategies to enhance endothelial coverage and the 
translation towards a human bio-engineered kidney. For the lung, Ren et al. described an 
extensive re-endothelialization study of scaffolds using human iPSC-derived endothelial cells 
(hiPSC-ECs) where combining arterial and venous infusion of both endothelial cells and 
pericytes resulted in 75% re-endothelialization9. However, as the microvascular diameter in 
the glomeruli is low, combined infusion of endothelial cells and relatively large pericytes in the 
kidney would most likely lead to obstructed glomerular arterioles and is therefore probably less 
feasible for the kidney. 
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The major function of pericytes is the support of endothelial cells via the local production of 
growth factors such as vascular endothelial growth factor (VEGF) and angiopoietin 1 (Ang-
1)9-11. These factors are well known for their instructiveness for endothelial cell adherence, 
survival and differentiation9-11 and often share the requirement of glycosaminoglycans (GAG) 
as extracellular matrix components to exert their effects12,13. Based on this knowledge, we 
hypothesized that, were GAGs maintained within the decellularized kidney matrix, pre-loading 
the kidney scaffolds with growth factors would provide a novel strategy to enhance endothelial 
localization without the need for co-infusion of pericytes. 
Here, we show an extensive characterization of the GAG landscape of the decellularized kidney, 
including the functional importance of these GAGs in growth factor binding. Human kidney 
scaffolds loaded with the growth factors VEGF and Ang-1 did result in improved endothelial 
cell adherence and survival. Moreover, we describe several new optimized, scalable strategies to 
bio-engineer the kidney vasculature from human iPSC-ECs in a custom made perfusion-culture 
system and provide a proof of concept for scale up via the re-endothelialization of a complete 
human decellularized kidney scaffold. 
Methods
Whole organ decellularization of rat and human kidneys
All animal experiments were approved by the animal care and use committee of the Leiden 
University Medical Center. Research consent was given for all human kidneys. Rat and human 
kidneys were decellularized adapted from a protocol described previously14. 
In short, 12 week old Lewis rats (Charles River) were systemically heparinized with 5000 U 
heparin (Leo Pharma, Balledrup, Denmark) and the kidneys were flushed with University of 
Winsconsin (UW) cold storage solution (Bridge to life, Elkhorn, WI) containing heparin (Leo 
Pharma). Kidneys were explanted and cannulated via the renal artery and renal vein with a 24G 
Neoflon (Becton Dickinson Medical, Erembodegem, Belgium), and ureter with a 26G Neoflon 
(Becton Dickinson Medical) and perfused with 1% SDS (w/v) (Sigma Aldrich) in PBS containing 
2% penicillin/streptomycin (Life technologies), 6µg/ml ciprofloxacine (Fresenius Kabi), 0.1% 
fungizone (w/v) (Bristol-Myers Squibb), and 2500E DNAse (pulmozyme, Roche) for 12 hours 
under a constant pressure of max 50 mmHg. Afterwards the kidneys were washed for 15 minutes 
with dH2O and perfused with 1% Triton-X 100 (v/v) (Sigma Aldrich) for 30minutes. Then the 
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kidneys were perfused with PBS containing antibiotic/antimycotic for at least 48 hours and kept 
in this solution until usage. Patency of both the arterial and venous vascular bed was confirmed 
by methylene blue perfusion (supplemental figure 1A). 
Human transplant grade kidneys discarded mainly for surgical reasons were flushed with 
UW cold storage solution containing heparin directly after procurement and were stored on 
ice. Within 30 hours, kidneys were again flushed with PBS with heparin (500 IE/L) and the 
perirenal fat and kidney capsule were removed. The renal artery was cannulated with a Luer-
lock connector (Cole-Parmer) and the kidney was perfused with 1% SDS in PBS containing 
antibiotics, antimycotics and DNAse as used with the rat kidneys, under a constant pressure of 
maximal 75 mmHg for 5 days. Afterwards the kidneys were perfused overnight with dH2O with 
antibiotics, antimycotics and DNAse. Then the kidneys were flushed with 1% (vol/vol) Triton-X 
100 (Sigma) for 1 day and afterwards flushed with PBS with antibiotics, antimycotics for at least 
5 days, all under a constant pressure of max. 75 mmHg. Kidneys were stored at 4 ˚C in PBS 
until further use. Samples of approximately 1cm3 were taken and either snap-frozen in liquid 
nitrogen, fixed for paraffin embedding or for EM. 
Immunofluorescence stainings
Biopsies of de- and recellularized kidneys were fixed overnight in 4% formaldehyde (Klinipath), 
stored in 70% ethanol and embedded in paraffin. 4 µm thick sections were cut and following 
rehydration of the tissue samples, antigen retrieval was performed by heating the slides in citrate 
buffer (pH 6). Primary antibodies against laminin (Sigma-Aldrich), collagenIV(NovusBio), 
fibronectin (Abcam), CD31 (Pharmingen), VEGF (Biovision) and Angiopoietin-1 (Santa-cruz), 
were used. GAGs were shown with the lectins WGA (Invitrogen), LEA (Sigma-Aldrich), heparan 
sulfate specific antibodies (clone 10E4 (Amsbio) and JM403 (Dr. J. van der Vlag, RadboudUMC, 
Nijmegen)) and a fluorescent-labeled hyaluronan specific binding protein neurocan-eGFP 
(custom made, adapted from previous published protocol18). As secundary antibodies anti-
mouse, anti-rat and anti-rabbit Alexa Fluor 488, 568 and 647 (Molecular Probes) were used. 
Nuclei were counterstained using Hoechst 33258 (ThermoFisher). Sections were imaged using 
SP8-WLL confocal microscopy and displayed using LAS-X software (Leica). 
Cell culture hgMVECs
Human glomerular microvascular endothelial cells (hgMVECs) (Bio-connect) were cultured in 
EGM2 (Lonza) in gelatin coated (Sigma-Aldrich) T175 culture flasks in a density of 2 million 
cells per flask. 
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Endothelial cell differentiation from hiPSCs and expansion method
Human pluripotent stem cell derived endothelial cells were generated and expanded as 
described previously2 with minor adaptation for large scale culture. In short hiPSCs (NCRM-1) 
were cultured in TeSR-E8 medium (StemCell Technologies) and passaged at day -4. For large 
scale culture the cells were passaged to a T175 cell culture flasks. Medium was refreshed at 
day -3 and at day 0 the differentiation starts by Mesoderm induction medium consisting of 
B(P)EL medium containing 30 ng/ml BMP4 (Miltenyi Biotec), 25 ng/ml Activin A (Miltenyi 
Biotec) 1.5 µM CHIR99021 (Tocris Bioscience) and 50 ng/ml VEGF165 (R&D Systems). At day 
3 medium was replaced by Vascular induction medium consisting of B(P)EL containing 50 ng/
ml VEGF and 10 µM SB431542 (Tocris Bioscience) and was refreshed again at day 7 and 9. At 
day 10 endothelial cells were isolated with CD31-dynabeads (Invitrogen) and the CD31-positive 
fraction was cultured in EC-SFM medium (GIBCO) on gelatin coated (Sigma-Aldrich) T175 cell 
culture flasks. Cells were either replated (1:3) or cryopreserved when the flask is fully confluent 
after isolation. CD31, VE-CAD, Tie2 and VEGFR2 (R&D systems) immunofluorescence was 
stained as described above on hiPSC-ECs cultured on coverslips and fixed with 4% PFA. Before 
recellularization experiments, cells were thawn using standard protocols and reseeded in gelatin 
coated T175 cell culture flasks with EC-SFM. Recellularization was performed with hiPS-EC at 
passage 2-3.
Growth factor loading scaffolds
20 µm slices of cryopreserved tissue of three different human decellularized kidneys were made 
with a microtome and placed on 18 mm coverslip in 24 well plates (Corning). All experiments 
were performed with 3 slices per kidney of three different donor kidneys. When indicated, 
scaffold slices were incubated with either 100 UI/ml hyaluronidase (Sigma-Aldrich) or 1/0.6 UI/
ml Heparinase I/HeparinaseIII (Sigma-Aldrich) and protease inhibitor (ThermoFischer) for 4 
hours at 37˚C. Samples were washed three times with PBS and coated with resp. 0, 10, 100 and 
1000 ng/ml VEGFA 165 (PreproTech) or Ang1 (R&D systems) in PBS overnight at 4 ̊ C. Samples 
were fixed with 4% paraformaldehyde (Klinipath) in PBS before staining. Scaffolds were stained 
for resp. VEGF, heparan sulfates (10E4), Ang1 and laminin as described above and images of 2 
areas per slide of 3 different kidney scaffolds were taken with confocal microscopy (Leica TSC 
SP8 WLL). Maximum intensity was analyzed in LAS-X software (Leica). 
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Endothelial cell adherence to human kidney scaffold
hgMVECs and iPS-ECs were incubated on human kidney slices placed on coverslips in 
a concentration of 50.000 cells per well in a 24-well plate. hgMVECs were cultured in EBM 
(Lonza) and iPS-ECs were cultured in EC-SFM without VEGF. Cells were incubated on scaffold 
slices for 24 hours and afterwards fixed with 4% paraformaldehyde (Klinipath) in PBS for 10 
minutes and washed three times with PBS. Slices were stained for CD31 and laminin, analyzed 
with fluorescence microscopy (Zeiss LSM500) (3 areas per slide) and the CD31/laminin ratio 
was determined in triplicates (Image J).
Whole organ recellularization set-up
The recellularization set-up contained a sterilized custom-made air-tight organ chamber, 
sterilized perfusion tubes (LS13 for rat kidneys and LS25 for human kidneys) (Masterflex), a 
pressure probe (Edwards Lifesciences) and a custom-made pressure controller. Pressure-driven 
perfusion was achieved with a masterflex pump. For gas exchange 3,35/4,65 mm silicon tubes 
(Helixmark, Freudenberg Medical) were used. At the end of the silicon tubing a filter was 
attached as a bubble trapper (Millex-FG, 0.20μm, Merck). The cannulated kidney artery, vein 
and ureter were connected to 3 way taps (Discofix, Braun). A 3 way tap with an inlet tube (LS-
13) for the cells was placed. A negative pressure of -30 mmHg was achieved by attaching a filter 
(Millex-FG, 0.20μm, Merck) and LS-25 (Masterflex) to the airtight chamber with a pressure 
probe (Edwards Lifesciences) and a custom-made pressure controller. 
Whole kidney scaffold rat re-endothelialization rat kidney with hgMVEC
Rat decellularized kidneys were placed in custom-made organ chambers and overnight perfused 
with 1000 ng/ml VEGF in EBM2 basal medium (Lonza) in a recellularization loop. Afterwards 
kidneys were flushed with fresh EGM2. During recellularization, the organ chamber pressure 
was set to -30 mmHg via a pressure-controled masterflex pump. For arterial infusion (n=1), 30 
million cells were resuspended in 15 ml medium and placed in an infusion bag (Transfer pack, 
600ml, Fenwall Inc.) on a shaker plate and infused into the renal artery at an average flow of 
90 μl/min into the recirculation loop under a maximum pressure of 175 mmHg. The bag was 
flushed with 5ml medium and 30ml of medium was added to the organ chamber. Medium was 
recirculated. For venous infusion (n=1), 30 million cells were infused via the renal vein at a flow 
of 1.2 ml/min at a maximum pressure of 20 mmHg. For arterial and venous infusion (n=4), 20 
million cells were resuspended in 7.5 ml EGM2 and infused into the renal vein at an average flow 
of 600 μl/min under a maximum pressure of 20 mmHg. The bag was flushed with 5ml medium. 
Cells were recirculated through the renal vein for 3 hours and then 10 million cells were infused 
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in 5 ml EGM2 over the renal artery with a maximum pressure of 75 mmHg and recirculated 
followed by 5 ml of EGM2. Medium was refreshed daily and the maximum pressure was kept 
at 100mmHg. Recellularized kidneys were perfused with live cell Hoechst (ThermoFisher) 
and harvested after 48 hours. Half of the kidney was fixed in PFA and placed in paraffin. The 
other half was snap frozen in liquid nitrogen. When indicated, hgMVECS were first labeled 
with Qtracker625 and Qtracker705 according to manufacturer’s protocol (ThermoFisher) and 
imaged using second harmonics generation (SHG) on a multiphoton microscope (Zeiss).
Re-endothelialization of rat kidney matrices with hiPSC-derived endothelial cells
The protocol used for whole organ recellularization with hiPSC-derived EC is comparable to the 
combined arterial and venous recellularization with hgMVECs with the exception that instead 
of EGM2 the kidney is perfused with EC-SFM. Kidneys were perfused either under a constant 
pressure of maximal 75mmHg or when the flow was above 1.2 ml/min a constant flow of 1.2 ml/
min. 
Medium was refreshed daily and recellularized kidneys were harvested either 48 hours (n=3), 5 
days (n=2) or 13 days (n=2) after recellularization as indicated. 
Re-endothelialization of human kidney scaffold with hiPS-derived endothelial cells
A decellularized human kidney was perfused o/n with 1 μg/ml VEGF and 1 μg/ml Ang1 in 
EC-SFM at a pressure of 50 mmHg resulting in a flow of 27 ml/min. Afterwards the kidney was 
perfused with fresh EGM2. Next the chamber pressure was set to -30 mmHg and 60 million cells 
were infused via the renal vein at 20 ml/min flow and kept in a recirculation loop for 3 hours. 
Afterwards 70 million cells were infused via the renal artery at a 20 ml/min flow. The chamber 
pressure was changed to 0 mmHg and the kidney was perfused via the renal artery at a flow of 20 
ml/min for 24 hours resulting in a pressure of 35-50 mmHg. Biopsies of 1cm3 were taken out of 
10 different areas of the kidney cortex, medulla and papilla and were either snapfrozen or fixed 
in 4% paraformaldehyde and parafinized. 
Quantification of endothelial coverage and proliferation
All recellularized kidneys were deparafinized and immunohistochemically stained with CD31 
and Ki-67 (BD Pharmingen) followed by rabbit anti-mouse-HRP (Dako) and NovaRed (Vector 
labs) and imaged in a slidescanner (3D Histech). From the rat kidneys one complete slide per 
recellularized kidney was analyzed. From the human recellularized kidney slides of 7 different 
areas of the kidney including cortex, medulla and papilla were analyzed. In these slides the cortex, 
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medulla, obstructed vessels and glomeruli were annotated by unbiased observers and CD31 
coverage was analyzed with Quant center software (3DHIstech). Percentage CD31 positivity 
compared to total tissue was calculated and compared to normal human kidney. Ki-67 (Abcam) 
positive nuclei per slide were counted and compared to the total nuclei per slide. 
Transmission Electron Microscopy
Small pieces (~1mm2) of recellularized kidney scaffold were fixed overnight at 4°C in 1.5% 
glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.1M sodium-cacodylate 
buffered solution, with a pH of 7.4. Afterwards, the tissue blocks were washed twice with sodium 
cacodylate buffer, then fixed in 1% osmium tetroxide (Electron Microscopy Sciences, Hatfield, 
PA) in 0.1M sodium cacodylate buffer for 1 hour. Samples were further rinsed twice with 0.1M 
sodium-cacodylate buffer, followed by dehydration steps of 70% ethanol (overnight), 80% 
ethanol (10 min), 90% ethanol (10 min), and 100% ethanol absolute (2x 15 min; 1x 30 min).
The probes were subsequently infiltrated with a mixture of 1:1 epon LX-112 (Ladd Research, 
Williston, VT) and propylene oxide (Electron Microscopy Sciences, Hatfield, PA) for 1 hour, 
then with pure epon for 2 hours, embedded in pure epon, mounted in BEEM plastic capsules 
(Agar Scientific, Essex, UK) and polymerized for 48 hours at 60°C. Ultrathin sections of 100 nm 
were collected on copper slot grids (Storck Veco B.V., Eerbeek, The Netherlands), covered with 
formvar film and a 7nm carbon layer. The sections were stained afterwards with an aqueous 
solution of 7% uranyl acetate (20 min), followed by Reynold’s lead citrate (10 min). Samples 
were analysed at an acceleration voltage of 120 kV with an FEI Tecnai 12 transmission electron 
microscope (FEI, Eindhoven, The Netherlands), equipped with a FEI 4k Eagle CCD camera. 
Scanning Electron Microscopy
Tissue samples were fixed and dehydrated using the same protocol as for TEM. The 100% ethanol 
absolute dehydration step was followed by critical point drying. Afterwards, the probes were 
further mounted on 0.5"SEM pin stubs (Agar Scientific, Essex, UK) covered with conductive 
carbon discs (Agar Scientific, Essex, UK), and coated with gold-palladium. Images were acquired 
with a JEOL JSM-6700F Field Emission Scanning Electron Microscope (JEOL (Europe) B.V.).
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Statistical analysis
Statistical analysis was performed by two-way analysis of variance with Bonferroni’s post hoc 
comparison. Differences were considered statistically significant when p<0.05. Values in graphs 
are presented as means with standard deviation. Data analysis was performed using GraphPad 
Prism, version 5.0 (Graph-pad Prism).
Results
Perfusion-decellularized human kidneys show preservation of microarchitecture and major 
ECM components including glycosaminoglycans
Human and rat kidneys were decellularized via the renal artery with 1% SDS followed by 1% 
Triton-X100 as described previously14 (Fig. 1A). Tissue micro-architecture was preserved as 
shown with scanning electron microscopy (SEM) (Fig 1B, C). Histology of the decellularized 
human kidneys showed preservation of extracellular matrix components collagen IV, 
fibronectin and laminin with complete removal of nuclei (Fig. 1D). Moreover, GAGs including 
heparan sulfates and hyaluronan were preserved (Fig. 1E). Similar results were obtained with rat 
decellularized kidneys (Supplementary Fig. 1). 
Decellularized human kidney matrix can be loaded with vascular growth factors through 
binding to glycosaminoglycans
As GAGs are still preserved after the decellularization method used, and GAGs are important for 
growth factor binding, we analyzed whether vascular growth factors can still bind to these GAGs. 
Indeed, we were able to load both the glomerular and tubular compartment of human kidney 
scaffold slices from three different donors with recombinant VEGFA 165, which localized to the 
heparan sulfates in the ECM (Fig. 2A, B). Moreover, removal of heparan sulfates by heparinase 
treatment led to lower VEGF binding to the scaffold, while hyaluronidase treatment did not 
influence VEGF binding (Fig. 2B and Supplementary Fig. 2). This indicates that the binding of 
VEGF to the scaffold is dependent on heparan sulfates and the binding domain of VEGF13,15. 
Kidney scaffolds from three different donors could also be loaded with Ang-1 (Fig. 2C, D). 
In this case, Ang-1 binding did not appear to be dependent upon the presence of the GAGs 
hyaluronan and heparan sulfate (Fig. 2D).
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Figure 1 Decellularized human kidneys show intact integrity and glycosaminoglycan (GAG) 
landscape. A) Macroscopic pictures of human kidney before (left) and after decellularization (right). 
B) Scanning electron microscopy (SEM) images of decellularized human kidney show preservation 
of tissue architecture after decellularization. C) Detailed SEM image of a decellularized glomerulus. 
D) Extracellular matrix components are preserved as shown by hematoxylin, collagen IV, fibronectin 
and laminin staining of human decellularized kidneys (lower panels) compared to native kidney 
(upper panels). E) The GAG landscape of the human kidney is preserved after decellularization as 
depicted by WGA, LEA, 10E4 (heparan sulfates), JM403 (heparan sulfates) and neurocan-eGFP 
(hyaluronan) stainings. Abbreviations: WGA: wheat germ agglutinin, LEA: lectin from Lycopersicon 
esculentum. Scalebar B,C 10 μm; D,E 100 μm.
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Growth factor loading is critical for endothelial cell adherence and survival on the human 
kidney matrix
The functional effects of growth factor loading on endothelial cell adherence and survival to the 
kidney matrix were analyzed. For this purpose, human glomerular microvascular endothelial 
cells (hgMVEC) were cultured on slices of human kidney scaffolds in triplicate with or without 
VEGF loading (Fig. 2E). An increase in endothelial cell adherence and survival was observed on 
VEGF-loaded scaffolds compared to non-loaded scaffolds, as quantified in figure 2F. Removal of 
heparan sulfates led to a decreased endothelial cell adherence in line with the decreased VEGF 
binding (Fig. 2F). Ang1 loading also had an effect on hgMVEC cell adherence and survival (Fig. 
2G, H). These data illustrate the importance of the growth factor binding capacity of the scaffold 
for endothelial cell adherence and survival, and are a novel strategy to enhance revascularization.
Combined arterial and venous recellularization in whole kidney scaffold is the best 
strategy to achieve an in situ bioengineered kidney vasculature 
For whole kidney scaffold recellularization, a custom-made, air tight, sterilizable organ culture 
chamber was developed. This chamber was designed in such a way that optimal recirculation 
of medium without air infusion could be achieved (Fig 3A, B). This organ culture chamber 
was connected to a pressure controlled perfusion system, allowing separate recellularization 
of the arterial, venous and ureteric compartments (Fig 3C,D). Different infusion protocols, 
via the artery, the vein, or first the vein followed by the artery after 3 hours were compared. 
Figure 2 Growth factor loading of the kidney scaffolds results in increased endothelial cell 
adherence and survival. A) Slices of human kidney scaffold can be loaded with VEGF which is 
heparan sulfate dependent. B) Quantification of VEGF loading capacity shows enhanced VEGF 
binding after VEGF loading. C) Scaffolds can also be loaded with Ang1, independent of heparan 
sulfates and hyaluronan. D) Quantification of Ang 1 binding. E) Representative images of CD31 
staining after 24 hour culture of hgMVEC on VEGF loaded scaffolds showing enhanced endothelial 
cell adherence and survival after VEGF loading which was not observed after removal of heparan 
sulfates. F) Quantification of re-endothelialization after VEGF loading. G) Representative images of 
hgMVEC culture on Ang1 loaded scaffolds show enhanced endothelial cell adherence and survival 
after Ang1 loading. H) Quantification of hgMVEC adherence and survival after Ang1 loading. 
Abbreviations: VEGF: vascular endothelial growth factor A 165, Ang1: angiopoietin 1, hgMVEC: 
human glomerular microvascular endothelial cells, ns: non-significant, * p<0,05, *** p<0,001, **** 
p<0,0001. Scalebars 100 μm. 
d.leuning-layout.indd   157 22/05/2018   16:43
158 Chapter 7
Using this device, human glomerular microvascular endothelial cells (hgMVECs) were infused 
into either the artery, vein or both the arterial and venous arm of the vasculature of growth factor 
loaded rat kidney scaffolds and scaffolds were then analyzed after 48 hours of culture. As shown 
in figure 3E, arterial perfusion of the cells led to large obstructions in the afferent arterioles in the 
cortex (30%), while hardly any cells were observed in the medulla and papilla (13%) (Fig. 3E). 
In contrast, venous infusion of cells led to re-endothelialization of the peritubular capillaries 
in both the cortex (100%) and medulla (25%) with some glomerular re-endothelialization 
(20%) (Fig. 3E). The combination of arterial and venous perfusion showed both glomerular and 
peritubular re-endothelialization. No cells were observed in the tubular compartment, as shown 
with laminin-CD31 double staining, confirming that the basement membrane remains intact 
after cell infusion. While arterial and venous infusion separately resulted in 20% glomerular 
re-endothelialization, combined infusion increased the coverage to 50%. Compared to arterial 
infusion, combined infusion also resulted in an increase of medullary re-endothelialization 
from 13% to 42%. However, there were still some obstructed afferent arterioles observed (17%) 
(Fig 3E). In order to trace hgMVECs administered into either the arterial or venous arm of the 
vasculature, hgMVECs were labeled with two different Qdots. Live-cell imaging with second 
harmonics generation (SHG) showed that peritubular capillaries and part of the glomeruli were 
re-endothelialized via the renal vein while the afferent arteriole and the glomeruli were re-
endothelialized via the renal artery (Fig. 3F). 
Figure 3. A novel arterio-venous delivery system for whole organ tissue engineering. A) 
Kidney matrices were cultured in custom-made organ chamber as shown in front view and B) 
side view. C) Schematic representation of recellularization set-up. D) Image of recellularization 
set-up. E) Representative images after whole organ recellularization of hgMVECs. Infusion via only 
the artery shows obstruction of the afferent arteriole and glomeruli, via only the vein shows re-
endothelialization of the peritubular capillaries in both the cortex and medulla and some glomeruli 
while combined infusion show re-endothelialization of both peritubular capillaries and glomeruli. F) 
Representative live-cell images with differential Qdot labeling and second harmonics generation 
(SHG) show re-endothelialization of peritubular capillaries and part of the glomeruli via the renal vein 
(Qdot 625, green) while the afferent arteriole and the glomeruli were re-endothelialized via the renal 
artery (Qdot 705, red). Abbreviations: SHG: second harmonics generation, recirc: recirculation, A: 
arterial inlet, V: venous inlet, U: ureteric inlet, p: pressure sensor. Scalebars 100 μm
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Induced pluripotent derived endothelial cells are able to adhere to, and survive on growth 
factor loaded human kidney scaffolds
Optimal bioengineering of an autologous replacement human kidney would require large 
numbers of human or patient-derived cells. In order to achieve this, we examined whether 
human iPSC-ECs (hiPSC-ECs) are a suitable candidate for re-endothelialization of the kidney 
scaffold. In order to obtain large quantities of hiPSC-ECs, a previously described hiPSC-EC 
differentiation protocol2 was adjusted for large scale production by increasing the culture surface 
during differentiation from a 6 well plate format towards the use of multiple T175 cell culture 
flasks (Fig. 4A). The resulting cells expressed the endothelial differentiation markers CD31 and 
VE-cadherin, and were positive for both VEGF receptor 2 and Tie2 (Fig. 4B), suggesting that 
they will be responsive to VEGF and Ang1. In agreement, VEGF loading of the scaffold resulted 
in increased adherence and survival of hiPSC-ECs on human kidney scaffold slices (Fig. 4C). A 
similar trend was observed with Ang1-loading and combined loading (Fig. 4C) as quantified in 
figure 4D.
Rat whole kidney scaffold re-endothelialization with hiPS-ECs
Growth factor loaded decellularized rat kidneys were recellularized with hiPSC-ECs via both 
the renal artery and vein as described above. Indeed, after 48 hours re-endothelialization of 
the glomeruli, the larger vessels and peritubular capillaries in both the cortex and medulla was 
observed (Fig 5A, B). Interestingly, much higher re-endothelialization of glomeruli could be 
achieved using the iPS-derived ECs (reaching 100% coverage) as compared to hgMVEC, where 
only 50% re-endothelialization of the glomeruli was achieved. This difference is most likely 
caused by the smaller cell size and high proliferative capacity of hiPS-ECs. 7.8% of proliferating 
hiPS-ECs could be observed 48 hours after recellularization, as illustrated by the Ki67 staining in 
figure 5E. Transmission electron microscopy (TEM) showed alignment of the hiPSC-ECs on the 
endothelial side of the glomerular basement membrane (Fig. 5C). Moreover, alignment within 
larger vessels was also observed (Fig. 5D). Cells stayed viable for the maximal duration of the 
current experiments (up to 13 days) at which time 80% of the cortex remained re-endothelialized 
and 36% of cells were proliferating (Fig. 5F).
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Figure 4. Scalability of hIPS-EC culture and ability to adhere to growth factor loaded scaffolds.  
A) Adjusted hIPS-EC differentiation protocol where large quantities of hIPS-ECs can be obtained.  
B) Representative images of hiPS-ECs show positivity for vascular endothelial markers CD31, VE-
cadherin, VEGF-receptor 2 and Tie2. C) Representative images of hiPSC-EC adherence and survival 
after VEGF, Ang1 or combined loading of the scaffold. D) Quantification of hiPS-EC adherence after 
VEGF, Ang1 and combined loading. Abbreviations: VEGF: vascular endothelial growth factor, Ang1: 
angiopoietin 1. Scalebar 50 μm
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Human whole kidney scaffold re-endothelialization using hiPSC-ECs
In order to evaluate whether this recellularization method would also be feasible for the much 
larger human kidneys, we re-vascularized a growth factor loaded human decellularized kidney 
with 6 x107 hiPSC-ECs via the renal vein followed by 7 x107 hiPSC-ECs via the renal artery and 
cultured the kidney for 24 hours (Fig. 6A). As shown in figure 6B and C, we were able to re-
endothelialize the cortex, medulla and papilla. Analysis of CD31 positivity in 7 biopsies taken 
from 7 different locations through the kidney showed an average cellular coverage of 80, 70, 27% 
respectively in the endothelial compartment of the cortex, medulla and papilla. Moreover, an 
average of 71% coverage in the glomeruli was observed throughout the recellularized kidney, 
whereas obstructed blood vessels within the recellularized scaffold were minimal (area< 0.03%). 
Representative immunofluorescent images of endothelial cell alignment respectively in the 
cortex (Fig. 6D), larger arteries (Fig. 6E), medulla (Fig. 6F) and papilla (Fig. 6G) are shown. 
hiPSC-ECs were able to proliferate in the human kidney scaffold (9,6% of the hiPSC-ECs), as 
shown in figure 6H. This indicates that our re-endothelization method is scalable to the level of 
an entire human kidney scaffold.
Figure 5 Re-endothelialization of rat decellularized kidney matrices with hiPS-ECs. A) Whole 
organ image of CD31 positivity in the whole re-endothelialized rat kidney scaffold. B) Representative 
images after hiPS-EC recellularization showing re-endothelialization in the cortex, including the 
glomeruli, the medulla/papilla and in the larger vessels. C) TEM image of a glomerulus show 
alignment of endothelial cells on the endothelial side of the glomerular basement membrane D) 
TEM image showing alignment in a larger vessel E) Representative image of Ki67 staining showing 
proliferating hiPS-ECs in both the cortex and medulla. F) Representative image of CD31 positivity 
after 13 days of culture in both the cortex and medullary/papillary region. Abbreviations: BF: bright 
field. Scalebar B, E,F 50μm, Scalebar C,D 5 μm. Dashed line: aligning endothelial cell, black/white 
arrow: CD31 dynabeads which are used for hiPS-ECs isolation, black arrow: remaining extracellular 
matrix between foot processes on podocyte side of the GBM. 


































Figure 6 Human kidney re-endothelialization with hiPS-ECs. A) Image of the human re-
endothelialized kidney in the custom made organ chamber during culture. B) Representative 
immunohistochemistry images of CD31 positivity showing re-endothelialization in the cortex, medulla 
and C) papilla. D) Representative CD31 immunofluorescent images show re-endothelialization 
of the kidney cortex, E) artery, F) medulla and G) papilla. CD31 dynabeads used in the iPS-EC 
differentiation protocol(white arrows) can still be observed H) Representative image of proliferating 
cells in the human re-endothelialized kidney. Abbreviations: BF: bright field. Scalebar B,C 500μm, 
Scalebar D, F, H 50 μm, scalebar E 25 μm. white arrow: CD31 dynabead, black/white arrow: 
proliferating cell.
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Discussion
The current study shows that, by using hiPSC-ECs combined with growth factor loading and 
a differential arterio-venous delivery system, it is possible to reconstitute both the macro and 
microvascular compartments of a human kidney scaffold. The improved delivery via simultaneous 
arterial and venous infusion, coupled with enhanced cellular localization and adherence due to 
growth factor pre-loading, resulted in a significant improvement in endothelial coverage of the 
delivered cells within the scaffold. In combination, these represent significant advances in the 
use of decellullarized kidney scaffolds as a platform for kidney bioengineering. 
Previously Peloso et al. showed preservation of some growth factors in human kidney scaffolds 
post decellularization, including low levels of VEGF16. In our protocol, levels of VEGF were also 
low after decellularization while at the same time the GAG landscape appeared to be preserved. 
The latter offered the possibility to reconstitute the growth factors on the kidney ECM as a novel 
strategy to increase endothelial cell localization. Our data show that such a step is critical for cell 
adherence and survival, and it appeared to be a key step in facilitating maximal coverage which 
in turn improved the feasibility of scale up for re-endothelialization of a human size kidney 
scaffold. 
Alternative strategies to enhance re-endothelialization have also been described, including 
combined infusion of endothelial cells and pericytes in the lung9 and CD31-conjugation in the 
kidney17. In the latter, CD31 antibody conjugation resulted in enhanced re-endothelialization 
in porcine kidney scaffolds to similar levels as reported here. However, revascularization was 
performed using a murine endothelial cell line. 
Our study, therefore, also underscores the need and potential of human pluripotent stem cells 
as a source of human endothelium. Their small size and their proliferative potential, which was 
supported by the scaffold, were key factors in achieving the scalability for re-endothelialization of 
a human kidney scaffold. Obviously, maintenance of genomic integrity during reprogramming 
and subsequent expansion together with improvements in the subsequent maturation of 
these cells into a safe transferable cellular phenotype will be critical aspects that need further 
development. This is the case for all proposed approached for tissue bio-engineering using 
pluripotent stem cells and is therefore at the center of attention in the stem cell field. 
Next to the vascular compartment, the epithelial compartment of the kidney will also require 
successful recellularization in order to obtain a full functional bio-engineered kidney. Song et 
al. showed that, when a rat kidney scaffold was recellularized with neonatal rat kidney cells, site 
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specific epithelial recellularization was observed8. Whether hiPSC-derived kidney progenitor 
cells3 show the same potential or whether recellularization with distinct subtypes of hiPSC-
derived kidney epithelial cells will be required still needs further investigation. 
Conclusion
Here, we show that preservation of the glycosoaminoglycan (GAG) landscape and the possibility 
to load the scaffold with growth factors such as VEGF and Angiopoietin-1 are critical to 
endothelial cell (EC) adherence and survival on a kidney scaffold. Using a new controlled arterio-
venous delivery and culture method of hiPSC-derived endothelial cells, we report the complete 
re-endothelialization of the kidney vasculature, including the glomerular and peritubular 
capillaries. Moreover, we show that this method is scalable towards the human kidney scaffold. 
These findings provide unique insight into a critical step to develop a human bioengineered 
kidney.
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Supplementary figure 1 Decellularized rat kidneys show intact integrity and glycosaminoglycan 
(GAG) landscape. A) Macroscopic pictures of, from left to right, a rat kidney before and after 
decellularization, methylene blue perfusion through the artery and vein to confirm the vascular 
patency and a representative image of a revascularized rat kidney. B) Scanning electron 
microscopy (SEM) images of decellularized rat kidney show preservation of tissue architecture after 
decellularization. C) SEM image of a decellularized glomerulus . D) Extracellular matrix components 
are preserved as shown by hematoxylin, Collagen IV, Fibronectin and laminin stainings of rat 
decellularized kidneys compared to rat native kidney. E) The GAG landscape of the rat kidney 
is preserved after decellularization. Abbreviations: WGA: wheat germ agglutinin, LEA: lectin from 
Lycopersicon esculentum. Scalebar B&C 10 μm, D&E 100 μm.











































Supplementary figure 2 Heparinase and hyaluronidase treatment of the scaffold. A) Slices 
of human kidney scaffold were enzymatically treated with either heparinase or hyaluronidase. 
Heparinase treatment was able to remove heparan sulfates (10E4) with no effect on hyaluronan 
(neurocan) while hyaluronidase was able to remove hyaluronan with no effect on heparan sulfates. 
B) Quantification of fluorescent intensity of resp. 10E4 and neurocan with and without enzymatic 
treatment of the scaffold. Abbreviations: ns: non-significant, *** p<0.001, **** p<0.0001
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Chapter 8
Summary and discussion
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The incidence of chronic kidney disease (CKD) and end stage renal disease (ESRD) is rising each 
year1. Kidney transplantation is currently the best therapy for patients with ESRD. However, 
there is a shortage of donor organs and the long term outcomes after kidney transplantation are 
compromised by the effects of rejection and nephrotoxicity of immunosuppressive therapies. 
There is therefore a need for new strategies to either prolong the survival of transplanted organs 
or to increase the numbers of (bio-engineered) kidneys suitable for transplantation. 
Mesenchymal stromal cell (MSC) therapy is an interesting novel approach to increase 
transplant survival as MSCs exhibit antifibrotic and immunomodulatory properties. MSCs may 
therefore play roles in the treatment of allograft rejection and fibrosis and in minimization of 
immunosuppressive therapies, in particular calcineurin inhibitors. In several preclinical studies 
bone marrow MSCs (bmMSCs) showed beneficial effects on renal function and graft survival2. 
The first clinical studies have been performed with bmMSCs in kidney transplantation, mainly 
focussing on safety and feasibility3-9. Currently, several clinical trials are on-going focussing on 
improving long-term transplant survival with minimization of immunosuppression, prevention 
of transplant rejection or reducing ischemia reperfusion injury. While the first results are 
promising, there are, however, still a lot of questions which should be addressed regarding, 
amongst others, monitoring after MSC infusion, mechanism of action and optimal timing, 
dosage and frequency of infusions (Chapter 2). 
Mesenchymal stromal cells are a heterogeneous cell population and can be isolated from the 
perivascular fraction of most organs, including the human kidney (hkPSCs)10-12. In chapter 3 
we show an extensive characterization of kPSCs compared to bmMSCs and show that hkPSCs 
contain strong transcriptional similarities compared to bmMSCs, but also show organotypic 
expression signatures, including the HoxD10 and HoxD11 nephrogenic transcription factors. 
Comparable to bmMSCs, hkPSCs showed immunosuppressive potential and, when co-cultured 
with endothelial cells, vascular plexus formation was supported which was specifically in the 
hkPSCs accompanied by an increased NG2 expression. hkPSCs did not undergo myofibroblast 
transformation after exposure to TGFβ, further corroborating their potential regulatory role 
in tissue homeostasis. This was further supported by the observation that hkPSCs induced 
accelerated repair in a tubular epithelial wound scratch assay which was mediated through HGF 
release. In vivo, in a neonatal kidney injection model, hkPSCs re-integrated and survived in the 
interstitial compartment, while bmMSCs did not show this potential. Moreover, hkPSCs gave 
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protection against the development of acute kidney injury in vivo in a model of rhabdomyolysis 
mediated nephrotoxicity. Overall, this suggests a superior therapeutic potential for the use of 
hkPSCs and/or their secretome in the treatment of kidney diseases.
For fluent clinical translation, we developed a clinical grade acceptable standard operation 
procedure (SOP) with the use of clinical grade materials and enzymes (chapter 4).
As both the culture of kPSCs and bmMSCs in a clinical grade manner is currently time 
consuming and costly, culture methods are now shifting towards bioreactor-based systems 
where cells are cultured on microcarriers13-16. However, little is known about how these changes 
in microenvironment influence the functionality of the cells. In chapter 5 we investigated 
whether the microenvironment, specifically the topography of the culture surface, influence 
the functionality of both kPSCs and bmMSCs. To this end, we cultured human bmMSCs 
and kPSCs in the TopoWell plate, a custom-fabricated multi well-plate containing 76 unique 
bioactive surface topographies. Using fluorescent imaging, we observed profound changes in 
cell shape, accompanied by major quantitative changes in the secretory capacity of the MSCs. 
The cytokine secretion profile was closely related to cell morphology which was influenced by 
the cell culture topography. Our data demonstrate that stromal cell function is determined by 
microenvironment structure and can be manipulated in an engineered setting. Our data also 
have implications for the clinical manufacturing of mesenchymal stromal cells, where surface 
topography during bioreactor expansion should be taken into account to preserve therapeutic 
properties.
Stromal cells from different organs show tissue-specific imprinting and properties10,11,17-19. 
However, the presence of functionally distinct stromal cell populations within one solid organ 
has not been described before. In Chapter 6 we show that not only the kidney cortex but also 
the kidney capsule contains a stromal cell population. These capsule stromal cells are important 
for the three dimensional organisation of the kidney during nephrogenesis20-25 and provide 
the barrier function of the capsule which is critical for homeostatic processes such as pressure 
natriuresis26. We postulated that stromal cells derived from the kidney capsule may therefore 
also have specific properties and functions. To this end, we isolated these capsule mesenchymal 
stromal cells (cMSC) from human cadaveric kidneys that were not suitable for transplantation. 
There were several similarities between cMSCs and kPSCs including support of vascular 
plexus formation, expression of phenotypic markers and resistance against myofibroblast 
transformation. However, compared to kPSCs, cMSCs showed distinct mRNA and miRNA 
expression profiles, showed increased immunosuppressive capacity, and displayed strongly 
reduced HGF production, contributing to the inability to enhance kidney epithelial repair. 
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Therefore cMSCs are a distinct, novel human kidney-derived MSC-population and these data 
underpin the large functional diversity of phenotypically similar stromal cells in relation to their 
anatomic site, even within one organ. 
Although the in-organ differential functionality of MSCs is of interest to our understanding of 
the structural biology of the kidney, cMSCs are less likely to be used as candidate for clinical 
therapies. In clinical trials usually 2 cell infusions of 1-2 million cells per kilogram body weight 
are given8. To obtain such cells numbers, cMSCs should be isolated from several different donors 
for infusion into one patient, which makes the use of cMSCs less feasible compared to other 
MSC sources. 
Next to MSC therapy to increase transplant survival, another future strategy to increase the 
numbers of available organs for transplantation may be kidney bio-engineering. For this purpose 
a human or human size kidney can be decellularized in order to obtain the kidney matrix 
without the cells (scaffold). This scaffold can then be recellularized with induced pluripotent 
stem cells (hiPSCs) derived kidney27- and endothelial cells28 derived from the patient. In 
chapter 7 we report the regeneration of kidney vasculature by repopulating the glomerular and 
peritubular vascular compartment of human and rat kidney matrices with human endothelial 
cells derived from human glomeruli and human induced pluripotent stem cells. In order to 
optimize re-endothelialization, we provide novel strategies such as growth factor loading and a 
new controlled arterio-venous delivery system. Using this novel approach we were able to scale 
up re-endothelialization using iPS-derived endothelial cells as an expandable source to a full 
human kidney matrix, and were able to achieve efficient cell delivery, adherence and survival of 
these endothelial cells as a first, but critical, step towards a human bioengineered kidney. 
Discussion and future perspectives
Already in Greek mythology there was a fascination for regeneration of organs and body parts. 
For example, the liver of Prometheus, destroyed every night by an eagle, regenerated every 
morning. Not only in mythology but also in early science there was an interest in regeneration 
as Aristotle (384-322 BC) already observed that a lizard is able to completely regenerate its lost 
tail29-31. 
Whereas the human body is not able to completely regenerate lost body parts, it does have a 
regenerative capacity. While some cell types, including kidney tubular epithelial cells, are able 
to self-renew32,33, other nephron segments such as the glomerulus have a limited regenerative 
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capacity. Stromal cells are of particular importance for tissue regeneration as stromal cells can, 
due to their perivascular location and spindle shaped morphology, communicate with several 
cell types in the organ including endothelial cells, tissue resident macrophages and dendritic cells 
and infiltrating leucocytes8,34. Stromal cells are therefore an interesting cell source for cellular 
therapy for kidney regeneration and are currently extensively studied for kidney transplantation, 
both preclinically and in clinical studies. For clinical application, many questions regarding MSC 
therapy still remain, including the best MSC source, the most effective delivery strategy and long 
term effects and safety (chapter 2). 
Little is known about the best MSC source for kidney transplantation patients. Most studies 
performed in the transplantation field have been performed with bmMSCs. However, as we 
show that bmMSCs do not produce substantial levels of HGF important for kidney regeneration 
(chapter 3), bmMSCs may not be the best option in kidney transplantation. kPSCs do show 
this potential, but are not as readily available and need longer culture times and thus have a 
higher risk of infection and the acquiring of genetic anomalies during culture. Another option 
would be umbilical cord derived MSCs (ucMSCs). Within the STELLAR consortium we and 
others showed that ucMSCs have comparable kidney regeneration capacity in vitro and are able 
to ameliorate kidney damage in vivo35. As umbilical cords are easily obtained and ucMSCs can 
be isolated at low passage in high quantities, ucMSCs are an interesting cell source for further 
exploration for kidney transplantation. 
Another issue to be resolved is the administration method of MSCs. Currently, MSCs are given 
intravenously to the patient8. However, it may be more potent to deliver the MSCs, or the MSC 
conditioned medium containing the factors important for kidney regeneration, to the kidney ex 
vivo before transplantation. This would decrease the potential risk of immunity, and potential 
long term negative effects of MSCs in the patient. Moreover, the MSC conditioned medium 
could be combined with ex situ machine perfusion or in situ regional perfusion resuscitation 
strategies36 and may in such a way be able to enhance transplant regeneration.
Perivascular stromal cells are only a small fraction of the cell population in the bone marrow 
and kidney. Therefore in vitro expansion is necessary to obtain sufficient cell numbers. This is 
a time consuming and, particular in a clinical setting where clean room facilities are necessary, 
costly process. Moreover, open procedures increase the risk of infections during culture. 
Therefore there is a growing interest in closed-system bioreactors13-16. We and others showed 
that both bmMSCs and kPSCs can be cultured on biodegradable microcarriers in a xeno-free 
and serum-free spinnerflask culture35. Moreover, kPSCs could be isolated from the total kidney 
cell suspension via magnetic NG2 separation using fully automated cell processing (CliniMACS 
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Prodigy ®)35. Combining these two techniques would result in a closed system isolation and 
culture method, diminishing the hands-on time and infection risks. However, stromal cells 
cultured with these novel techniques should be extensively characterized as we and others 
showed that the functionality of stromal cells can be different when cells are cultured on different 
materials, surface shape and surface stiffness (chapter 5, 37-41). 
The field of regenerative medicine made enormous progress since the discovery in 2006 that 
differentiated adult cells can be reprogrammed into induced pluripotent stem cells (iPSC)42. 
In particular the combination of iPSC-technology with more recent differentiation strategies 
of iPSC towards several different cell types in the body, including neural43, retinal pigment 
epithelial (RPE) cells44, β-cells45, kidney27 and endothelial cells28 make iPS-derived cells and 
tissues interesting new therapeutic strategies for regeneration. In fact, the first clinical study 
with autologous iPS-derived RPE cells for macular degeneration was initiated in 2014. Although 
currently on hold due to mutations observed in the second patient’s iPSCs, it is anticipated to 
resume46. More trials are to be expected with iPS-derived cells. 
Although the kidney is a complex organ, consisting of around 2 million nephrons containing 
more than 20 distinct cell types, it turned out to be possible to create iPS-derived nephrons in 
3D structures (organoids) by mimicking embryonic development. These organoids show self-
organization into nephrons containing glomeruli, proximal tubules, early loop of Henles, distal 
tubules and collecting ducts27. 
While these findings hold great potential, for example for drug screening purposes, the size of the 
kidney organoids at present is too small to use directly for renal replacement therapy. Moreover, 
nephron structures within the organoids lack a collecting system and a connected vasculature. 
Using the kidney extracellular matrix as an instructive guidance for iPS-derived kidney- and 
endothelial cells may be a method to overcome these hurdles towards a bio-engineered kidney 
(chapter 7), 47,48. 
The concept of a bio-engineered kidney using the decellularized extracellular matrix is based on 
the theory that the instructive capacity of the matrix is site specific and results in site selective cell 
engraftment. We show that the instructive capacity can be used for enhanced human endothelial 
cell adherence and survival in whole organ kidney matrices based on the preservation of the 
glycosaminoglycan (GAG) landscape (chapter 7). To gain a functional bio-engineered organ, 
however, also the epithelial side and stromal compartment of the kidney should be re-cellularized. 
Song et al. showed that by recellularizing rat kidney matrices with rat neonatal kidney cells, 
indeed side selective engraftment was observed with podocytes in the glomerular structures and 
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tubular cells in the tubular compartment of the nephron47. However, whether this is also possible 
with iPS-derived kidney progenitor cells still needs to be further elucidated. Moreover, culture 
methods of iPSC-derived kidney progenitor cells should be optimized to enable the production 
of large cell quantities necessary to recellularized a human or human size kidney matrix. 
Besides the hurdles mentioned above, there are still several other obstacles such as sterility, 
thrombogenicity and immunogenicity, which need to be resolved. The vascular compartment, 
for example, needs to be completely re-endothelialized to prevent thrombosis. Moreover, little 
is known about the immunogenicity of the scaffold after recellularization. A massive influx of 
immune cells is observed in a transplanted empty scaffold48. Whether this is also the case for 
transplanted re-cellularized scaffolds still needs to be further investigated. 
Moreover, there are also still safety issues regarding iPSC for clinical application, such as 
genetically stability and risks of tumorigenicity46. In the end, direct reprogramming of adult 
fibroblasts into the desired cell type without a pluripotent state in between may be a safer option 
49,50. However, whether with this methods sufficient cell numbers of all cell types can be acquired 
is currently not known. 
With all these hurdles in mind, it has to be seen whether a transplantable bio-engineered kidney 
will be possible in the future. But even when this will turn out to be unfeasible, a lot of novel 
knowledge about the instructiveness of the extracellular matrix is obtained along the way. This 
knowledge itself may provide important clues for organ regeneration in situ. In fact, recently 
it has been described that the method to obtain the decellularized matrix is feasible in situ51. 
One could think of a future were non-functional parts of an organ are decellularized in vivo 
and, combined with strategies to enhance cell adherence, proliferation and functionality, such as 
growth factor loading, can instruct the body itself to regenerate this matrix. 
Not only in the scientific world, but also from a commercial perspective, the field of regenerative 
medicine is increasing. According to the World Regenerative Medicines Market forecast 2015-
2022 the field of regenerative medicine is projected to reach $30,237 million by 2022, mainly in 
the field of cellular therapies52 . Unfortunately, the increasing interest in the field and resulting 
potential gains also has its drawbacks. There is a growing industry in stem cell tourism based on 
unproven treatments and several allegations of research misconduct have been reported31,53-55. 
As there are currently still major issues to be resolved regarding iPS- derived product safety, such 
as genetically stability and risks of tumorigenicity46, it is of importance that the general public, 
in particular the patients, get a realistic view about the possibilities of stem cell therapies. The 
research community has a major responsibility in this in their communication with the media. 
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To conclude, the field of regenerative medicine holds, despite the mentioned hurdles, a lot of 
promises for kidney transplantation on both the short and long term. However, time will tell 
whether all aspects, including iPS-based therapies and bio-engineered organs, will be clinically 
available in the future or will be a modern myth. 
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De mogelijkheid om je lichaam te regenereren is iets waar men al in de Griekse mythologie door 
was gefascineerd. De lever van Prometheus, die elke nacht verwoest werd door een arend, kon 
elke ochtend weer regenereren. Niet alleen mythologisch maar ook wetenschappelijk was er 
toen al interesse in regeneratie. Aristoteles (384-322 v.C.) observeerde al dat een salamander bij 
verlies van zijn staart in staat is deze volledig te regenereren. 
Hoewel de mens niet zomaar een lichaamsdeel terug kan laten groeien, komen er steeds meer 
opties om organen te laten regenereren. In dit proefschrift wordt gekeken wat er binnen dit 
gebied van de regeneratieve geneeskunde mogelijk is wat betreft de regeneratie van nieren. 
De nieren zijn van levensbelang, ze filteren de afvalstoffen uit het bloed, reguleren de bloeddruk 
en water- en zouthuishouding en spelen een belangrijke rol bij de botstofwisseling en de 
aanmaak van rode bloedcellen. Zonder werkende nieren kan men niet leven en daarom is bij 
nierfalen nierfunctie vervangende therapie nodig. Hiervoor zijn er twee opties: dialyse (een 
kunstnier) en transplantatie. Transplantatie is hierbij de voorkeurstherapie aangezien de lange 
termijn overleving en de kwaliteit van leven beter zijn vergeleken met dialyse. Helaas is er een 
tekort aan donororganen en gaan donororganen niet een levenlang mee als gevolg van afstoting 
en toxiciteit van de afweeronderdrukkende therapie noodzakelijk na transplantatie. In dit 
proefschrift wordt bestudeerd of het veld van de regeneratieve geneeskunde nieuwe strategieën 
biedt om deze problemen te verhelpen door 1) donornieren langer mee te laten gaan en 2) de 
beschikbaarheid van (in het lab gemaakte) nieren te vergroten. 
Een optie om donororganen langer mee te laten gaan is mesenchymale stromale cell (MSC) 
therapie. MSCs zijn cellen die in elk orgaan dicht tegen de bloedvaten zitten en die via het 
uitscheiden van verscheidene stoffen, waaronder groeifactoren en cytokines, in staat zijn 
weefselhomeostase te geven. MSCs kunnen uit het beenmerg worden geïsoleerd (bmMSCs) 
en kunnen, als ze als celtherapie gegeven worden, het immuunsysteem onderdrukken 
en weefselherstel geven. In hoofdstuk 2 worden de eerste klinische ervaringen, de 
werkingsmechanismen en toekomstperspectieven van MSCs voor niertransplantatie besproken. 
De focus voor MSC-therapie is op dit moment op MSCs geïsoleerd uit het beenmerg. MSCs 
kunnen echter ook uit andere organen geïsoleerd worden, waaronder de nier. Doordat de 
MSCs uit de nier komen, hebben ze mogelijk nierspecifieke eigenschappen en daardoor zijn ze 
mogelijk ook meer geschikt voor therapie bij niertransplantatie. In hoofdstuk 3 worden uit de 
nier geisoleerde MSCs uitvoerig vergeleken met bmMSCs en zien we dat de nierMSCs, in ieder 
geval in een laboratorium setting, beter nierherstel kunnen geven. 
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Om een vloeiende overgang mogelijk te maken naar het onderzoeken van nierMSCs in een 
klinische setting, hebben we deze cellen met klinisch toepasbare materialen en methoden 
geïsoleerd en gekweekt. Het gedetailleerde isolatieprotocol hiervan kan teruggevonden worden 
in hoofdstuk 4. 
Aangezien organen maar voor een heel klein percentage (<0.01%) uit MSCs bestaan, moeten 
MSCs in het laboratorium vermeerderd worden. De methodes die hiervoor op het moment 
gebruikt worden zijn echter tijdrovend en duur. Om deze redenen wordt er steeds meer gekeken 
naar nieuwe methodes zoals kweken van de MSCs op bolletjes (microcarriers) in bioreactoren. 
Deze microcarriers hebben echter een andere vorm en kunnen van ander materiaal zijn 
vergeleken met het celkweekplastic waar MSCs nu op gekweekt worden. Het is daarom 
belangrijk om te weten of dit soort wijzigingen invloed hebben op de functie van de MSCs. 
In hoofdstuk 5 hebben we onderzocht of dit soort wijzigingen, met name de vorm van het 
kweekoppervlak, invloed hebben op de functie van de MSCs. Er is daarbij gekeken naar de 
uitgescheiden groeifactoren en cytokines door zowel beenmergMSCs en nierMSCs. We zien 
dat de vorm van het kweekoppervlak effect heeft op de hoeveelheden van de uitgescheiden 
factoren. Het is daarom van belang om bij het ontwerp van bioreactoren goed te bestuderen of 
de functionaliteit van de MSCs niet veranderd. 
Zoals de verschillen tussen bmMSCs en nierMSCs al laten zien, zijn MSCs een heterogene 
celpopulatie. In hoofdstuk 6 laten we zien dat zelfs binnen een orgaan, in dit geval de nier, 
2 verschillende MSC populaties gevonden kunnen worden. Naast de nierMSCs die uit de 
nierschors geïsoleerd zijn, kan er ook een MSC populatie worden geïsoleerd uit het nierkapsel 
(kapselMSCs). Deze kapselMSCs hebben andere karakteristieken in vergelijking met de 
nierMSCs, waarschijnlijk doordat ze een andere rol hebben tijdens de ontwikkeling van de nier. 
Alle hierboven genoemde MSCs hebben de potentie als celtherapie om donororganen 
langer mee te laten gaan en de hoeveelheid immuunonderdrukkende therapie noodzakelijk 
na transplantatie te verminderen. Echter, in de meest ideale situatie zou er helemaal geen 
immuunonderdrukkende therapie nodig zijn. Dit zou het geval zijn als een patiënt met nierfalen 
getransplanteerd zou kunnen worden met een nier gemaakt uit zijn of haar eigen cellen. Dit zou 
kunnen door het maken van een geinduceerde pluripotente stamcellen (iPSC) van de patiënt. 
Deze iPSC kunnen differentiëren in alle soorten cellen van het lichaam zoals niercellen en de 
cellen van de bloedvaten (endotheelcellen). 
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Organen bestaan echter niet alleen uit cellen maar ook uit bindweefsel. Dit bindweefsel, 
extracellulaire matrix genaamd, biedt structuur aan een orgaan en bevat componenten die 
belangrijk zijn voor celfunctie en overleving. Door organen te behandelen met een zeepoplossing 
kunnen alle cellen verwijderd worden en blijft de instructieve extracellulaire matrix over. Deze 
extracellulaire matrix kan vervolgens als 3D omgeving gebruikt worden om iPSC-nier en 
endotheelcellen in te groeien om op deze manier een nieuwe nier te maken. 
Dit kan vergeleken worden met verhuizen, als men de meubels uit een huis verwijderd (de 
cellen) blijft het huis, door de stevigheid van de muren (extracellulaire matrix) intact. Bovendien 
is nog steeds te zien waar de badkamer was en waar de woonkamer (instructiviteit van de 
extracellulaire matrix) en door deze eigenschappen zullen nieuwe bewoners hun meubelen (de 
iPSC-nier en endotheelcellen) zeer waarschijnlijk weer in dezelfde kamers neerzetten. 
In hoofdstuk 7 hebben we verscheidene strategieën onderzocht om met behulp van iPS-
endotheelcellen en een gedecellularizeerde niermatrix, de bloedvaten opnieuw te bekleden. 
We laten zien dat de matrix kan worden geladen met groeifactoren en dat, in combinatie met 
infusie via de nierslagader en nierader, de bloedvaten opnieuw bekleed kunnen worden met 
endotheelcellen. Dit was niet alleen mogelijk in het kleine rattenmodel, maar ook in een humane 
nier. Hoewel dit een belangrijke eerste stap is, wordt op deze manier nog geen functionele nier 
gemaakt. Hiervoor zullen op z’n minst, naast de bloedvaten, ook de andere celtypes in de nier 
toegevoegd moeten worden. 
Ten slotte geeft hoofdstuk 8 een beschouwing van de verschillende hoofdstukken van dit 
proefschrift en worden de mogelijkheden en aandachtspunten van de regeneratieve geneeskunde 
bij niertransplantatie beschreven. Regeneratieve geneeskunde is een ongelofelijk snel bewegend 
veld met veel potentie. In het enthousiasme van het veld wordt echter af en toe voorbijgegaan 
aan wat op dit moment haalbaar en veilig is voor de mens. Met name in de media worden af en 
toe beloften gemaakt die, op dit moment, (nog) niet waar te maken zijn. Met deze kanttekening 
in gedachte, geeft het veld van de regeneratieve geneeskunde veelbelovende nieuwe alternatieven 
in het veld van niertransplantatie. In de toekomst zal blijken of alle aspecten, ook de ambitieuze 
projecten zoals een in het laboratorium gemaakte nier, daadwerkelijk klinisch toepasbaar zijn of 
een moderne mythe zullen blijven.
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